AWARD NUMBER:  W81XWH-14-1-0442

TITLE:  Reinnervation of Paralyzed Muscle by Nerve-Muscle-Endplate Band Grafting

PRINCIPAL INVESTIGATOR:  Liancai Mu, M.D., Ph.D.,

CONTRACTING ORGANIZATION:  Hackensack University Medical Center
                            Hackensack, NJ 07610

REPORT DATE:  October 2017

TYPE OF REPORT:  Annual

PREPARED FOR:  U.S. Army Medical Research and Materiel Command
               Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT:  Approved for Public Release; Distribution Unlimited
                          Unlimited Distribution A

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
# Report Title
Reinnervation of Paralyzed Muscle by Nerve-Muscle-Endplate Band Grafting

## Authors
Liancai Mu, MD, PhD; Stanislaw Sobotka, PhD; Jingming Chen, MD

Email: lmu@hackensackumc.org

## Performer's Organization
Hackensack University Medical Center, 30 Prospect Avenue, Hackensack, NJ 07601-1914 USA

##赞助/监视机构名称和地址
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

## 安全分类

<table>
<thead>
<tr>
<th>分布和可访问声明</th>
<th>限制</th>
</tr>
</thead>
<tbody>
<tr>
<td>批准公开发布</td>
<td>分布无限</td>
</tr>
</tbody>
</table>

## 摘要
Our immediate reinnervation experiments have demonstrated that NMEG-NMZ technique resulted in optimal functional recovery, extensive axonal regeneration and endplate reinnervation. However, it remains unknown if this method has the potential for delayed muscle reinnervation. In the past year, we performed long-term (3, 6, and 9 months) denervation experiments to determine the denervation-induced neuromuscular alterations. Our results showed that prolonged denervation resulted in a progressive reduction of muscle mass and myofiber size. In the denervated muscles, normal axons almost disappeared, whereas MEPs were still detected in 9-month-denervated muscles, indicating that MEPs are more stable when compared with nerve axons after denervation. Preservation of the original MEPs in the denervated muscle favors reinnervation with NMEG-NMZ. We subsequently performed delayed (3-month delay) reinnervation experiments. Our data showed that NMEG-NMZ resulted in satisfactory recovery of muscle mass (82% of the control), axon counts (74%), and functional recovery (79% of control).

## Subject Terms
Peripheral nerve injury, muscle reinnervation, nerve-muscle-endplate band grafting, nerve regeneration, motor endplate band, native motor zone, muscle force measurement, functional recovery
<table>
<thead>
<tr>
<th>Section</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>4</td>
</tr>
<tr>
<td>2. Keywords</td>
<td>5</td>
</tr>
<tr>
<td>3. Accomplishments</td>
<td>5</td>
</tr>
<tr>
<td>4. Impact</td>
<td>16</td>
</tr>
<tr>
<td>5. Changes/Problems</td>
<td>18-19</td>
</tr>
<tr>
<td>6. Products</td>
<td>19-21</td>
</tr>
<tr>
<td>7. Participants &amp; Other Collaborating Organizations</td>
<td>21-22</td>
</tr>
<tr>
<td>8. Special Reporting Requirements</td>
<td>22-24</td>
</tr>
<tr>
<td>9. Appendices</td>
<td>25-103</td>
</tr>
</tbody>
</table>
1. INTRODUCTION:

There are 200,000 and 300,000 cases with peripheral nerve injury (PNI) in the United States and Europe, respectively, each year. Muscle paralysis caused by PNI is commonly treated by nerve repair, nerve grafting, nerve transfer, muscular neurotization, tubulization techniques, and many other techniques. Unfortunately, the currently available methods result in poor muscle reinnervation and functional recovery. Therefore, there is a pressing need to seek novel methods of reinnervation for restoration of motor function of PNI-related paralyzed muscles.

In our proposed work, we used nerve-muscle-endplate band grafting (NMEG) technique to reinnervate experimentally denervated muscle in a rat model. The core hypothesis driving this research is that the outcomes of our originally developed NMEG procedure, in which a NMEG was implanted to an endplate-free area in the target muscle, could be promoted by creating an ideal environment that physically facilitates axon-endplate connections and biologically enhances axon regeneration. To test this hypothesis, we modified our originally designed NMEG. Specifically, a NMEG pedicle (6 x 6 x 3 mm) was harvested from the native motor zone (NMZ) of the sternohyoid (SH) muscle (donor) and implanted to the NMZ of the ipsilateral denervated sternomastoid (SM) muscle (recipient). The idea is that a transferred NMEG could provide an abundant source of nerve terminals and motor endplates (MEPs) for axonal regeneration and muscle reinnervation. NMEG has sufficient pedicle-recipient muscle interfaces, which provide enough space for axonal regeneration. The axons could start to regenerate at multiple points in the implanted NMEG and grow across the pedicle-recipient muscle interfaces to reach the denervated MEPs in the target muscle. The NMEG-NMZ procedure physically shortens regeneration distances and facilitates rapid MEP reinnervation to avoid irreversible loss of the denervated MEPs in the target muscle. MEP regions of muscle fibers are preferentially reinnervated as a consequence of some special property of the muscle fiber at this site. Synaptic basal lamina at the MEP contains molecules that direct the formation of synaptic specializations on regenerating axon terminals and myofibers. Some other chemotropic substance released from the MEPs may attract the regenerating axons in the vicinity. In addition, we used intraoperative 1-hour electrical stimulation (ES) and focal administration of exogenous neurotrophic factors (ENF), including nerve growth factor (NGF) and basic fibroblast growth factor (FGF-2) to improve biological environment for accelerating axonal regeneration. Our studies showed that the outcomes of NMEG-NMZ were promoted by additional use of intraoperative 1-hour ES or local application of ENF.

In this research, two reinnervation models (immediate and delayed) are used. Immediate reinnervation is performed immediately after SM nerve transection, while delayed reinnervation is performed at the end of 3 months after SM nerve transection. The animals are randomly assigned to 10 groups (15 rats/each group), 8 NMEG-NMZ (NN)-related treatment groups and 2 technique control groups (immediate and delayed direct nerve implantation, DNI). The animals undergo postoperative evaluations after a 3-month recovery period. Multiple techniques are used to determine the effects of NMEG-NMZ and adjunctive treatments (i.e., ES and ENF) on functional recovery and muscle reinnervation. We have completed immediate reinnervation experiments, including 4 NN-related treatment groups and 1 DNI group. The results have been published in 4 articles.

For the delayed reinnervation experiments, we have completed part of the experiments on rats in 4 NN-related treatment groups (i.e., 3-mon-Del-NN; 3-mon-Del-NN/ENF; 3-mon-Del-NN/ES; and 3-mon-Del-NN/ES/ENF), 1 DNI group (3-mon-Del-DNI), and 1 denervation group. The results have been summarized in this report and 2 manuscripts have been submitted to scientific journals for publication. Taken together, we have obtained excellent results from our proposed studies as described below.
2. **KEYWORDS:**

| Peripheral nerve injury, muscle reinnervation, nerve-muscle-endplate band grafting, nerve regeneration, motor endplate band, native motor zone, muscle force, functional recovery |

3. **ACCOMPLISHMENTS:** The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction.

**What were the major goals and objectives of the project?**

*List the major goals of the project as stated in the approved SOW. If the application listed milestones/target dates for important activities or phases of the project, identify these dates and show actual completion dates or the percentage of completion.*

**Goal 1:** To evaluate functional recovery of the paralyzed muscles treated by the NMEG-NMZ technique with/without ES and ENF.

**Goal 2:** To determine the extent of neural regeneration and axon-endplate connections in the treated muscles.

**Goal 3:** To document histological and immunohistochemical alterations in the treated muscles.

**Milestones:**
- Surgical procedures for immediate reinnervation are accomplished in year 1 and those for delayed reinnervation are completed in year 3.
- Electrophysiological studies in Goal 1 are accomplished in year 3.
- The timetable for conducting the studies on neural and muscular tissues in Goals 2 and 3 is in years 2-4.

**What was accomplished under these goals?**

*For this reporting period describe: 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting activities to reporting accomplishments.*

**Major Activities**

We have performed the following major activities for this reporting period.

**Animal surgeries**

We performed 162 operations on rats in the delayed reinnervation groups (3-mon-Del-DNI; n = 60 rats) for nerve surgery (i.e., nerve transection, NMEG-NMZ plus ES, or ENF injection, and DNI procedure) or force measurement (15 rats/group). Each rat in the delayed reinnervation groups was subjected to 3 operations (muscle denervation, NMEG-NMZ transplantation or DNI procedure, and muscle force measurement). We also performed operations on rats (n = 21) in denervation group (2 operations for each rat). All the surgical procedures were successfully performed (Fig. 1).

NN = NMEG-NMZ transplantation; ES = intraoperative 1-hour electrical stimulation; ENF = focal administration of exogenous neurotrophic factors (i.e., NGF and FGF-2); 3-mon-Del = 3-month-delay; DNI = direct nerve implantation.
**Muscle force measurements**

Muscle force measurements were performed on 90 SM muscles of 45 rats 3 months after surgery. Specifically, the rats in 3 delayed reinnervation groups (3-mon-Del-NN/ES, 3-mon-Del-NN/ENF, and 3-mon-Del-NN/ES/ENF groups; 15 rats/per group) underwent force measurements (Fig. 2). For each rat, muscle force was measured from the target and contralateral control muscles. The force data from the rats in 3-mon-Del-NN, 3-mon-Del-NN/ES, and 3-mon-Del-NN/ENF groups were analyzed.

**Tissue studies**

Tissue studies were performed after experiments. Specifically, the right experimental and left control SM muscles for each animal were removed, measured, photographed, and prepared for neuromuscular analyses. The muscle samples (n = 264; 4 samples/each animal) from 66 animals in 3-mon-Del-NN, 3-mon-Del-NN/ES, 3-mon-Del-NN/ENF (n = 15/each group), and denervation (n = 21) groups were sectioned and stained using histochemical and immunohistochemical techniques to analyze muscle structure, myofiber morphology, axons, and motor endplates. The data from the target SM muscles were compared with those from the controls.

• **Specific Objectives**

For this reporting period, the data from muscle force measurements and tissue analyses for the animals in 3-mon-Del-NN and denervation (3-, 6, and 9-month denervation) groups were analyzed and the major findings are summarized and presented in this report (see Key Outcomes). Both studies have produced 2 manuscripts which have been submitted to scientific journals for publication.

The SM muscle samples from animals in 3-mon-Del-NN/ENF and 3-mon-Del-NN/ES groups have been collected and analyzed to determine the efficacy of NMEG-NMZ reinnervation and beneficial effects of intraoperative 1-hour ES and neurotrophic factors (a mixture of NGF and FGF-2) on the outcomes of NMEG-NMZ technique. Manuscripts will be written and submitted to scientific journals for publication during the following year.

**Objective 1:** To determine the degrees of functional recovery of the delayed reinnervation with NMEG-NMZ technique.

**Objective 2:** To document the extent of axonal regeneration in the muscles with delayed reinnervation by NMEG-NMZ.

**Objective 3:** To determine the mean endplate count and extent of endplate reinnervation of the muscles with delayed reinnervation with NMEG-NMZ.

**Objective 4:** To investigate alterations in the muscle mass and myofiber morphology of the muscles with delayed reinnervation by NMEG-NMZ.

**Objective 5:** To determine spatiotemporal alterations of the myofibers, motor endplates and axons in the NMZ of long-term denervated muscles.

• **Major Procedures**

3-mon-Del-NMEG-NMZ (3-mon-Del-NN)

The right SM muscle in the rat was exposed and denervated by resecting a 5-mm segment of its innervating nerve (first surgery). Three months after muscle denervation, NMEG-NMZ implantation was performed (2nd surgery). The details regarding the surgical procedures for NMEG-NMZ technique have been given in our recent publications. Briefly, the NMZs of the right SM (Fig. 1A) and SH (Fig. 1B) were outlined in the middle region of each muscle.
Then, a muscular defect with the same dimensions as the NMEG was made in the denervated SM muscle (Fig. 1C, D). A NMEG pedicle was harvested from the NMZ of the right SH donor muscle (Fig. 1D). It contained a block of muscle, a SH nerve branch, nerve terminals, and a motor endplate (MEP) band. The superficial muscle fibers on the ventral aspect of the NMEG pedicle were removed to create a denuded surface for better axon regeneration. The NMEG was embedded in the muscle defect of the right SM and sutured with 10-0 nylon microsutures (Fig. 1E). Thus, the denervated SM was reinnervated with NMEG-NMZ. Schematic illustrations summarize the surgical procedures (Fig. 1F).

**Fig. 1.** Images showing the locations of native motor zones (NMZ) of the sternomastoid (SM) and sternohyoid (SH) muscles of the rat and surgical procedures for NMEG-NMZ transplantation. (A) Stained and fresh right SM showing the NMZ of the muscle (outlined region). SM nerve (arrowhead) and nerve terminals were mapped out with Shiner’s stain (left image), whereas the motor endplate (MEP) band (arrow in the middle image) was visualized with whole mount acetylcholinesterase (AChE) staining. A fresh SM (right image) illustrated the NMZ outlined during surgery (bracket). (B) NMZ of the SH. (C) Surgically outlined NMZ in the SM (arrows) and in the SH (boxed region). The arrowhead indicates the SM nerve. H = hyoid bone; L = left; R = right; S = sternum. (D) A NMEG pedicle from the NMZ of the right SH and a muscular defect (between arrows) on the SM muscle. (E) The NMEG was implanted into the recipient bed and sutured (green arrows). The SH nerve branch (large black arrow) and its vessels (small black arrow) can be seen on the implanted NMEG. (F) Schematic illustrations summarize the surgical procedures by localizing the NMZs of the SM (F1) and SH (F2), denervating the SM and creating a muscular defect in the NMZ of the muscle (F3), and suturing the NMEG pedicle (F4) from the SH (F5).
3-mon-Del-NMEG-NMZ plus exogenous neurotrophic factors (3-mon-Del-NN/ENF)

The animals in 3-mon-Del-NN/ENF (n = 15) and 3-mon-Del-NN/ES/ENF (n = 15) groups underwent NMEG-NMZ implantation and a single focal administration of a mixture of NGF and FGF-2 to optimize the neural environment for enhancing nerve regeneration. Before NMEG-NMZ implantation, the muscular defect of the SM was covered with 0.2 ml fibrin sealant containing recombinant rat NGF and rat FGF-2 (R&D Systems, Minneapolis, MN) at a concentration of 100 ng/ml for NGF and 100 µg/ml for FGF-2. Then, the NMEG pedicle was adhered by fibrin glue to the recipient bed and sutured with four to six 10-0 nylon microsutures. The fibrin-based growth factor delivery system was used for the slow continual release of the factors directly to the target to accelerate axon regeneration and enhance recovery of motor function. The goal of this experiment was to investigate the effect of local application of exogenous NGF and FGF-2 on the outcomes of our NMEG-NMZ reinnervation technique.

3-mon-Del-NMEG-NMZ plus 1-hour electrical stimulation (3-mon-Del-NN/ES)

The rats in 3-mon-Del-NN/ES (n = 15) and 3-mon-Del-NN/ES/ENF (n = 15) groups underwent an intraoperative 1-hour of ES prior to NMEG-NMZ implantation. The SH nerve branch supplying the NMEG was placed on bipolar stainless steel hook electrodes and stimulated. The nerve was stimulated for 1 h with a continuous train of 20 Hz square pulses of 3 V, 0.1 ms delivered by a stimulation and recording system (National Instruments Corp, Austin, Texas) controlled by user-written LabVIEW software (National Instruments Corp). The nerve distance between stimulating electrode and NMEG was about 5 mm. Throughout the ES procedure, the muscle pedicle and its innervating SH nerve branch stimulated were regularly bathed with warm mineral oil. Immediately after stimulation, the NMEG pedicle was embedded in the muscle defect NMZ in the recipient SM muscle and sutured with four to six 10-0 nylon microsutures.

3-mon-Del-direct nerve implantation (3-mon-Del-DNI)

The rats in 3-mon-Del-DNI group (n = 15) underwent DNI procedure. For each rat, the right SM nerve was transected to paralyze the muscle (first surgery). Three months after muscle denervation, the proximal SM nerve stump was inserted into the NMZ of the muscle.

Muscle force measurement will be performed during the next reporting period.

Long-term (3-, 6-, and 9-month) muscle denervation experiments

In this study, 21 rats were subjected to denervation experiments. This study was designed to determine spatiotemporal alterations of the myofibers, motor endplates (MEPs) and axons in the NMZ of long-term denervated muscles for exploring if NMEG-NMZ would have the potential for delayed reinnervation. The 21 rats were randomly allocated into 3 subgroups (3-month-denervation, 6-month-denervation, and 9-month denervation; n = 7/each subgroup). The SM muscle was denervated by resecting a 5-mm segment of SM nerve. At the end of the experiment 3, 6, and 9 months after denervation, both SM muscles for each rat were harvested, photographed, and weighed. Wet muscle weights, shown to closely reflect the degree of denervation, were reported as a ratio of the denervated to the contralateral control side. Each of the removed SM muscles (n = 42) was divided into three segments: rostral, middle, and caudal. The muscle segments (n = 126) were then frozen in melting isopentane cooled with dry ice and cut on a cryostat (Reichert-Jung 1800; Mannheim, Germany) at –25°C. The rostral and caudal segments were cut transversely and serial cross-sections (10 µm) were stained histologically to examine myofiber morphology and measure muscle fiber diameter. The middle segment containing the NMZ was cut sagittally (60 µm) and immunostained to detect and quantify nerve axons and MEPs.

The data from the denervated muscles were compared with those from contralateral controls.
Muscle force measurement

The rats (n = 45) in 3 delayed reinnervation groups (3-mon-Del-NN/ES, 3-mon-Del-NN/ENF, and 3-mon-Del-NN/ES/ENF groups; 15 rats/per group) underwent maximal tetanic force measurements from reinnervated and ipsilateral control SM muscles (n = 90) 3 months after NMEG-NMZ reinnervation to examine the degree of functional recovery of the reinnervated muscles. During the experiment, the rat was placed supine on a heating pad, and the core body temperature was monitored with a rectal thermistor and maintained at 36°C.

Muscle force of the right SM was measured first by electrically stimulating the SH nerve branch supplying the NMEG, whereas muscle force of the left control muscle was measured by stimulating the intact SM nerve. The details regarding muscle force measurement have been given in our previous publications. Briefly, the distal tendon of the SM muscle was severed, tied with 2-0 silk suture, and connected to a servomotor lever arm with a force transducer.

Isometric contraction of the SM muscle was produced with 200-millisecond trains of biphasic rectangular pulses. The duration of each phase of stimulation pulse was set at 0.2 milliseconds and the train frequency was set at 200 pulses per second. The stimulation current was gradually increased until the tetanic force reached a plateau. A break of at least 1 minute was taken between two stimulations. Muscle force was measured when muscle was stretched at optimal tension of 0.8 N. Maximal muscle force was calculated as average muscle contraction to 5 stimulation currents, ranging from 0.6 to 1.0 mA. The force generated by the contraction of the SM muscle was transduced with the servomotor of a 305B lever system and displayed on a computer screen. Muscle force was reported as a ratio of the operated to the control side.

Tissue preparation

A total of 264 muscle samples (4 samples/each animal) from 66 rats were studied. The muscle samples were obtained from 3 experimental groups [3-mon-Del-NN, 3-mon-Del-NN/ES, and 3-mon-Del-NN/ENF groups (n = 15 rats/each group)] and 3 denervation subgroups [3-, 6-, and 9-month-denervation (n = 7 rats/each subgroup)]. The muscle samples were removed, measured, photographed, sectioned, and stained using various staining techniques.

As described above, each of the removed SM muscles was divided into three segments: rostral, middle, and caudal. The rostral and caudal segments were cut transversely and stained with routine hematoxylin and eosin staining to examine alterations in muscle structure and myofiber morphology. The middle segment containing the NMZ and/or NMEG was cut sagittally (60 µm) and immunostained with neurofilament staining to count regenerated axons and double fluorescence staining to identify innervated and non-innervated motor endplates. The density of the regenerated axons on a stained section was measured with public domain ImageJ software (v. 1.45s; NIH, Bethesda, Maryland). The innervated and non-innervated motor endplates in each muscle were computed.

Key Outcomes

Denervation Study

The muscle samples from animals with prolonged (3-, 6-, and 9-months) denervation were studied to determine spatiotemporal alterations of the myofibers, MEPs and axons in the NMZ of long-term denervated muscles for exploring if NMEG-NMZ technique would have the potential for delayed reinnervation.
Our results showed that the prolonged denervated SM muscles exhibited a progressive reduction in wet muscle weight (38%, 31%, and 19% of the control) and fiber diameter (52%, 40%, and 28% of the control) for 3-, 6-, and 9-month denervation, respectively (Figs. 2-3).

Fig. 2. Comparison of muscle mass and myofiber morphology between control and denervated sternomastoid (SM) muscles in the rat. (A) Photographs of the removed control SM and denervated SM muscles, showing a progressive decline in muscle mass with denervation time. (B) Hematoxylin and eosin-stained cross-sections from the control and denervated SM muscles, showing a progressive reduction in fiber size of the denervated SM. 3-mon-den, 3-month-denervation; 6-mon-den, 6-month-denervation; 9-mon-den, 9-month-denervation.

Fig. 3. Comparison of myofiber diameters of the sternomastoid (SM) muscles between denervated and control sides and among denervation groups. (A) Distribution of mean fiber diameters of the denervated and control SM muscles. (B) Ratio of the mean fiber size of the denervated to control muscles. Note that the fiber diameters of the denervated muscles are reduced progressively with denervation time. Vertical bars represent standard error.
We found that the denervated MEPs were still detectable even 9 months after denervation (Fig. 4). The mean number of the denervated MEPs was 79%, 65%, and 43% of the control in the 3-, 6-, and 9-month denervated SM, respectively. In contrast, the intramuscular degenerated axons became fragmented and only some accumulations of axon debris were identified in the long-term denervated muscles.

Denervation-induced neuromuscular alterations cause impairment of muscle functional properties that represent major impediments to successful surgical interventions. The knowledge on the morphological and histochemical changes in myofibers and MEPs at different time points following long-term denervation provides the baseline for application of the NMEG-NMZ reinnervation technique to treat PNI-induced chronic muscle paralysis. Our findings support the view that postsynaptic acetylcholine receptor (AChRs) of the vertebrate MEPs are remarkably stable in that they persist for long periods following denervation. The MEP band is a potential site for clinical and experimental manipulations since MEP is the physiological interface between the motoneuron and the muscle fiber. Persistence of MEPs in the long-term denervated SM suggests that some surgeries targeting the MEPs such as NMEG-NMZ techniques should be effective for delayed reinnervation. Our results suggest that the muscles denervated for less than 6 months should have a good chance to be successfully reinnervated by NMEG-NMZ technique based on the preserved muscle mass and the number of the preserved original MEPs in the denervated muscles.

For optimal outcome of NMEG-NMZ and other reinnervation techniques in the treatment of long-term denervated muscle, more work is needed to reveal specific strategies to rescue muscle from atrophy and prevent MEP degradation following PNI. Therapeutic strategies aimed at preserving MEPs would be the most effective for successful functional recovery of the delayed reinnervated muscle by NMEG-NMZ and/or DNI-NMZ techniques.
Delayed Muscle Reinnervation with NMEG-NMZ Technique

We have demonstrated that NMEG-NMZ results in optimal functional recovery in immediate reinnervation model. However, it remains unknown if this technique is effective for delayed muscle reinnervation. Based on our observations from denervation study, we performed delayed reinnervation experiments. The animals in the 3-mon-Del-NMEG-NMZ (3-mon-Del-NN) group underwent delayed reinnervation 3 months after SM denervation. Three months after muscle reinnervation with NMEG-NMZ, maximal tetanic force, muscle weight, fiber morphology, regenerated axons, and MEPs were analyzed to evaluate outcomes. The results are summarized below.

Functional recovery

The degree of functional recovery of the treated SM muscles was assessed by muscle force measurement as compared with that of the contralateral control muscle in each animal. The average maximal muscle force of the reinnervated SM muscles was measured to be 79% of the control (Fig. 5). The results showed that NMEG-NMZ was also effective for 3-month delayed reinnervation.

Muscle mass and myofiber morphology

NMEG-NMZ resulted in satisfactory recovery of muscle mass of the reinnervated muscle as indicated by wet weights of the reinnervated and control SM. The mean wet weight of the reinnervated SM (0.324 g) were smaller than the control (0.396 g), but larger than that of 6-month-denervated (0.115 g) muscles (Fig. 6A-C). The average weight of the reinnervated muscles was 82% of the control. H&E-stained sections showed that the fiber size of the reinnervated SM was smaller than that of the contralateral control, but larger than that of the 6-month-denervated SM (Fig. 6A’-C’). The denervated muscles exhibited increased connective tissue with small atrophic fibers.
Axonal regeneration

The muscle sections immunostained for neurofilament (NF) showed that 3-month delayed reinnervation by NMEG-NMZ resulted in very good axonal regeneration (Fig. 7). The extent of axonal regeneration and muscle reinnervation was evaluated by quantifying the NF-immunoreactive (NF-ir) axons within the target and control muscles using public domain ImageJ software v1.45s (NIH, Bethesda, MD). Specifically, the mean count and area of the NF-ir axons in the reinnervated muscles (Fig. 7A-A’) were 70% and 66% of the control, respectively (Fig. 7B-B’).

![Reinnervated % Area](image1)

![Control % Area](image2)

**Fig. 7.** Photomicrographs of sagittal sections immunostained for neurofilament (NF) from the right reinnervated (A) and left control (B) sternomastoid (SM) muscles of a rat. In a stained section, images were taken from 3 microscopic fields. Bar = 100 µm for A and B. (A’, B’) Images (A) and (B) were converted to black and white by using ImageJ software to calculate the number and percent area of NF-positive axons (darkly stained threads and dots) in each section. For this animal, as compared with the left control SM (mean axon count 798, mean area 1.118), the right reinnervated SM exhibits good muscle reinnervation, as indicated by the mean axon count (593, 74.3% of control) and mean area (0.598, 53.5% of the control).

**MEP reinnervation**

The muscle sections immunostained with double fluorescence staining (Fig. 8) visualized MEP band (Fig. 8A, D, G) and individual innervated (visible axon attachment) and noninnervated (no visible axon attachment) MEPs (Fig. 8B, C, E, F, H, I) in the control, reinnervated, and denervated SM muscles. In the reinnervated muscles, the regenerating axons (green) from the implanted NMEG pedicle grew across the NMZ to innervate the denervated MEPs (Fig. 8D-F). On average, 75% of the MEPs in the operated muscles were reinnervated by regenerated axons. Axonal sprouts and newly formed small MEPs were identified in the reinnervated muscles. In the denervated muscles, only noninnervated MEPs were identified (Fig. 8G, H, I). The denervated muscles showed the presence of shrunken and distorted MEPs with thin lengthened shapes.
Fig. 8. Images of double-immunofluorescence staining of sagittal sections from control (A-C), reinnervated (D-F), and 6-month-denervated (G-I) sternomastoid (SM) muscles. The immunostained sections show labeled axons (green) and their innervating motor endplates (MEPs, red) in both the control and reinnervated muscles. The 6-month-denervated SM exhibited MEPs without innervating axons. Low-power view of the stained sections (A, D, G) shows the MEP band within a given muscle. High-power view of the stained sections (B, C, E, F, H, I) shows innervated (arrows) and non-innervated (arrowheads) MEPs as well as terminal axons (arrows in C and F). Scale bars = 150 µm for (A), (D) and (G); 100 µm for (B), (E) and (H); and 20 µm for (C), (F) and (I).

We observed that a decrease in presynaptic nerve terminals preceded the decrease in the postsynaptic AChRs at MEPs. After SM muscle denervation, the denervated MEPs retained for long periods at least for 9 months although the MEP count was gradually decreased and MEP shape was altered (Fig. 8G-I). These findings are helpful for determining the proper timing for reinnervation of denervated muscles by NMEG-NMZ, DNI-NMZ, and/or other procedures targeting MEPs.
• Summary

The results from our studies on long-term muscle denervation (3-, 6-, and 9-month denervation) and 3-month-delayed reinnervation with NMEG-NMZ in rats performed in year 3 allow us to make the following conclusions.

First, our denervation study was designed to determine if the NMEG-NMZ technique is effective for delayed reinnervation that is not uncommon in clinical practice. For this purpose, it is important to know the decreasing rate of the MEPs in the completely denervated muscle and determine the time point when all the denervated MEPs cannot be detectable in the target muscle. This information is useful for estimating the time window to perform delayed reinnervation with NMEG-NMZ technique. Our results showed that prolonged denervation resulted in a progressive reduction of muscle mass and myofiber size. Fiber atrophy was more pronounced in the 9-month-denervated muscles than that in the 3- and 6-month-denervated muscles. In the denervated muscles, normal axons almost disappeared, whereas MEPs were still detected in 9-month-denervated muscles, indicating that MEPs are more stable when compared with nerve axons after denervation. Preservation of the original MEPs in the denervated muscle favors NMEG-NMZ reinnervation.

Second, our delayed reinnervation experiments showed that NMEG-NMZ technique was also effective for 3-month delayed reinnervation. The results showed that NMEG-NMZ resulted in satisfactory outcomes following 3-month delayed reinnervation, as indicated by very good recovery of muscle force (79% of the control), muscle mass (82%), axon counts (70%), and reinnervated MEPs (75%). Our observations suggest that NMEG-NMZ technique may be effective for restoration of motor function of the muscles denervated even for 6 months according to the preserved muscle mass, regenerated axons, and reinnervated MEPs in the 3-month-denervated SM.

Finally, further studies are needed for the development of therapeutic strategies to rescue muscle from atrophy and protect MEPs from degradation after muscle denervation. Muscle atrophy is one of the main factors for hampering successful recovery from muscle denervation. In the absence of alternative primary treatments, sensory protection appears has the potential for providing temporary trophic support to prevent denervation atrophy, thereby preserving muscle volume for delayed reinnervation. Therapeutic strategies aimed at preserving MEPs would be the most effective for successful functional recovery of the delayed reinnervated muscle by NMEG-NMZ and/or DNI-NMZ techniques. One therapeutic strategy would be the direct delivery of exogenous neurotrophic factors to the MEP zone in the denervated muscle, which may delay or prevent myofiber atrophy and degradation of MEPs following PNI. Maintenance of original MEPs in the long-term denervated muscle could facilitate rapid axon-MEP connections, thereby improving functional outcomes of NMEG-NMZ, DNI-NMZ, and/or other nerve repair procedures.

What opportunities for training and professional development has the project provided?
If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project.
“Training” activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. “Professional development” activities result in increased knowledge or skill in one’s area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.

How were the results disseminated to communities of interest?
If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.

What do you plan to do during the next reporting period to accomplish the goals?
If this is the final report, state “Nothing to Report.”

Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.

The following experiments will be performed during the next reporting period.

• **Force data analysis (3-mon-Del-NN/ES/ENF group)** – The force data from the SM muscles (n=30 muscles) of the rats in 3-mon-Del-NN/ES/ENF group (n = 15) will be analyzed during the next reporting period.

• **Muscle force measurement (3-mon-Del-DNI group)** – The rats in 3-mon-Del-DNI group (n = 15) will undergo muscle force measurement (n = 30 muscles) during the next reporting period.

• **Tissue studies (3-mon-Del-NN/ES/ENF)** – The muscle samples (n = 60) from the rats (n = 15) in 3-mon-Del-NN/ES/ENF group will be sectioned, stained, and analyzed.

4. **IMPACT:** Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

What was the impact on the development of the principal discipline(s) of the project?
Our studies on the prolonged muscle denervation and 3-month-delayed reinnervation demonstrated that NMEG-NMZ has the potential for delayed reinnervation. Further research will focus on improving the efficacy of NMEG-NMZ in the treatment of chronic muscle paralysis by using additional therapies to preserve muscle mass and MEPs after muscle denervation. We believe that NMEG-NMZ technique will become a useful method to treat our patients with muscle paralysis caused by peripheral nerve injuries.

What was the impact on other disciplines?
If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.

Nothing to report.

What was the impact on technology transfer?
If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:

- transfer of results to entities in government or industry;
- instances where the research has led to the initiation of a start-up company; or
- adoption of new practices.

Nothing to report.

What was the impact on society beyond science and technology?
If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:

- improving public knowledge, attitudes, skills, and abilities;
- changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or
- improving social, economic, civic, or environmental conditions.

Nothing to report.
5. **CHANGES/PROBLEMS:** The Project Director/Principal Investigator (PD/PI) is reminded that the recipient organization is required to obtain prior written approval from the awarding agency Grants Officer whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, “Nothing to Report,” if applicable:

**Changes in approach and reasons for change**
*Describe any changes in approach during the reporting period and reasons for these changes. Remember that significant changes in objectives and scope require prior approval of the agency.*

<table>
<thead>
<tr>
<th>Nothing to report.</th>
</tr>
</thead>
</table>

**Actual or anticipated problems or delays and actions or plans to resolve them**
*Describe problems or delays encountered during the reporting period and actions or plans to resolve them.*

<table>
<thead>
<tr>
<th>Nothing to report.</th>
</tr>
</thead>
</table>

**Changes that had a significant impact on expenditures**
*Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.*

<table>
<thead>
<tr>
<th>Nothing to report.</th>
</tr>
</thead>
</table>

**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**
*Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.*

**Significant changes in use or care of human subjects**

<table>
<thead>
<tr>
<th>Nothing to report.</th>
</tr>
</thead>
</table>

**Significant changes in use or care of vertebrate animals.**

<table>
<thead>
<tr>
<th>Nothing to report.</th>
</tr>
</thead>
</table>
Significant changes in use of biohazards and/or select agents

Nothing to report.

6. PRODUCTS: List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state “Nothing to Report.”

- Publications, conference papers, and presentations
  Report only the major publication(s) resulting from the work under this award.

  **Journal publications.** List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume: year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).

The studies under this award have produced 6 peer-reviewed articles. Four articles have been published in scientific journals and two manuscripts are under review.


**Books or other non-periodical, one-time publications.** Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each
Other publications, conference papers, and presentations. Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.

* We participated in Neuroscience Society Annual Meeting 2016 and presented part of our data from this research.


- Website(s) or other Internet site(s)
  List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.

  Nothing to report.

- Technologies or techniques
  Identify technologies or techniques that resulted from the research activities. In addition to a description of the technologies or techniques, describe how they will be shared.

  Nothing to report.

- Inventions, patent applications, and/or licenses
  Identify inventions, patent applications with date, and/or licenses that have resulted from the research. State whether an application is provisional or non-provisional and indicate the application number. Submission of this information as part of an interim research
performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.

Nothing to report.

Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment, and/or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:

- data or databases;
- biospecimen collections;
- audio or video products;
- software;
- models;
- educational aids or curricula;
- instruments or equipment;
- research material (e.g., Germplasm; cell lines, DNA probes, animal models);
- clinical interventions;
- new business creation; and
- other.

Nothing to report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?
Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate “no change.”

Example:

Name: Mary Smith
Project Role: Graduate Student
Researcher Identifier (e.g. ORCID ID): 1234567
Nearest person month worked: 5

Contribution to Project: Ms. Smith has performed work in the area of combined error-control and constrained coding.
Funding Support: The Ford Foundation (Complete only if the funding support is provided from other than this award).

Liancai Mu no change
Stanislaw Sobotka no change
Jingming Chen no change
Themba Nyirenda no change
Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”

If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.

Nothing to report.

What other organizations were involved as partners?

*If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.

Provide the following information for each partnership:

**Organization Name:**

**Location of Organization:** (if foreign location list country)

**Partner’s contribution to the project** (identify one or more)

- Financial support;

- In-kind support (e.g., partner makes software, computers, equipment, etc., available to project staff);

- Facilities (e.g., project staff use the partner’s facilities for project activities);

- Collaboration (e.g., partner’s staff work with project staff on the project);

- Personnel exchanges (e.g., project staff and/or partner’s staff use each other’s facilities, work at each other’s site); and

- Other.

Nothing to report.

8. SPECIAL REPORTING REQUIREMENTS

**COLLABORATIVE AWARDS:** For collaborative awards, independent reports are required from BOTH the Initiating PI and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to [https://ers.amedd.army.mil](https://ers.amedd.army.mil) for each unique award.
QUAD CHARTS: If applicable, the Quad Chart (available on https://www.usamraa.army.mil) should be updated and submitted with attachments.

A quad chart has been updated and submitted with attachments (page 24).

9. APPENDICES: Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.

In Appendices, published articles and submitted manuscripts have been attached (pages 25-103).
Reinnervation of Paralyzed Muscle by Nerve-Muscle-Endplate Band Grafting
ERMS Number 12223004
W81XWH-14-1-0442

PI: Liancai Mu, MD, PhD  Org: Hackensack University Medical Center  Award Amount: $800,000

Study/Product Aim(s)
Aim 1: To evaluate functional recovery of the paralyzed muscles treated by NMEG-NMZ technique with/without ES and ENF.
Aim 2: To determine the extent of neural regeneration and axon-endplate connections in the treated muscles.
Aim 3: To document histological and immunohistochemical alterations in the treated muscles.

Approach
- Microsurgical procedures (NMEG-NMZ and DNI techniques).
- Intra-operative 1-hour electrical stimulation (ES).
- Focal administration of exogenous NGF and FGF-2.
- EMG and muscle force measurements.
- Various staining methods to label regenerating axons, MEPs.
- Analyze muscle fiber types and myosin heavy chains.

Timeline and Cost

<table>
<thead>
<tr>
<th>Activities</th>
<th>CY 1</th>
<th>CY 2</th>
<th>CY 3</th>
<th>CY 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physiological evaluations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neural studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle studies &amp; data analyses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Estimated Budget ($K)
$200k $200k $200k $200k

Goals/Milestones
CY1 Goal – Microsurgery, functional evaluations, and neural studies.
- Perform surgeries, muscle force measurement, and nerve staining.
CY2 Goal – Microsurgery, functional evaluations, and tissue studies.
- Perform surgeries, force and tissue studies.
CY3 Goal – Functional evaluation and tissue studies.
- Complete surgeries and perform force and tissue studies.
CY4 Goal – Tissue studies, data collection, and data analyses.
- Investigate nerve regeneration and muscle fiber type and myosin heavy chain composition.

Comments/Challenges/Issues/Concerns
If timelines change, comment here.
If off by more than one quarter in spending, comment here.

Budget Expenditure to Date
Projected Expenditure: $50,000
Actual Expenditure: $16,442

Updated: (9/25/2017)
Original Research

Reinnervation of denervated muscle by implantation of nerve-muscle-endplate band graft to the native motor zone of the target muscle

Liancai Mu1 | Stanislaw Sobotka1,2 | Jingming Chen1 | Themba Nyirenda1

Abstract

Introduction: Motor endplate reinnervation is critical for restoring motor function of the denervated muscle. We developed a novel surgical technique called nerve-muscle-endplate band grafting (NMEG) for muscle reinnervation.

Methods: Experimentally denervated sternomastoid muscle in the rat was reinnervated by transferring a NMEG from the ipsilateral sternohyoid muscle to the native motor zone (NMZ) of the target muscle. A NMEG pedicle contained a block of muscle (~6 × 6 × 3 mm), a nerve branch with axon terminals, and a motor endplate band with numerous neuromuscular junctions. At 3 months after surgery, maximal tetanic muscle force measurement, muscle mass and myofiber morphology, motoneurons, regenerated axons, and axon-endplate connections of the muscles were analyzed.

Results: The mean force of the reinnervated muscles was 82% of the contralateral controls. The average weight of the treated muscles was 89% of the controls. The reinnervated muscles exhibited extensive axonal regeneration. Specifically, the mean count of the regenerated axons in the reinnervated muscles reached up to 76.8% of the controls. The majority (80%) of the denervated endplates in the target muscle regained motor innervation.

Conclusions: The NMZ of the denervated muscle is an ideal site for NMEG implantation and for the development of new microsurgical and therapeutic strategies to achieve sufficient axonal regeneration, rapid endplate reinnervation, and optimal functional recovery. NMEG-NMZ technique may become a useful tool in the treatment of muscle paralysis caused by peripheral nerve injuries in certain clinical situations.

Keywords

motor endplate, muscle force measurement, muscle reinnervation, native motor zone, nerve regeneration, nerve-muscle-endplate band grafting, peripheral nerve injury

1 | Introduction

Traumatic peripheral nerve injuries (PNIs) to the head/neck and extremity are a significant cause of morbidity and disability in both military and civil circumstances today (Brininger, Antczak, & Breland, 2008; Eser, Aktekin, Bodur, & Atan, 2009; Kretschmer, Antoniadis, Braun, Rath, & Richter, 2001; Noble, Munro, Prasad, & Midha, 1998). There are 200,000 and 300,000 cases with PNIs in the United States...
and Europe, respectively, each year (Ichihara, Inada, & Nakamura, 2008; Wiberg & Terenghi, 2003). Approximately, 100,000 patients undergo peripheral nerve surgery in the United States and Europe annually (Kelsey, Praemer, Nelson, Felberg, & Rice, 1997). In the past decades, multiple techniques such as nerve end-to-end anastomosis (EEA), end-to-side neurorrhaphy, nerve grafting, nerve transfer, muscular neurotization, tubulization techniques, and many others have been developed for the reinnervation of denervated muscles (McAllister, Gilbert, Calder, & Smith, 1996; de Medinaceli, Prayon, & Merle, 1993; Siemionow & Brzezicki, 2009). However, the currently available methods result in poor muscle reinnervation and functional recovery. For example, EEA is commonly used when the two stumps of an injured nerve can be approximated without tension. Unfortunately, only about 50% of patients regain useful function (Lee & Wolfe, 2000; Wong & Crumley, 1995). Factors behind poor functional recovery include tension of the anastomosis, neuroma formation, scarring, and loss of the nerve fiber population (Green, Berke, & Graves, 1991). Studies have shown that in EEA, fewer nerve fibers could pass through the coaptation site and reach the target muscle (Myckatyn & Mackinnon, 2004). When a tension-free EEA is not technically possible, end-to-side neurorrhaphy is an alternative to repair an injured nerve when the proximal nerve stump is unavailable (Al-Qattan, 2001). The distal stump of an injured nerve is sutured to the side of an intact donor nerve. However, this procedure induces less axon regeneration and functional recovery compared to EEA (De Sa, Mazzer, Barbieri, & Barreira, 2004; Sanapanich, Morrison, & Messina, 2002).

A significant nerve defect is a common clinical situation. At present, autologous nerve grafts, nerve transfers, and tubulization techniques with natural or artificial conduits are used for nerve-gap repair. Unfortunately, nerve grafting has been associated with poor functional outcomes when there is a long distance from the level of the injury to the target muscle. The recovery rate of motor function after autogenous nerve grafting is <40% (Moneim & Omer, 1998). Tubulization techniques are feasible only in short nerve gaps. If the gap exceeds 1.0–1.5 cm, regeneration is poor. Longer defects (4.0–6.0 cm) result in useful reinnervation in only 13% of cases with reconstruction of upper extremity PNs with conduits (Merle, Dellen, Campbell, & Chang, 1989; Stanec & Stanec, 1998). For the PNs in which the proximal nerve stump is unavailable, nerve transfer is an option. Nerve transfer is the surgical coaptation of a healthy nerve donor to a denervated nerve. A nerve branch that innervates expendable muscles can be used to repair a functionally more important distal stump of an injured nerve. Many nerve-to-nerve transfers have been employed to repair the injured nerves in the hand and upper extremity with mixed results (Lee & Wolfe, 2012). In some cases, nerve repair or nerve-grafting procedures are inapplicable because of the lack of a nerve stump. In this situation, direct nerve implantation or muscular neurotization may be used (Brunelli & Brunelli, 1980, 1993). In neurotization, the proximal stump of the original nerve or a healthy but less valuable foreign motor nerve is implanted into the target muscle to reinnervate a more important motor territory that has lost its innervation through irreparable damage to its nerve.

More recently, we have developed a new reinnervation technique called "nerve-muscle-endplate band grafting (NMEG)" (Mu, Sobotka, & Su, 2011). The development of the NMEG procedure for muscle reinnervation is based on the idea that a paralyzed muscle could be reinnervated by transferring a NMEG from a neighboring donor muscle. A healthy endplate band with a nerve branch and terminals that innervates an expendable muscle can be transplanted to a more functionally important denervated muscle for restoring its motor function. Over the past years, we have studied the NMEG technique by determining innervation patterns (Mu et al., 2011; Zhang, Mu, Su, & Sobotka, 2011) and contractile properties of the rat recipient and donor muscles (Sobotka & Mu, 2010), and conducted surgical feasibility studies and a series of reinnervation experiments using the NMEG technique and conventional EEA in a rat model (Mu et al., 2011; Sobotka & Mu, 2011, 2013a,b, 2015). Several lines of evidence from a number of quantitative analyses demonstrated that the NMEG procedure results in encouraging functional recovery (67% of the control) (Mu et al., 2011). However, entire muscle reinnervation and complete functional recovery was not achieved. We found that approximately one-third of the distal myofibers in the target muscle were not reinnervated 3 months after surgery (Mu et al., 2011; Sobotka & Mu, 2015). These findings suggest that partial muscle reinnervation accounts for incomplete functional recovery. We assumed that implantation site of the NMEG would be a critical factor influencing outcomes. In our previous studies, a NMEG was implanted into an aneural region in the recipient muscle. In this case, regenerating axons from the NMEG pedicle may need more time to reach the most distal muscle fibers and form new motor endplates (MEPs).

The purpose of this study was to test our hypothesis that optimal outcomes may be achieved by implanting the NMEG into the NMZ in the target muscle, as such a procedure (NMEG-NMZ) could reduce nerve regeneration distances and facilitate rapid MEP reinnervation. At 3 months after surgery, maximal tetanic force measurement, muscle mass and myofiber morphology, motoneurons, regenerated axons, and axon-endplate connections of the reinnervated muscles were analyzed and compared with those of the contralateral controls.

## 2 | MATERIALS AND METHODS

### 2.1 | Animals

Thirty-two adult female Sprague-Dawley rats (Taconic Laboratories, Cranbury, NJ, USA), weighing 200–250 g, were used. The animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee. All animals were handled in accordance with the Guide for Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85–23, revised 1996). The animals were kept in a 22°C environment in a 12:12-hour light–dark cycle, with food and water ad libitum. The rats were individually housed in standard cages in the state-of-the-art animal housing facilities of Hackensack University Medical Center.

### 2.2 | Surgical procedures

Thirty-two rats were randomly distributed into reinnervation (n = 15) and denervation (n = 17) groups. In this study, SH and SM muscles
were chosen to serve as a donor and recipient, respectively, because they were used in our previous studies (Mu et al., 2011; Sobotka & Mu, 2010, 2013b, 2015). On the day of the experiment, the rats were anesthetized via an intraperitoneal injection of a ketamine (80 mg/kg) and xylazine (5 mg/kg) mixture. With the rat supine, a midline cervical incision was made extending from the hyoid bone to the sternum to expose the right SM and SH muscles and their innervating nerves.

All the rats in both groups underwent denervation of the right SM muscle. With the aid of an Olympus SZX12 Stereo zoom surgical microscope (Olympus America Inc., Center Valley, PA, USA), the right SM muscle was denervated by resecting a 5-mm segment of its innervating nerve and the cut ends of the nerve were then coagulated with a bipolar cautery to prevent nerve regeneration.

Immediately after muscle denervation, the rats in reinnervation group were subjected to NMEG-NMZ transplantation. First, the NMZs in the right SM and SH muscles were outlined according to the motor point (the entry point of the motor branch into the muscle) (Figure 1a and b). The NMZ of either SM or SH in the rat is located in the middle segment of the muscle that contains intramuscular nerve terminals and a MEP band as demonstrated by our previous studies (Mu

![Images showing the locations of native motor zones (NMZ) of the recipient sternomastoid (SM) and donor sternohyoid (SH) muscles of the rat and surgical procedures for NMEG-NMZ transplantation.](attachment:image)

**Figure 1** Images showing the locations of native motor zones (NMZ) of the recipient sternomastoid (SM) and donor sternohyoid (SH) muscles of the rat and surgical procedures for NMEG-NMZ transplantation. (a) Stained and fresh right SM showing the NMZ of the muscle (outlined region). SM nerve (arrowhead) and its intramuscular nerve terminals were mapped out with Shiner’s stain (left image), whereas the motor endplate (MEP) band (arrow in the middle image) was visualized with whole mount acetylcholinesterase (AChE) staining. A fresh SM (right image) illustrated the NMZ outlined during surgery (between fiber cuts on the surface of the muscle as indicated by arrows and bracket). (b) Stained and fresh right SH showing that the NMZ of the SH is also located in the middle of the muscle. (c) A photograph from a rat during surgery, showing surgically outlined NMZ in the recipient SM (between fiber cuts as indicated by arrows) and in the donor SH (boxed region). The arrowhead indicates the SM nerve. The dashed line indicates the midline between both SH muscles. H = hyoid bone; L = left; R = right; S = sternum. (d) A NMEG pedicle was harvested from the NMZ of the right SM and a muscular defect (between arrows) was made on the SM muscle. (e) The NMEG was implanted into the recipient bed and sutured (green arrows). The SH nerve branch (large black arrow) and its accompanying blood vessels (small black arrow) can be seen on the implanted NMEG. (f) Schematic illustrations summarize the surgical procedures by localizing the NMZs of the SM (F1) and SH (F2), denervating the SM and creating a muscular defect in the NMZ of the muscle (F3), and suturing the NMEG pedicle (F4) harvested from the SH (F5).
et al., 2011; Zhang et al., 2011). Second, a muscular defect (recipient bed) with the same dimensions as the NMEG pedicle was made in the NMZ of the right denervated SM muscle (Figure 1c and d). Third, a NMEG pedicle was harvested from the NMZ of the right SH donor muscle as described in our previous publication (Mu et al., 2011). Briefly, the SH nerve branch was identified on the lateral margin of the NMZ of the muscle. A NMEG pedicle containing a block of muscle (~6 × 6 × 3 mm), axon terminals, and a MEP band with numerous neuromuscular junctions was outlined and harvested from the SH muscle in continuity with its pedicle of motor nerve branch and feeding vessels (Figure 1e). A functioning NMEG was confirmed by observing its twitch contractions on nerve stimulation. Fourth, the superficial muscle fibers on the ventral aspect of the NMEG pedicle were removed to create a denuded surface for better neural regeneration. Finally, the well-prepared NMEG was embedded in the SM muscle defect and sutured with four to six 10-0 nylon microsutures (Figure 1e). Thus, the denervated SM muscle was reinnervated with NMEG-NMZ technique. Figure 1f summarizes the surgical procedures for NMEG-NMZ implantation. After surgery, the wound was closed in layers with interrupted simple sutures of 4-0 prolene.

2.3 | Postoperative evaluations

At the end of the 3-month recovery period, outcomes of the NMEG-NMZ technique were evaluated functionally and histochemically. The removed SM muscles from the rats in the reinnervation and denervation groups were analyzed using histological and immunohistochemical methods.

2.3.1 | Determining the degree of functional recovery

Maximal tetanic force measurement was used to evaluate the functionality of the NMEG-NMZ reinnervated muscles. The force was measured on the experimental and the contralateral control side and expressed in percentage of the control side. Muscle force measurement is a useful approach to assess the mechanical function and contractile properties of a muscle (van der Meulen, Urbanchek, Cederna, Eguchi, & Kuzon, 2003; Yoshimura et al., 2002). Our studies (Mu et al., 2011; Sobotka & Mu, 2011, 2013a,b, 2015) and others’ (Goding, Cummings, & Bright, 1989; Marie et al., 1999; Meikle, Trachy, & Cummings, 1987) used force measurement to detect the degree of functional recovery of the reinnervated cervical strap muscles. The details regarding the force measurement of the rat SM muscle have been given in our publications (Mu et al., 2011; Sobotka & Mu, 2010, 2011, 2013a,b, 2015). Briefly, the right reinnervated and the left control SM muscles in each animal were exposed and dissected free from the surrounding tissues. The rostral tendon of each muscle was severed close to the insertion, tied with a 2-0 suture, and attached to a servomotor lever arm (model 305B Dual-Mode Lever Arm System; Aurora Scientific Inc, Aurora, Ontario, Canada). Muscle force of the right reinnervated SM was measured by stimulating the SH nerve branch supplying the NMEG, whereas that of the left control muscle was measured by stimulating the intact SM nerve. Each of the nerves was identified, isolated, and draped over a bipolar stimulating electrode for nerve stimulation. Trains of biphasic rectangular pulses of different current were delivered to the stimulated nerve using our stimulation and recording system that is built based on a multifunctional National Instruments Acquisition Board (National Instruments Corp, Austin, TX, USA) and is controlled by user-written LabVIEW software (National Instruments Corp).

Isometric contraction of the SM muscle was produced with 200-millisecond trains of biphasic rectangular pulses. The duration of each phase of stimulation pulse was set at 0.2 milliseconds and the train frequency was set at 200 pulses per second. The stimulation current was gradually increased until the tetanic force reached a plateau. A break of at least 1 min was taken between two stimulations. The maximum value of muscle force during the 200-millisecond contraction was identified, as well as initial passive tension before stimulation. The difference between the maximal active force and the preload passive force was used as the muscle force measurement. The force generated by the contraction of the SM muscle was transduced with the servomotor of a 305B lever system and displayed on a computer screen. At the moment of force measurement, the lever arm was stationary, and the muscle was adjusted to the optimal length for the development of maximum force. During the experiment, the animal was placed supine on a heating pad (homeothermic blanket system; Stoelting, Wood Dale, IL, USA). The core body temperature was monitored with a rectal thermistor and maintained at 36°C. The muscle and nerve examined were bathed regularly with warmed mineral oil throughout the testing to maintain muscle temperature between 35°C and 36°C.

The force data were obtained and processed by an acquisition system built from a multifunction I/O National Instruments Acquisition Board (NI USB 6251; 16 bit, 1.25 Ms/s; National Instruments) connected to a Dell laptop with a custom-written program using LabVIEW 8.2 software. The system produced stimulation pulses, which, after isolation from the ground through an optical isolation unit (Analog Stimulus Isolator model 2200; AM Systems, Inc, Carlsborg, Washington, DC, USA), were used for the current controlled nerve stimulation. The acquisition system was also used to control muscle length and to collect a muscle force signal from the 305B Dual-Mode Lever System. Collected data were analyzed offline with DIAdem 11.0 software (National Instruments).

2.3.2 | Tracking the origin of the axons in the SM muscles reinnervated with NMEG-NMZ technique

Immediately after tetanic tension measurements, five experimental animals were subjected to retrograde horseradish peroxidase (HRP) neuronal labeling to track the origin of the axons innervating the reinnervated SM muscles. As the NMEG was harvested from the right SH muscle and transplanted into the denervated right SM muscle, the HRP injected into the right SM should label SH motoneurons if muscle reinnervation was successful. The details regarding HRP labeling have been given in our previous publications (Mu et al., 2011;
Zhang et al., 2011). Briefly, 30% HRP (type VI A; Sigma Chemical, St. Louis, MO, USA) solution was injected at two points (5 μl per point) into the MEP band in the right reinnervated SM and the left SH (control) with Hamilton microsyringe. After a survival time of 48 h, the animals were deeply anesthetized with sodium pentobarbital (60 mg/kg intraperitoneally) and perfused transcardially with 200 ml of a fixative solution containing 1% paraformaldehyde, 1.25% glutaraldehyde, and 3% dextrose in 0.1 mol/L phosphate buffer at pH 7.4 and 4°C. After perfusion, the fixed lower medulla oblongata and cervical spinal cord (C1-C4) were dissected out, postfixed 4 hr at 4°C in the same fixative, and then stored in graded concentrations (10% and 25%) of phosphate-buffered sucrose solution at pH 7.4 and 4°C for 2 hr and overnight, respectively. The fixed medulla and upper cervical spinal cord were frozen and sectioned at 40 μm on a cryostat in the transverse plane. The sections were reacted for 20 min in the dark with 3,3’,5,5’-tetramethylbenzidine as the chromogen to develop the HRP reaction product. The processed sections were mounted on gelatin-coated slides and counterstained with 1% aqueous neutral red (pH 4.8).

The stained serial sections were examined under a Zeiss photomicroscope (Axiohot-2; Carl Zeiss, Goettingen, Germany) and photographed with a digital camera (Spot-32; Diagnostic Instruments, Keene, NH, USA) attached to the photomicroscope. The distributions of the SM and SH motoneurons in the medulla oblongata and spinal cord were recorded to see if the right-treated SM was controlled by SH motoneurons.

2.3.3 Examining muscle mass, implanted NMEG, and myofiber morphology

At the end of the experiments, SM muscles on both sides in each animal were removed, weighed, and photographed. A muscle mass ratio was calculated (muscle mass ratio = weight of reinnervated muscle/weight of contralateral muscle). Five NMEG-NMZ reinnervated right SM muscles were processed with Sihler’s stain, a whole mount nerve mapping technique to see if the NMEG was precisely implanted into the NMZ of the target muscle. The details regarding Sihler’s stain have been given in our previous publication (Mu et al., 2010). Briefly, the removed muscles were fixed for 3 weeks in 10% unneutralized formalin; macerated for 2 weeks in 3% aqueous potassium hydroxide (KOH) solution; decalcified for 1 week in Sihler solution I (one volume glacial acetic acid, one volume glycerin, and six volumes 1% w/v aqueous chloral hydrate); stained for 3 weeks in Sihler solution II (one volume stock Ehrlich’s hematoxylin, one volume glycerin, and six volumes 1% w/v aqueous chloral hydrate); destained for 3 hr in Sihler solution I; immersed for 1 hr in 0.05% w/v lithium carbonate solution to darken the nerves; cleared for 3 days in 50% v/v aqueous glycerin; and preserved for 4 weeks in 100% glycerin with a few thymol crystals for transparency. After transillumination by a xenon light source (model 610; Karl Storz, Endoscopy-America, Culver City, CA, USA), the stained muscles were dissected and photographed.

The removed SM muscles (n = 30) from 10 rats with NMEG-NMZ reinnervation and five rats with denervation were sectioned and stained using histological and immunohistochemical techniques. Each SM muscle was divided into three segments: rostral, middle, and caudal. The muscle segments were frozen in melting isopentane cooled with dry ice and cut on a cryostat (Reichert-Jung 1800; Mannheim, Germany) at −25°C. The rostral and caudal segments were cut transversely and serial cross sections (10 μm) were stained with routine hematoxylin and eosin (H&E) staining to examine the effects of NMEG-NMZ reinnervation or denervation on the muscle mass and myofiber morphology. In contrast, the middle muscle segment containing the NMZ and/or NMEG was cut sagittally (60 μm) and sections were stained using immunohistochemical methods to detect axons and MEPs as described below.

2.3.4 Documenting nerve regeneration and MEP reinnervation

Immunohistochemical staining for neurofilament (NF)

Some sagittal sections were immunostained with a monoclonal antibody against phosphorylated NF (SMI-31; Covance Research Products, Berkeley, CA, USA) as a marker for all axons as described in our previous publication (Mu et al., 2015). Briefly, the sections were:

1. treated in PBS containing 0.3% Triton and 2% BSA for 30 min;
2. incubated with primary antibody SMI-31 (dilution 1:800) in PBS containing 0.03% Triton at 4°C overnight;
3. incubated for 2 hr with the biotinylated secondary antibody (anti-mouse, 1:1000; Vector, Burlingame, CA, USA);
4. treated with avidin-biotin complex method with a Vectastain ABC kit (1:1000 ABC Elite; Vector); and
5. treated with diamobenzidine-nickel as chromogen to visualize peroxidase labeling. Control sections were stained as described except that the incubation with the primary antibody was omitted.

The muscle sections immunostained for NF permit to show how the regenerating axons from the implanted NMEG reinnervate the denervated SM and quantify the density and spatial distribution of the regenerating axons in the target muscle. The extent of axonal regeneration and muscle reinnervation was evaluated by quantifying the NF-immunoreactive (NF-ir) axons within the treated muscles as described in our previous publications (Sobotka & Mu, 2013a, 2015). The intramuscular axonal density was assessed by estimating the number of the NF-ir axons and the area fraction of the axons within a section area (1.0-mm²). For a given muscle, three sections stained for NF were selected at different spatial levels to count NF-ir axons. For each section, five microscopic fields with NF-ir axons were identified and photographed in an order from ventral to dorsal aspect of the muscle. Areas with NF-positive stained were outlined, measured with public domain ImageJ software (v. 1.45s; NIH, Bethesda, Maryland). For each rat, the number and the area fraction of the NF-ir axons in the operated muscle were compared with those in the contralateral control.

Double fluorescence staining

Double fluorescence staining was used to label axons and MEPS as described (Grumbles, Sesodia, Wood, & Thomas, 2009) with some modifications. Briefly, some sagittal muscle sections were:

1. dried and then placed in Zamboni fixative with 5% sucrose for 20 min at
4°C; (2) washed several times with 1.5-T buffer with 0.05% Tween-20 and treated with 0.1 mol/L of glycine in 1.5-T buffer for 30 min, and dipped in 100% methanol at ~20°C; (3) blocked in 1.5-T buffer containing 4% normal goat serum for 30 min to inhibit nonspecific protein binding; (4) incubated overnight at 4°C with primary antibodies (SM-31 to detect neurofilaments and SM-81 to label thinner axons; Covance Research Products Inc); (5) washed in 1.5-T buffer with 0.05% Tween-20 and incubated at room temperature for 2 hr both with a secondary antibody (goat anti-mouse antibody conjugated to Alexa 488) and with a-bungarotoxin conjugated with Alexa 596 (Invitrogen Corporation, Carlsbad, CA, USA); and (6) washed in 1.5-T buffer with 0.05% Tween-20 and coverslipped.

The stained sections were viewed under a Zeiss fluorescence microscope and photographed. SM-31 and SM-81 detected axons (green), while a-bungarotoxin labeled postsynaptic acetylcholine receptor (ACHR) site in the MEPs (red). For each muscle sample, at least 100 labeled MEPs were randomly selected from three stained sections at different spatial levels through the muscle to determine the percentages of the innervated (visible axon attachment) and noninnervated (no visible axon attachment) MEPs.

2.4 Data analysis

Wet muscle weights, force values, the number and area fraction of NF-ir axons, and innervated and noninnervated MEPs of the SM muscles in each rat were computed. The variables of the reinnervated SM muscles were expressed as the percentages of the values of the contralateral control muscles. All data were reported as mean ± SD. The Student t-test (paired, two tailed) was used to compare differences in the mean muscle force, mean muscle weight, and mean number and area fraction of NF-ir axons between operated and unoperated SM muscles. A difference was considered statistically significant at p < 0.05.

3 RESULTS

3.1 Maximal tetanic muscle force

Maximum tetanic tension in the NMEG-NMZ reinnervated SM and the contralateral control muscles were evaluated at the end of the 3-month recovery period. The averaged force values for the treated and control muscles are summarized in Figure 2. For each rat, the percentage of functional recovery of the SM muscle reinnervated with NMEG-NMZ technique was determined as compared with that of the contralateral control muscle. Our previous studies have demonstrated that optimal muscle length could be achieved by stretching the muscle with moderate tension of 0.08 N (Mu et al., 2011; Sobotka & Mu, 2010). Electric stimulation of the nerve branch innervating the NMEG at low intensity (0.02–0.03 mA) produced visible muscle contraction. A lower (0.0075–0.01 mA) stimulation threshold was obtained when the nerve innervating the left intact SM muscle was stimulated. An increase in the stimulation current resulted in an increase in muscle force until it reached horizontal asymptote. During nerve stimulation on the operated side, this saturation level was reached with 0.2 mA. The saturation level was reached at smaller current (0.1 mA) on the control side. The reinnervated SM showed an average maximum tetanic force of 0.87 ± 0.23 N (control, 1.06 ± 0.10 N; p < 0.005). Therefore, the reinnervated SM muscles produced 82% of the maximal tetanic tension of the contralateral control muscles.

3.2 HRP-labeled motoneurons innervating NMEG-NMZ reinnervated SM muscle

The location of HRP-labeled motoneurons on the operated side could demonstrate the source of innervation of the NMEG-NMZ reinnervated muscle. As reported in our previous studies, the SM motoneurons were concentrated in the lower medulla oblongata and spinal ventral grey horn in the C1 to C2 (Mu et al., 2011; Zhang et al., 2011). The SM motoneurons in C1 were concentrated mainly in the dorsomedial region, whereas the SH motoneurons at this level were located in the ventromedial region of the ventral horn (Mu et al., 2011). In this study, HRP injections into the right reinnervated SM muscle labeled motoneurons in the ventromedial region of the ventral horn in the C1 to C2, which were consistent with those labeled by HRP injections into the left intact SH muscle (Figure 3). These findings indicate
**FIGURE 3** Motoneurons labeled with retrograde horseradish peroxidase (HRP) neuronal tracing in rats. (a) A transverse section from upper cervical spinal cord segment C1 in a normal adult rat, showing different locations of the sternomastoid (SM) and sternohyoid (SH) motoneurons. The HRP solution was injected into the right (R) SM and left (L) SH muscles. Note that in C1, the SH motoneurons were confined to the ventromedial (VM) region, whereas SM motoneurons were located in the dorsomedial (DM) region of the ventral horn of the spinal cord. (b) A transverse section from C1 after HRP injections into the right reinnervated SM muscle and the left intact SH muscle in a rat. Note that the motoneurons controlling the right reinnervated SM were located in the same region as that innervating the SH (VM in C1). Bar = 100 μm.

**FIGURE 4** Images from the reinnervated, normal control, and denervated SM muscles showing gross appearance, muscle mass, myofiber morphology, and NMEG implantation site. (a) A pair of SM muscles removed from a rat 3 months after NMEG-NMZ surgery. Note that the mass of the right (R) reinnervated SM muscle was close to that of the left (L) control muscle. The boxed region in the right SM is the location of the implanted NMEG. (b) A SM muscle denervated by resecting a 5-mm segment of its innervating nerve for 3 months. Note that the denervated SM showed a more significant loss of muscle mass as compared with the reinnervated and normal SM muscles. (c–d) Sihler’s stained SM muscles showing the difference in the NMEG implantation site between NMEG-NMZ technique (c) and our originally designed NMEG procedure (d). Note that the NMEG pedicle containing a SH nerve branch (blue arrow) and intramuscular nerve terminals was implanted into the NMZ (outlined region in c) of the SM in the middle portion of the muscle for NMEG-NMZ reinnervation. In contrast, the NMEG pedicle was implanted into the caudal MEP-free area of the target muscle in our originally designed NMEG procedure (d). Green arrow indicates a microsuture surrounding the implanted NMEG pedicle. The implanted NMEG contained a SH nerve branch (blue arrow) and nerve terminals. Black arrow in d indicates the SM nerve branch. (e–g) Hematoxylin and eosin-stained transverse sections of the SM muscles. Note that 3 months after surgery, NMEG-NMZ reinnervated SM (e) exhibited very good preservation of muscle structure and myofiber morphology with less fiber atrophy as compared with the normal (f) and denervated (g) muscles. Bar = 100 μm for e through g.
that the axons innervating the treated SM muscles were derived solely from the implanted SH nerve and controlled by the SH motoneurons. Retrograde HRP labeling also confirmed that the NMEG-NMZ microsurgery was successfully performed.

### 3.3 | Muscle weight, location of the implanted NMEG, and myofiber morphology

In each rat, gross appearance and size of the operated SM was similar to those of the contralateral control muscle (Figure 4a). The reinnervated SM muscles were greater in size than the SM muscles with complete denervation for 3 months (Figure 4b). The mean value and standard deviation of the wet weight was 0.332 ± 0.047 g for the reinnervated SM muscles, whereas 0.374 ± 0.044 g for the contralateral control muscles (Table 1). The differences in muscle weights of the reinnervated and control muscles were relatively small but consistent across all animals and therefore statistically significant (p < 0.0001). The reinnervated SM muscles weighed 89% of the weight of contralateral control muscles (Table 1). The mean percent of wet weight (89% of the control) of NMEG-NMZ reinnervated SM muscles was much higher than that of the denervated SM muscles (44% of the control; p < 0.0001).

The location of the implanted NMEG within the right SM muscle was determined. Sihler’s stain showed that microsurgery for NMEG-NMZ reinnervation was successfully performed as indicated by precise implantation of the NMEG into the NMZ of the target muscle (Figure 4c). Each of the implanted NMEG contained a SH nerve branch and numerous nerve terminals, indicating that the treated SM was reinnervated by the SH nerve. In our original NMEG procedure, however, the NMEG pedicle obtained from the ipsilateral SH muscle was implanted into the caudal endplate-free area in the SM muscle (Figure 4d).

### 3.4 | Axonal regeneration and MEP reinnervation

The muscle sections from NMEG-NMZ reinnervated SM processed with NF staining exhibited abundance of NF-ir axons. In the reinnervated SM, the regenerating axons from the implanted NMEG supplied the denervated NMZ and reached the most distal portion of the muscle, achieving almost full muscle reinnervation (Figure 4e) as compared with the contralateral control (Figure 4f) and denervated (Figure 4g) muscles.

### TABLE 1 | Wet muscle weight measurement for the right reinnervated and left control sternomastoid (SM) muscles in rats (n = 15)

<table>
<thead>
<tr>
<th>Animal no.</th>
<th>Body weight, g</th>
<th>Right SM, g</th>
<th>Left SM, g</th>
<th>Ratio R/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>333</td>
<td>0.309</td>
<td>0.333</td>
<td>0.928</td>
</tr>
<tr>
<td>2</td>
<td>328</td>
<td>0.332</td>
<td>0.397</td>
<td>0.836</td>
</tr>
<tr>
<td>3</td>
<td>319</td>
<td>0.318</td>
<td>0.357</td>
<td>0.891</td>
</tr>
<tr>
<td>4</td>
<td>285</td>
<td>0.287</td>
<td>0.328</td>
<td>0.875</td>
</tr>
<tr>
<td>5</td>
<td>386</td>
<td>0.245</td>
<td>0.316</td>
<td>0.775</td>
</tr>
<tr>
<td>6</td>
<td>373</td>
<td>0.373</td>
<td>0.407</td>
<td>0.916</td>
</tr>
<tr>
<td>7</td>
<td>281</td>
<td>0.320</td>
<td>0.343</td>
<td>0.933</td>
</tr>
<tr>
<td>8</td>
<td>330</td>
<td>0.396</td>
<td>0.437</td>
<td>0.906</td>
</tr>
<tr>
<td>9</td>
<td>329</td>
<td>0.305</td>
<td>0.327</td>
<td>0.933</td>
</tr>
<tr>
<td>10</td>
<td>355</td>
<td>0.335</td>
<td>0.358</td>
<td>0.936</td>
</tr>
<tr>
<td>11</td>
<td>380</td>
<td>0.341</td>
<td>0.392</td>
<td>0.870</td>
</tr>
<tr>
<td>12</td>
<td>304</td>
<td>0.326</td>
<td>0.338</td>
<td>0.964</td>
</tr>
<tr>
<td>13</td>
<td>358</td>
<td>0.433</td>
<td>0.462</td>
<td>0.937</td>
</tr>
<tr>
<td>14</td>
<td>315</td>
<td>0.373</td>
<td>0.410</td>
<td>0.910</td>
</tr>
<tr>
<td>15</td>
<td>328</td>
<td>0.290</td>
<td>0.398</td>
<td>0.729</td>
</tr>
<tr>
<td>Average</td>
<td>333.6</td>
<td>0.332</td>
<td>0.374</td>
<td>0.889</td>
</tr>
<tr>
<td>STDEV</td>
<td>31.8</td>
<td>0.047</td>
<td>0.044</td>
<td>0.065</td>
</tr>
</tbody>
</table>

L, left; R, right.
**FIGURE 5** Images of the immunostained sections of the NMEG-NMZ reinnervated and contralateral control SM muscles of a rat. (a–b) Images of sagittal sections of the right reinnervated (a) and left control (b) SM muscles. The sections were immunostained with antibody against neurofilament (NF) and photographed from ventral (top) to dorsal (bottom) surfaces of the muscle. Note that the nerve fascicles and axons (darker stained threads and dots) in the right NMEG-NMZ reinnervated SM are distributed throughout the thickness of the muscle. (a′–b′) The stained sections in a and b were opened using ImageJ software and converted to 8-bit (binary) images, color thresholded, and particle analyzed for nerve morphometry. The density of the axons was evaluated by estimating the number and area fraction of the NF-positive axons within a section area (1.0 mm²). For this rat, as compared with the left control SM (mean axon count: 398; mean area: 2.92) the right SM exhibited very good muscle reinnervation as indicated by the mean axon count (283; 71% of the control) and the mean area (2.32; 80% of the control). Bar = 100 µm for a through b. (c–e) Images of sagittal sections immunostained with double fluorescence staining of the right reinnervated SM muscle of a rat, showing axon-endplate connections. Regenerated axons (green) were detected with SMI-31 monoclonal against neurofilaments, while motor endplates (MEPs; red) were labeled with α-bungarotoxin. Note that the regenerated axons branched extensively into fields of MEPs in the NMZ of the target muscle (c). The majority of the MEPs in the treated muscle were reinnervated by regenerated axons (arrows in e), while some MEPs in the same muscle were unoccupied by regenerated axons (arrowheads in d and e). Bar = 100 µm for c through e.

**4 | DISCUSSION**

In this study, we have demonstrated that NMEG-NMZ technique resulted in optimal recovery of muscle force (82% of the control). The reinnervated muscles exhibited good preservation of muscle mass (89% of the control) and myofiber morphology. In the treated muscles, the mean count and area of the axons reached up to 76.8% and 75.6% of the controls, respectively, and the majority (80%) of the denervated MEPs regained motor innervation. The optimal outcomes are attributed to the unique advantages of the NMEG-NMZ technique.
Specifically, the regenerating axons from the NMEG could rapidly reinnervate the denervated MEPs in the target muscle and form functional synapses.

A transferred NMEG could provide an abundant source of nerve terminals and MEPs for nerve regeneration and muscle reinnervation. NMEG has sufficient pedicle-recipient muscle interfaces, which provide enough space for axonal regeneration. The axons could start to regenerate at multiple points in the implanted NMEG and grow across the pedicle-recipient muscle interfaces to reach the recipient muscle fibers. The NMEG-NMZ technique described here is based on the concept that denervated MEPs in the NMZ of the target muscle are preferential sites for reinnervation. One reason for the impaired target reinnervation could be degradation of MEPs during prolonged denervation. The NMEG-NMZ procedure physically shortens regeneration distances and facilitates rapid MEP reinnervation to avoid irreversible loss of the denervated MEPs in the target muscle. The importance of nerve regeneration onto the sites of the original MEPs is highlighted by various animal experiments. Recent studies (Ma et al., 2011) have shown that poor motor recovery after peripheral nerve injury resulted from a failure of synapse reformation because of the delay in motor axons reaching their target. Barbour, Yee, Kahn, and Mackinnon (2012) emphasized that “Functional motor recovery after peripheral nerve injury is predominantly determined by the time to motor endplate reinnervation and the absolute number of regenerated motor axons that reach target.” The MEP is a highly specialized structure, optimized for the rapid transmission of information from the presynaptic nerve terminal to the postsynaptic muscle fiber. It serves to efficiently communicate the electrical impulse from the motor neuron to the skeletal muscle to signal contraction. MEP regions of mammalian muscle fibers are preferentially reinnervated as a consequence of some special property of the muscle fiber at this site. Studies have demonstrated that after nerve injury regenerating axons preferentially form synapses at original synaptic sites (Bennett, McLachlan, & Taylor, 1973; Covault, Cunningham, & Sanes, 1987; Gorio, Carmignoto, Finesso, Polato, & Nunzi, 1983; Sanes, Marshall, & McMahan, 1978). As reported, 30 days after nerve transection, all the regenerating nerve fibers grew into and innervated the regions of the original MEPs (Iwayama, 1969). The MEPs may exert an attraction on the regenerating axons. Synaptic basal lamina at the MEP contains molecules that direct the formation of synaptic specializations on regenerating axon terminals and myofibers (McMahan & Wallace, 1989). Some other chemotropic substance released from the MEPs may attract the regenerating axons in the vicinity. Using direct nerve implantation model, some investigators observed preferential reinnervation of the native MEPs in the target muscle by abundant regenerating axons and sprouts (Guth & Zalewski, 1963; Sakellariades, Sorbie, & James, 1972).

NMEG-NMZ technique would have the potential for clinical application. It could be considered in selected clinical cases with extremity nerve injuries when no other repair options are possible. This method would be useful especially for treating laryngeal and facial paralysis. One of the most important problems involved in rehabilitation surgery of the recurrent laryngeal nerve (RLN) arises from the fact that this nerve carries fibers innervating antagonistic muscle groups (abductor and adductor muscles) which perform different functions during phonation, respiration, and swallowing. After RLN damage or nerve repair, some axons grow in a misdirected fashion. This leads to abductor axons innervating adductor muscles and vice versa, resulting in “synkinesis”, in which both opening (abductor) and closing (adductor) muscles activate in a dysfunctional way (Crumley, 2000). Synkinetic reinnervation is responsible for poor functional outcome as a result of simultaneous contraction of antagonistic muscles. To avoid synkinesis and functional failures, selective reinnervation of the glottis opener and of the glottis-closing musculature is commonly performed. Up to date, ansa cervicalis is a commonly used candidate as a potential donor.

<table>
<thead>
<tr>
<th>Animal no.</th>
<th>Right SM</th>
<th>Left SM</th>
<th>Ratio (R/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Count</td>
<td>%Area</td>
<td>Count</td>
</tr>
<tr>
<td>1</td>
<td>765</td>
<td>0.366</td>
<td>980</td>
</tr>
<tr>
<td>2</td>
<td>652</td>
<td>0.494</td>
<td>854</td>
</tr>
<tr>
<td>3</td>
<td>726</td>
<td>0.925</td>
<td>996</td>
</tr>
<tr>
<td>4</td>
<td>769</td>
<td>0.475</td>
<td>1004</td>
</tr>
<tr>
<td>5</td>
<td>494</td>
<td>0.305</td>
<td>708</td>
</tr>
<tr>
<td>6</td>
<td>822</td>
<td>0.303</td>
<td>1065</td>
</tr>
<tr>
<td>7</td>
<td>857</td>
<td>0.544</td>
<td>1091</td>
</tr>
<tr>
<td>8</td>
<td>583</td>
<td>0.264</td>
<td>696</td>
</tr>
<tr>
<td>9</td>
<td>576</td>
<td>0.601</td>
<td>854</td>
</tr>
<tr>
<td>10</td>
<td>904</td>
<td>0.773</td>
<td>1096</td>
</tr>
<tr>
<td>11</td>
<td>766</td>
<td>0.457</td>
<td>871</td>
</tr>
<tr>
<td>12</td>
<td>289</td>
<td>1.073</td>
<td>381</td>
</tr>
<tr>
<td>13</td>
<td>283</td>
<td>2.320</td>
<td>398</td>
</tr>
<tr>
<td>Average</td>
<td>653</td>
<td>0.685</td>
<td>846</td>
</tr>
</tbody>
</table>

L, left; R, right.

**TABLE 2** Quantitative comparison of count and %area of neurofilament-immunoreactive axons between right operated and left control sternomastoid (SM) muscles in rats (n = 13)
for selective reinnervation of the laryngeal adductor and abductor muscles (Crumley, 1991). The donor nerve can be directly implanted into a target muscle or prepared as a nerve-muscle pedicle (NMP) to reinnervate the paralyzed muscle (Tucker, 1989). The NMP method involves transferring a donor nerve branch with a small piece of muscle tissue (a 2- to 3-mm cube) from a cervical strap muscle to a paralyzed laryngeal muscle. Surgical methods for reanimation of the paralyzed face include cross-facial nerve graft, nerve transfers, and free muscle transplantation (Hoffman, 1992; Terzis & Konofaos, 2008). The NMP transfer or direct nerve implantation has been also used for the selective reinnervation of paralyzed facial muscles to avoid synkinesis (Goding et al., 1989; Hall, Trachy, & Cummings, 1988). Although some authors (Tucker, 1989) reported good results, others reported poor muscle reinnervation and functional recovery (Fata, Malmgren, Gacek, Dum, & Woo, 1987; Rice & Burstein, 1983) after NMP transfer. There are several factors leading to poor outcome. First, a NMP is designed at the point where a nerve branch enters the muscle without consideration of the MEPs and nerve terminals. Second, the pedicle is too small to contain donor nerve terminals and MEPs. Finally, the pedicle may contain only a nerve stump, serving as direct nerve implantation as both methods resulted in similar outcomes (Goding et al., 1989; Hall et al., 1988). The results from this study suggest that NMEG-NMZ technique could be an option for the treatment of laryngeal and facial paralysis.

Although our experiments showed the potential of NNMEG-NMZ in immediate muscle reinnervation, this study also has some limitations. For example, postoperative evaluations were performed at the end of 3 months after surgery. Three-month recovery period may be not enough to provide a complete picture of what occurs after NMEG-NMZ. Further studies are needed to determine morphological and functional alterations at different time points after NMEG-NMZ reinnervation. This information would be helpful for better understanding the time-related changes of muscle reinnervation and functional recovery. In addition, it remains unknown if the NMEG-NMZ has the potential for delayed reinnervation that is not uncommon in clinical practice. One of our ongoing studies is to determine the efficacy of NMEG-NMZ for chronic muscle denervation. For this purpose, it is important to know the decreasing rate of the endplates in the completely denervated muscle and to determine the time point when all the endplates cannot be detected.

In conclusion, this study showed that the NMZ of the target muscle is the best site in the target muscle for NMEG implantation. NMEG-NMZ procedure could shorten axon regeneration distances and facilitate rapid endplate reinnervation, thereby avoiding muscle atrophy and contributing to optimal functional recovery. Our results have demonstrated that NMEG-NMZ technique resulted in extensive axonal regeneration, MEP reinnervation, and optimal functional recovery. This method can be used for treatment of laryngeal and facial paralysis. Further technical improvements and studies to identify the NMZ in laryngeal musculature will be required before this technique can be applied in a clinically meaningful fashion. In addition, it could be one alternative to reinnervate other denervated muscles when no other repair options are possible. Although NMEG-NMZ technique has treatment potential in immediate muscle reinnervation, further work is warranted to determine its effectiveness for delayed muscle reinnervation.

ACKNOWLEDGMENTS

This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs under Award No. W81XWH-14-1-0442 (to Liancai Mu). The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. In conducting research using animals, the investigators adhere to the laws of the United States and regulations of the Department of Agriculture. This protocol was approved by the USAMRMC Animal Care and Use Review Office (ACURO) for the use of rats. The authors thank the anonymous reviewers for their constructive comments on the manuscript.

CONFLICT OF INTEREST

None declared.

REFERENCES


How to cite this article: Mu L, Sobotka S, Chen J, Nyirenda T. Reinnervation of denervated muscle by implantation of nerve-muscle-endplate band graft to the native motor zone of the target muscle. Brain Behav. 2017;7:e00668.
https://doi.org/10.1002/brb3.668
NERVE GROWTH FACTOR AND BASIC FIBROBLAST GROWTH FACTOR PROMOTE REINNERSVATION BY NERVE–MUSCLE–ENDPLATE GRAFTING

LIANCAl MU, MD, PhD, 1 STANISLAW SOBOTKA, PhD, 1,2 JINGMING CHEN, MD, 1 and THEMBA NYIRENDA, PhD 1

1 Department of Biomedical Research, Hackensack University Medical Center, 40 Prospect Avenue, Hackensack, New Jersey, 07601, USA
2 Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, New York, New York, USA

Accepted 17 June 2017

ABSTRACT: Introduction: This study was designed to test whether exogenous application of nerve growth factor (NGF) and basic fibroblast growth factor (FGF-2) to muscles reinnervated with nerve–muscle–endplate band grafting (NMEG) could promote specific outcomes. Methods: The right sternomastoid muscle in adult rats was experimentally denervated and immediately reinnervated by implanting an NMEG pedicle from the ipsilateral sternohyoid muscle. A fibrin sealant containing NGF and FGF-2 was focally applied to the implantation site. Maximal tetanic force, muscle weight, and number of regenerated axons, and motor endplates were analyzed 3 months after treatment. Results: Mean tetanic force, wet muscle weight, and number of regenerated axons in the treated muscles were 91%, 92%, and 84% of the contralateral controls, respectively. The majority of endplates (86%) in the treated muscles were reinnervated by regenerated axons. Conclusion: Focal administration of NGF and FGF-2 promotes efficacy of the NMEG technique.

Muscle Nerve 000:000–000, 2017

Peripheral nerve injury (PNI) may cause muscle paralysis, which is commonly treated by nerve repair, nerve grafting, nerve transfer, direct nerve implantation, and various other techniques. 1–5 Despite advances in microsurgical techniques for nerve reconstruction, functional recovery is rarely complete. Considerable evidence has shown that functional motor recovery after PNI and nerve repair is determined predominantly by the absolute number of regenerated motor axons that reach the target and the time to motor endplate (MEP) reinnervation. 6–8 Efforts have been made to improve functional recovery after PNI and repair by improvement of surgical techniques and by creating an optimal microenvironment for nerve regeneration. To facilitate MEP reinnervation to treat PNI-induced muscle paralysis, we developed a surgical method called “nerve–muscle–endplate band grafting” (NMEG) for muscle reinnervation in a rat model. 9 The NMEG reinnervation technique is based on the concept that a paralyzed muscle can be reinnervated by transplanting an NMEG from a neighboring donor muscle. A healthy nerve branch and terminals that innervate a non-essential muscle can be transplanted to a more functionally important denervated muscle for restoring its motor function. Of course, reprogramming of the motor neurons in the central nervous system is necessary to restore normal function of the reinnervated muscle. The departure here from more conventional nerve implantation 10 is that tissue containing motor nerve terminals, rather than the nerve itself, is implanted. In our animal model, an NMEG pedicle containing a nerve branch and a muscle block with nerve terminals and MEPs was harvested from the sternohyoid (SH) muscle and transplanted into the ipsilateral experimentally denervated sternomastoid (SM) muscle. Our studies have demonstrated the importance of MEP reinnervation in motor recovery of the target muscle. Specifically, 3 months after implantation of the NMEG into an MEP-free area, the mean contractile force of the treated muscles was 67% of the controls. 9 In contrast, implantation of the NMEG into the native motor zone (NMZ) of the target muscle yielded better functional recovery (82%). 11 We hypothesized that the outcomes of NMEG–NMZ would be promoted by local application of neurotrophic factors to the implanted NMEG and NMZ of the target muscle to increase the rate of nerve regeneration and axon–MEP connections. Exogenous application of neurotrophic factors, including nerve growth factor (NGF) and basic fibroblast growth factor (FGF-2), has been used locally in nerve reconstructive procedures such as nerve repair 12–14 and tubulization. 15,16 Studies have shown that use of NGF and FGF-2 improves axonal regeneration and functional recovery after PNI and nerve repair. 15,17–21 As reported, administration of NGF enhances nerve regeneration and motor recovery. 13,14,22–26 FGF-2 is a potent factor

Abbreviations: AChR, acetylcholine receptor; BSA, bovine serum albumin; FGF-2, basic fibroblast growth factor; H&E, hematoxylin & eosin; MEP, motor endplate; NF, neurofilament; NF-ir, neurofilament-immunoreactive; NGF, nerve growth factor; NMEG, nerve–muscle–endplate band grafting; NMZ, native motor zone; NMEG-NMZ, nerve–muscle–endplate band grafting-native motor zone; PBS, phosphate-buffered saline; PNI, peripheral nerve injury; SH, sternohyoid muscle; SM, sternomastoid muscle

Key words: basic fibroblast growth factor; muscle reinnervation; native motor zone; nerve growth factor; nerve–muscle–endplate band grafting

Funding: Office of the Assistant Secretary of Defense for Health Affairs (W81XWH-14-1-0442 to L.M.).

Disclaimer: Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense.

Correspondence to: L. Mu; e-mail: liancai.mu@hackensackmeridian.org

© 2017 Wiley Periodicals, Inc.

Published online 00 Month 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/mus.25726

NGF and FGF-2 Promote Reinnervation
that promotes axonal growth,\textsuperscript{16,17,29–31} increases the number of proliferating Schwann cells and regenerating axons\textsuperscript{17,32} and MEPs,\textsuperscript{33} and enhances functional recovery.\textsuperscript{33} The neurotrophic factors can be administered locally by direct injection into the target nerve\textsuperscript{34} or muscle\textsuperscript{35} or by using a surgically implanted osmotic pump for growth factor delivery.\textsuperscript{35–37} according to nerve injury and repair models. Recently, local application of a fibrin sealant containing neurotrophic factors has been extensively used in PNI and repair models for the slow continual release of factors directly to the damaged and/or repaired nerve for accelerating axonal regeneration and subsequent functional recovery.\textsuperscript{15,28,38–41} Some investigators\textsuperscript{13,40} have used an enzyme-linked immunosorption assay to quantify in vitro the release characteristics of the exogenous neurotrophic factors in fibrin, and demonstrated a sustained release. The factors could be released locally in vitro over periods of 2 weeks\textsuperscript{13,40} or 4 weeks.\textsuperscript{40} Experimental studies suggested that the fibrin-based drug-delivery system for neurotrophic factor release could be a promising strategy for improving axonal regeneration and functional restoration.

The goal of this study was to investigate the effect of focal administration of fibrin sealant containing exogenous NGF and FGF-2 on outcomes of our NMEG–NMZ reinnervation technique.

**METHODS**

**Animals.** Twenty-two 3-month-old female Sprague-Dawley rats (Taconic Laboratories, Cranbury, New Jersey), weighing 200–250 g, were used in this study. The proposed experiments were reviewed and approved by the institutional animal care and use committee and by the USAMRMC Animal Care and Use Review Office. All animals were handled in accordance with the *Guide for Care and Use of Laboratory Animals*, published by the National Institutes of Health (NIH Publication No. 85-23, revised 1996), and complied with the laws of the United States and regulations of the Department of Agriculture. The rats were maintained in a 22°C environment with a 12/12-hour light–dark cycle with free access to food and water.

**Surgical Procedures and Focal Administration of Exogenous Neurotrophic Factors.** Twenty-two rats were randomly assigned into reinnervation (n = 15) and denervation (n = 7) groups. Both groups of animals were anesthetized by an intraperitoneal injection of a mixture of ketamine (80 mg/kg) and xylazine (5 mg/kg). Under an operating microscope, the right SM muscle was denervated by resecting a 5-mm segment of its innervating nerve.

Immediately after muscle denervation, the rats in the reinnervation group underwent NMEG–NMZ surgery and neurotrophic factor therapy. The details regarding NMEG–NMZ transplantation have been described previously.\textsuperscript{11} First, the NMZs in the right SM and SH muscles were outlined according to the motor point and location of intramuscular nerve terminals and MEP band (Fig. 1A–H). Second, an NMEG pedicle was obtained from the NMZ of the right SH donor muscle. The pedicle contained a block of muscle (~6 × 6 × 5 mm), axon terminals, and an MEP band. The superficial muscle fibers on the ventral aspect of the NMEG pedicle were removed to create a denuded surface for better axonal regeneration (Fig. 1I). Third, a muscular defect, with the same dimensions as the NMEG pedicle, was made in the NMZ of the right denervated SM muscle (Fig. 1I). Fourth, a fibrin sealant (fibrinogen 90 mg/ml, thrombin 500 IU/ml, 4 mmol/L CaCl\textsubscript{2}; Baxter Healthcare Corp., Westlake Village, California), containing NGF and FGF-2, was applied locally to the SM muscle defect as combinations of neurotrophic factors yield better results than a single factor alone.\textsuperscript{35,42–44} Specifically, the target SM received a single focal administration of a mixture of exogenous NGF and FGF-2. The muscular defect was covered with 0.2 ml of fibrin sealant containing recombinant rat NGF and rat FGF-2 (R&D Systems, Minneapolis, Minnesota) at a concentration of 100 ng/ml for NGF and 100 μg/ml for FGF-2. As reported, intramuscular injections of both neurotrophic factors at these concentrations resulted in better functional recovery.\textsuperscript{35} Finally, the NMEG was implanted into the SM muscle defect and sutured with 4–0 10-0 nylon microsutures (Fig. 1J). After surgery, the wound was closed.

Three months after the experiments, the animals underwent postoperative outcome measurements that included functional evaluation and neuromuscular analyses. For each animal, all assessments were performed from both SM muscles, with the contralateral SM serving as a control.

**Nerve Stimulation and Force Measurement.** The degree of functional recovery of the treated muscles was assessed by measuring the maximal tetanic force, as described in our previous publications.\textsuperscript{9,11,45–49} Briefly, the right treated and the left control SM muscles in each animal were exposed and dissected free from the surrounding tissues. The rostral tendon of each muscle was then divided at its insertion, tied with a 2-0 suture, and attached to a servomotor lever arm (Model 305B Dual-Mode Lever Arm System; Aurora Scientific, Inc., Aurora, Ontario, Canada). At the moment of force measurement, the lever arm was stationary, and the muscle was adjusted to the optimal length by stretching the muscle with moderate tension of 0.08 N for the development of maximum force.\textsuperscript{9,45} Muscle force of the right treated SM was measured by stimulating the SH nerve branch supplying the NMEG, whereas that of the left control muscle was measured by stimulating the intact SM nerve. Each of the nerves was isolated and draped over a bipolar stimulating electrode for nerve stimulation. Trains of biphasic rectangular pulses of different current were delivered to the stimulated nerve using our stimulation and recording system, which is based on the multifunction acquisition board (National Instruments Corp., Austin, Texas) and controlled by user-written LabVIEW software (National Instruments). Isometric contraction of the SM muscle was produced with 200-ms trains of biphasic rectangular pulses. Stimuli were single pulses of 0.2-ms duration and the train frequency was set at 200 pulses/s. The stimulation current was gradually increased until the tetanic force reached a plateau. A break of at least 1 minute was taken between 2 stimulations. The maximum value of muscle force during the 200-ms contraction was identified, as well as initial passive tension before stimulation. The difference between the maximal active force and the preloaded passive force was used as the muscle force measurement. The force generated by the contraction of the SM muscle was
transduced with the servomotor of a 305B lever system and displayed on a computer screen. During the experiment, body temperature was maintained at 36°C by an electric heating pad thermostatically controlled from a rectal thermistor. The muscle and nerve examined were bathed regularly with warmed mineral oil throughout the testing.

The force data were obtained and processed by an acquisition system built from a multifunction I/O.

**FIGURE 1.** Native motor zone (NMZ) within the sternomastoid (SM) and sternohyoid (SH) muscles of rats and surgical procedures for nerve–muscle–endplate band grafting (NMEG). (A–D) NMZ of the right SM, as outlined during surgery [between arrows in (A)], in removed fresh muscle [between arrows in (B)], and in muscles processed with Sihler stain (C) and acetylcholinesterase stain (D). Note that a single motor nerve branch [arrowheads in (A)–(C)] enters into the middle of the muscle and that the NMZ of the muscle contains intramuscular nerve terminals [arrow in (C)] and a motor endplate (MEP) band [arrow in (D)]. H, hyoid bone; L, left; R, right; S, sternum. (E–H) NMZ of the SH muscle. Note that the right SM muscle has been removed to show the SH nerve [arrowhead in (E)]. (I–J) Surgical procedures. An NMEG pedicle was harvested from the right SH muscle (I). A muscular defect (between arrows) was made in the denervated NMZ of the right SM (I). The NMEG was embedded into the muscular defect made in the SM and sutured [green arrows in (J)]. Note that the implanted NMEG contains a nerve branch (large black arrow) and blood vessels [small black arrow in (J)].
acquisition board (16 bit, 1.25 ms/s; NI USB 6251; National Instruments) connected to a Dell laptop computer with a custom-written program using LabVIEW v8.2 software. The system produced stimulation pulses, which, after isolation from the ground through an optical isolation unit (Analog Stimulus Isolator Model 2200; AM Systems, Inc., Carlsborg, Washington), were used for the current-controlled nerve stimulation. The acquisition system was also used to control muscle length and to collect a muscle force signal from the 305B lever system. Collected data were analyzed offline with DIAdem v11.0 software (National Instruments). For each rat, the percentage of functional recovery of the treated SM was determined by comparing the treated muscle with the contralateral control muscle.

Muscle Weight Measurement and Tissue Preparation. At the end of the experiments, both SM muscles from each rat were harvested, photographed, and weighed. As a measure of the effectiveness of muscle reinnervation, wet muscle weight and myofiber morphology were examined. The wet muscle weights were reported as a ratio of the treated side to the contralateral control side. Each of the removed SM muscles was divided into 3 segments: rostral, middle, and caudal. The muscle segments were then frozen in melting isopentane cooled with dry ice and cut on a cryostat (Model 1800; Reichert-Jung, Mannheim, Germany) at −25°C. The rostral and caudal segments were cut transversely and serial cross-sections (10 μm) were stained with routine hematoxylin and eosin (H&E) to examine muscle structure and myofiber morphology. The middle segment containing the NMZ and/or NMEG was cut sagittally (60 μm) and stained immunohistochemically to quantify regenerated axons and MEPS.

Immunohistochemical Detection of Regenerated Axons and Innervated MEPS. Regenerated axons and innervated MEPS were detected with immunohistochemical methods as described in what follows.

Neurofilament Staining. Some sagittal sections were immunostained with monoclonal antibody SMI-31 as a marker for all axons (Covance Research Products, Berkeley, California) as described elsewhere. Briefly, the sections were treated in phosphate-buffered saline (PBS) containing 0.3% Triton and 2% bovine serum albumin (BSA) for 30 minutes, incubated with SMI-31 primary antibody (1:800) in PBS containing 0.03% Triton at 4°C overnight, treated for 2 hours with anti-mouse biotinylated secondary antibody (1:1,000; Vector Labs, Burlingame, California), processed with the avidin–biotin complex method using a VectaStain ABC kit (1:1,000; ABC Elite; Vector), and treated with diaminobenzidine–nickel as chromogen to visualize peroxidase labeling. Control sections were stained as described, except that the incubation with the primary antibody was omitted. The stained sections were examined under a fluorescence microscope (Axioplan-1; Carl Zeiss, Gottingen, Germany) and photographed with a USB 3.0 digital microscope camera (Infinity 3.3URC; Lumenera Corp., Ottawa, Ontario, Canada). The extent of axonal regeneration and muscle reinnervation was evaluated by quantifying the neurofilament-immunoreactive (NF-ir) axons within the treated muscles as described in our previous publications. The intramuscular axonal density was assessed by computing the number of the NF-ir axons and the area fraction of the axons within a section area (1.0 mm²). For a given muscle, 3 stained sections at different spatial levels through the muscle were selected to count NF-ir axons. For each section, 5 microscopic fields with NF-ir axons were identified and photographed. Areas with NF-positive staining were outlined and measured with public domain ImageJ software v1.45s (National Institutes of Health, Bethesda, Maryland). For each rat, the number and the area fraction of the NF-ir axons in the treated muscle were compared with those in the contralateral control.

Double-Fluorescence Staining. MEPS and their innervating axons were labeled with double-fluorescence staining.
as described previously\textsuperscript{11,51} with some modifications. Briefly, some sagittal sections were fixed for 20 minutes in Zamboni fixative with 5% sucrose at 4°C. The fixed sections were washed extensively in 1.5 Tris buffer (pH 7.6), treated with 0.1 mol/L of glycine in 1.5 Tris buffer for 30 minutes, and dipped in 100% methanol at –20°C. The sections were blocked in 1.5 Tris buffer containing 4% normal goat serum for 30 minutes to inhibit non-specific protein binding. Axons and terminals were detected by incubating the sections overnight at 4°C with primary antibodies (SMI-31 to detect neurofilaments, and SMI-81 to detect thinner axons; 1:1,000; Covance Research Products, Inc., Berkeley, California). After washing with 1.5 Tris buffer, the sections were incubated at room temperature for 2 hours with Alexa Fluor 488 donkey anti-mouse IgG secondary antibody (1:500; Invitrogen Corp., Carlsbad, California). Postsynaptic acetylcholine receptors (AChRs) at MEPs were labeled with Alexa Fluor 596–conjugated α-bungarotoxin (1:500; Invitrogen). The stained sections were rinsed in 1.5 Tris buffer and mounted with mounting medium (VectaShield; Vector Labs).

The stained axons (green) and MEPs (red) in each section were examined under a Zeiss fluorescence microscope and photographed using the USB 3.0 digital microscope camera. For each sample, at least 100 labeled MEPs were randomly selected from stained sections to determine the percentages of the innervated (visible axon attachment) and non-innervated (no visible axon attachment) MEPs.

**Statistical Analysis.** Force values, wet muscle weights, the number and area fraction of NF-ir axons, and innervated and non-innervated MEPs of the SM muscles in each rat were determined. The variables of the treated SM muscles are expressed as a percentage of the values of the contralateral control muscles. All data are reported as mean ± standard deviation. The Student t-test (paired, 2-tailed) was used to compare differences in the mean muscle force, mean muscle weight, and mean number and area fraction of NF-ir axons between treated and control SM muscles. $P<0.05$ was considered statistically significant.

**RESULTS**

**Maximal Tetanic Muscle Force.** Muscle force data were successfully collected from both sides in 14 rats. Three months after surgery, electric stimulation of the SH nerve innervating the implanted

\[ \text{NGF and FGF-2 Promote Reinnervation} \]
NMEG resulted in vigorous contractions of all treated muscles. The average threshold of nerve stimulation current that produced visible muscle contraction was 0.031 mA (standard deviation 0.010 mA, median 0.030 mA) on the treated side, but was only about one third of this value on the control side (mean 0.013 mA, standard deviation 0.009 mA, median 0.008 mA) (Fig. 2A). Increasing stimulation current was accompanied by a greater muscle force until it reached a horizontal asymptote. This saturation level was reached with higher current (0.2 mA) on the treated side than the control side (0.05 mA). The group average values of tetanic force of SM muscles from the treated (mean 1.193 N, standard deviation 0.195 N, median 1.239 N) and control (mean 1.316 N, standard deviation 0.195 N, median 1.335 N) sides are summarized in Figure 2B and C. The treated SM produced 91% of the maximal tetanic tension of the contralateral control.

**Wet Muscle Weight and Myofiber Morphology.** The size of the treated SM was similar to that of the contralateral control, but larger than that of 3-month-denervated SM (Fig. 3A and B). The mean value and standard deviation of the wet weight for the treated SM muscles and the contralateral control muscles are summarized in Table 1. The mean weight of the denervated SM muscles was 0.138 ± 0.062 g. The difference in average muscle weight was relatively small between treated and control muscles, but was consistent across rats and, therefore, statistically significant ($P<0.00001$, $t = 6.839$, paired $t$-test). The average ratio of treated to control muscles (0.92) was substantially larger than the average ratio (0.38) of denervated to control muscles in rats that had SM muscle denervation without treatment ($P<0.00001$, $t = 14.226$, unpaired $t$-test). H&E-stained cross-sections showed that myofiber morphology of the treated SM (Fig. 3C) was close to that of the contralateral control (Fig. 3D) and better than that of the denervated muscle (Fig. 3E). Remarkable fiber atrophy was found in the denervated muscles.

**Regenerated Axons and Innervated MEPs.** NF staining showed that NF-ir axons were confined to the NMZ of the treated and contralateral control SM muscles. The treated SM exhibited extensive axonal regeneration. By counting NF-ir axons (green) per field at 200× magnification, we observed that, in the treated SM, the regenerating axons from the implanted NMEG supplied the denervated NMZ and reached the most distal portion of the muscle (Fig. 4). Table 2 shows the mean number and area fraction of the NF-ir axons for each muscle in each animal. The mean number of the NF-ir axons in the treated muscles was 84% of the control. Regenerated axons in the treated muscles were more abundant than those in the muscles reinnervated by NMEG−NMZ surgery alone (77% of the control; $P = 0.049$, $t = 2.05$, unpaired $t$-test).

The muscle sections immunostained with double-fluorescence staining showed the innervated and non-innervated MEPs. In the treated SM muscles, the regenerating axons grew across the NMZ to innervate the denervated MEPs (Fig. 5A−C). The majority of the denervated MEPs (86%) in the treated muscles were reinnervated by regenerating axons. In the treated muscles, innervated and non-innervated MEPs (Fig. 5A−E), small, newly formed MEPs (Fig. 5F and G), and axonal sprouts (Fig. 5H and I) were identified. Terminal axons within the innervated MEPs were visualized (Fig. 5J and K). In 3-month-denervated muscles, denervated MEPs were still present. However, only a few fragments and/or accumulations of decomposed axons (arrows) and non-innervated MEPs (no visible axon attachment) were observed (Fig. 5L).

**DISCUSSION**

In this study we have demonstrated that NMEG−NMZ and NGF/FGF-2 co-treated muscles exhibited better muscle reinnervation and functional recovery when compared with those treated only with NMEG−NMZ microsurgery.11 Our findings indicate that focal application of exogenous NGF and FGF-2 promotes reinnervation by NMEG.

Poor motor recovery after PNI and nerve repair is closely related to insufficient axonal regeneration and reinnervation of the denervated MEPs in
the target muscle. One of the critical reasons for the impaired target reinnervation could be degradation of MEPs during prolonged denervation. Our studies have documented that the NMZ of the target muscle is the best site to design microsurgical procedures such as NMEG and/or direct nerve implantation into the NMZ for muscle reinnervation. The regenerating axons from the implanted nerve or NMEG pedicle could easily reach and reinnervate the denervated MEPs in the NMZ of the target muscle. We have shown that the NMEG-NMZ technique resulted in better functional recovery (82% of the control) when compared with our originally designed NMEG procedure (67% of the control). The suboptimal functional outcome of our original NMEG procedure could be due, at least in part, to the fact that the NMEG pedicle was implanted into an aneural region in the target muscle. In this case, regenerating axons from the implanted NMEG pedicle may need more time to reach the most distal muscle fibers and form new MEPs. The potential advantages of NMEG-NMZ technique over the original NMEG procedure include reduced nerve

FIGURE 4. Photomicrographs of the immunostained sagittal sections from right treated (A) and left control (B) sternomastoid (SM) rat muscles. The sections were immunostained with antibody against neurofilament (NF). Images were taken from 5 microscopic fields in each section. Note that the nerve fascicles and axons (darker stained threads and dots) in the right treated SM are distributed throughout the thickness of the muscle. Bar = 100 μm for (A) and (B). (A’, B’) Images (A) and (B) were opened using ImageJ software and converted to 8-bit (binary) images, color thresholded, and particle analyzed for nerve morphometry. The density of the axons was evaluated by calculating the number and percent area of the NF-positive axons in each section. For this animal (rat no. 13), as compared with the left control SM (mean axon count 902, mean area 0.899), the right SM shows very good muscle reinnervation, as indicated by the mean axon count (779, 86.4% of control) and mean area (0.824, 91.7% of the control).
regeneration distances and rapid axon–MEP connections. The re-established functional synapses could avoid muscle atrophy and achieve optimal functional recovery.

Innervation that occurs at the NMZ contains numerous intramuscular nerve terminals and MEPs.11,52 The MEP is a highly specialized structure that initiates action potential propagation required for excitation/contraction coupling to generate force for movement and maintain myofiber properties.53–55 Existing evidence favors the view that MEP regions of mammalian muscle fibers are preferentially reinnervated as a consequence of some special property of the muscle fiber at this site. After nerve injury and/or direct nerve implantation,64,65 regenerating axons and sprouts preferentially grow into the sites of the original MEPs and form synapses. The synaptic basal lamina at the MEP contains molecules that direct the formation of synaptic specializations on regenerating axon terminals and myofibers.63 Some other chemotropic substance released from the MEPs may exert an attraction on the regenerating axons. Successful restoration of muscle function after microsurgery is highly dependent on the absolute number of nerve fibers that enter the denervated muscle, the rate at which they grow distally, and the number of functional synapses they establish with the muscle. The optimal outcomes of this study should be attributed to the potential advantage of the NMEG–NMZ technique and the additive effects of NGF and FGF-2 on nerve regeneration. Specifically, NMEG–NMZ microsurgery creates an ideal condition that physically facilitates axon–MEP connections. The regenerating axons derived from the implanted NMEG could rapidly contact the denervated MEPs and form functional synapses in the target muscle. A transplanted NMEG provides an abundant source of nerve terminals and has sufficient pedicle–recipient muscle interfaces, which provide enough space for axonal regeneration. The axons

---

### Table 2. Comparison of count and percent area of neurofilament-immunoreactive axons between right treated and left control sternomastoid (SM) muscles in rats (n = 15).

<table>
<thead>
<tr>
<th>Animal no.</th>
<th>Right SM</th>
<th>Count</th>
<th>%Area</th>
<th>Left SM</th>
<th>Count</th>
<th>%Area</th>
<th>Ratio (R/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>683</td>
<td>0.738</td>
<td>896</td>
<td>1.056</td>
<td>0.762</td>
<td>0.699</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>866</td>
<td>0.605</td>
<td>995</td>
<td>0.803</td>
<td>0.870</td>
<td>0.753</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>926</td>
<td>0.801</td>
<td>1,033</td>
<td>0.982</td>
<td>0.896</td>
<td>0.816</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>901</td>
<td>0.674</td>
<td>1,128</td>
<td>0.874</td>
<td>0.799</td>
<td>0.771</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>587</td>
<td>0.509</td>
<td>898</td>
<td>0.786</td>
<td>0.654</td>
<td>0.648</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>955</td>
<td>1.200</td>
<td>1,074</td>
<td>0.996</td>
<td>0.889</td>
<td>1.205</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>493</td>
<td>0.605</td>
<td>723</td>
<td>0.862</td>
<td>0.682</td>
<td>0.702</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>889</td>
<td>0.826</td>
<td>834</td>
<td>0.974</td>
<td>1.066</td>
<td>0.848</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>510</td>
<td>0.721</td>
<td>670</td>
<td>0.865</td>
<td>0.761</td>
<td>0.834</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>809</td>
<td>1.002</td>
<td>876</td>
<td>1.033</td>
<td>0.924</td>
<td>0.970</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>917</td>
<td>0.801</td>
<td>1,056</td>
<td>0.796</td>
<td>0.868</td>
<td>1.006</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>558</td>
<td>0.725</td>
<td>801</td>
<td>0.854</td>
<td>0.697</td>
<td>0.849</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>779</td>
<td>0.824</td>
<td>902</td>
<td>0.899</td>
<td>0.864</td>
<td>0.917</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>882</td>
<td>0.879</td>
<td>997</td>
<td>1.120</td>
<td>0.885</td>
<td>0.785</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>970</td>
<td>0.934</td>
<td>993</td>
<td>0.982</td>
<td>0.977</td>
<td>0.951</td>
<td></td>
</tr>
<tr>
<td>Average</td>
<td>782</td>
<td>0.790</td>
<td>925</td>
<td>0.925</td>
<td>0.840</td>
<td>0.850</td>
<td></td>
</tr>
<tr>
<td>SD</td>
<td>170</td>
<td>0.17</td>
<td>131</td>
<td>0.10</td>
<td>0.11</td>
<td>0.14</td>
<td></td>
</tr>
</tbody>
</table>

L, left; R, right.
could start to regenerate at multiple points in the implanted NMEG and grow across the pedicle-receptor interfaces to reach the recipient muscle fibers. In this study, application of NGF and FGF-2 to the NMEG-NMZ-reinnervated muscles provided trophic support and a biologically permissive environment to accelerate the processes of axonal regeneration and muscle reinnervation. The beneficial effects of NGF and FGF-2 on axonal regeneration and functional recovery observed in our study are in line with previous reports.\textsuperscript{13,15,17–21,26,29,32,33}

In many peripheral nerve regeneration studies, a number of exogenous neurotrophic factors have been extensively investigated.\textsuperscript{69} Due to their relatively short half-life \textit{in vivo},\textsuperscript{70,71} the growth factors were administered weekly for several weeks after microsurgery for muscle reinnervation.\textsuperscript{27}
Therefore, effort was focused on the delivery of growth factors over a more prolonged time period,\textsuperscript{72,73} such as the local use of a fibrin sealant containing neurotrophic factors.\textsuperscript{13,14,29,38–40} Several different neurotrophic factors have already been tested in clinical trials for the treatment of peripheral nerve disease, with variable results. Clinical uses for NGF have been proposed for Parkinson and Alzheimer diseases,\textsuperscript{74} and other neurotrophic factors have also been advocated, such as ciliary neurotrophic factor to treat amyotrophic lateral sclerosis.\textsuperscript{75} Increasing evidence suggests that, in the future, application of exogenous neurotrophic factors may become a valuable therapeutic tool to accelerate motor nerve regeneration and reduce muscle atrophy. Our findings may provide a rationale to consider surgical and biological solutions to improve nerve regeneration and MEP reinnervation. This combination may prove useful as a strategy to treat PNI-related muscle paralysis.

The authors thank the anonymous reviewers for their constructive comments on this manuscript.

REFERENCES
17. Grothe C, Nidhksh G. The role of basic fibroblast growth factor in peripheral nerve regeneration. Anat Embryol (Berl) 2001;204:171–177.


52. Sobotka S, Chen J, Nyirenda T, Mu L. Outcomes of muscle reinnervation with direct nerve implantation into the native motor zone of the target muscle. J Reconstr Microsurg 2017;33:77–86.


Intraoperative 1-Hour Electrical Nerve Stimulation Enhances Outcomes of Nerve–Muscle-Endplate Band Grafting Technique for Muscle Reinnervation

Stanislaw Sobotka, PhD, DSc1,2 Jingming Chen, MD1 Themba Nyirenda, PhD1 Liancai Mu, MD, PhD1

1Department of Research, Upper Airway Research Laboratory, Hackensack University Medical Center, Hackensack, New Jersey
2Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York

J Reconstr Microsurg 2017;33:533–543.

Address for correspondence Stanislaw Sobotka, PhD, DSc, Department of Research, Hackensack University Medical Center, Hackensack, NJ 07601 (e-mail: stanislaw.sobotka@mountsinai.org).

Peripheral nerve injury (PNI) is a major source of chronic disabilities and remains a challenging problem for microsurgeons. Approximately 100,000 patients undergo peripheral nerve surgery in the United States and Europe annually.1 Despite advances in microsurgery and extensive studies on nerve repair, the presently available methods for muscle reinnervation result in poor functional recovery. Therefore, there is a pressing need to seek new strategies for treating PNI-related muscle paralysis.

Increasing evidence suggests that functional motor recovery after PNI and nerve repair is predominantly determined by motor endplate (MEP) reinnervation and the

Abstract

Background  Increasing evidence suggests that 1-hour electrical nerve stimulation during surgery improves nerve regeneration and functional recovery. However, it remains unknown if this approach has beneficial effects on the outcomes of our recently developed nerve–muscle-endplate band grafting-native motor zone (NMEG-NMZ) technique for muscle reinnervation.

Methods  In this study, NMEG-NMZ transplantation was performed in a rat model. The right sternomastoid muscle was experimentally denervated and immediately reinnervated by implanting a NMEG harvested from the ipsilateral sternohyoid (SH) muscle into the NMZ of the target muscle. Before implantation of the NMEG, the SH nerve branch innervating the NMEG was subjected to intraoperative 1-hour continuous electrical stimulation (20 Hz). Three months after surgery, the degree of functional recovery was evaluated with muscle force measurement and the extent of nerve regeneration and endplate reinnervation was examined using histological and immunohistochemical methods.

Results  A combination of NMEG-NMZ with electrical nerve stimulation resulted in a greater degree of functional recovery than the NMEG-NMZ alone. The mean muscle force of the treated muscles was 90% of the contralateral control. The muscle mass was recovered up to 90% of the control. The mean number and percentage of area of the regenerated axons in the treated muscles was computed to be 81 and 84% of the control muscles, respectively. On average, 83% of the denervated endplates in the treated muscles were reinnervated by regenerated axons.

Conclusion  Intraoperative brief nerve stimulation promotes nerve regeneration, endplate reinnervation, and functional recovery of the muscles reinnervated with NMEG-NMZ technique.

Keywords
► electrical nerve stimulation
► nerve regeneration
► muscle force measurement

Copyright © 2017 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.
ISSN 0743-684X.
absolute number of regenerated motor axons that reach target.\textsuperscript{2–5} Recently, we developed a novel reinnervation technique called nerve–muscle-endplate band grafting (NMEG) in a rat model.\textsuperscript{6} The idea is that a healthy MEP band with a nerve branch and terminals that innervates an expendable muscle can be transplanted to a more functionally important denervated muscle for restoring its motor function. Our originally designed surgical procedure that involved implantation of a NMEG into a MEP-free area in the recipient muscle yielded encouraging functional recovery (67% of the control).\textsuperscript{8} As MEP reinnervation is critical for motor recovery, we modified the surgical procedures by implanting the NMEG into the native motor zone (NMZ) of the target muscle. NMEG-NMZ technique resulted in better muscle reinnervation and functional recovery (82% of the control) as compared with our original NMEG implantation.\textsuperscript{7} We hypothesized that the outcomes of NMEG-NMZ might be improved by using supplementary strategies that accelerate nerve regeneration and MEP reinnervation.

Among the strategies used for enhancing axon regeneration, electrical stimulation (ES) to the injured peripheral nerve is a promising approach. Several authors\textsuperscript{8–17} have developed a clinically feasible technique of 1 hour low-frequency (20 Hz) ES of the proximal nerve stump just after surgical repair of a transected peripheral nerve to enhance peripheral nerve regeneration. The authors reported that intraoperative brief ES greatly accelerates axon growth across the site of nerve repair and promotes functional recovery.\textsuperscript{12–15}

The purpose of this study was to explore whether 1 hour low-frequency ES of the nerve branch innervating the NMEG pedicle has beneficial effects on the outcomes of NMEG-NMZ reinnervation.

Materials and Methods

Experiments involved the use of 23 3-month-old female Sprague-Dawley rats (Taconic Laboratories, Cranbury, NJ) weighing between 200 and 250 g at initial operation. All procedures were approved by the Animal Care and Use Committee of Hackensack University Medical Center and the USAMRMC Animal Care and Use Review Office and adhered to the Guide for the Care and Use of Laboratory Animals published by National Research Council (US) Committee, 8th edition, National Academies Press (US), Washington, DC, 2011. The animals were housed at a constant temperature (22°C) on a 12-hour light-dark cycle and were provided with food and water. All efforts were made to minimize the number of animals and their suffering in the experiments.

Surgical Procedures and Electrical Stimulation

Twenty-two rats were randomly divided into NMEG-NMZ (n = 15) and denervation (n = 7) groups. For NMEG-NMZ, sternohyoid (SH) and sternomastoid (SM) muscles were chosen to serve as a donor and recipient, respectively, because this model was used in our recent studies.\textsuperscript{7}

Animals were anesthetized with an intraperitoneal injection of a mixture of ketamine (80 mg/kg) and xylazine (5 mg/kg) and operated on using aseptic technique. With the rat supine, a midline cervical incision was made extending from the hyoid bone to the sternum to expose the right SM and SH muscles and their innervating nerves. All rats in both groups underwent denervation of the right SM by the excision of a 5-mm segment of its nerve just proximal to its motor point in the middle of the muscle under an Olympus SZX12 Stereo zoom surgical microscope (Olympus America Inc, Center Valley, Pennsylvania). The cut ends of the nerve were coagulated with a bipolar cautery to prevent nerve regeneration.

Immediately after muscle denervation by the excision of a segment of the native nerve to the right SM muscle, the rats in NMEG-NMZ group underwent NMEG-NMZ transplantation as described.\textsuperscript{7} Briefly, the NMZs in the right SM and SH muscles were outlined during surgery according to the entry point of the motor branch into each muscle (►Fig. 1). A muscular defect with the same dimensions as the NMEG pedicle was made in the NMZ of the right denervated SM muscle. An NMEG pedicle was harvested from the NMZ of the SH in the middle portion of the right SH muscle. The nerve to the SH muscle was not transected but dissected free along with the NMZ and muscle fibers of that zone. The NMEG pedicle was composed of a block of muscle (~6 × 6 × 3 mm), a nerve branch and vessels, intramuscular axon terminals, and a MEP band with numerous neuromuscular junctions. The superficial muscle fibers on the ventral aspect of the NMEG pedicle were removed to create a denuded surface for better reconnection of SH nerve with target SM muscle.

After harvesting of the NMEG pedicle, brief low-frequency ES was performed. The SH nerve branch supplying the NMEG pedicle was placed on bipolar stainless steel hook electrodes and stimulated using a stimulation and recording system (National Instruments Corp, Austin, Texas) controlled by user-written LabVIEW software (National Instruments Corp). The nerve was stimulated for 1 hour with a continuous train of 20 Hz square pulses of 3 V, 0.1 millisecond delivered by a stimulation and recording system (National Instruments Corp) controlled by user-written LabVIEW software (National Instruments Corp). The nerve distance between stimulating electrode and NMEG was ~5 mm. Throughout the stimulation procedure, the muscle pedicle and its innervating SH nerve branch stimulated were regularly bathed with warm mineral oil. Immediately after nerve stimulation, the NMEG pedicle was embedded in the SM muscle defect and sutured with four to six 10–0 nylon microsutures (►Fig. 1). After surgery, the wound was closed in layers with interrupted simple sutures of 4–0 Prolene.

Three months after NMEG-NMZ transplantation and electrical stimulation, functional recovery, nerve regeneration, and muscle reinnervation were evaluated using electrophysiological, morphohistological, and immunohistochemical techniques. For each animal, contralateral intact SM served as a control.

Maximal Tetanic Force Measurement

The rats in the NMEG-NMZ group were subjected to maximal tetanic force measurement to examine the degree of functional recovery of the reinnervated SM muscles. The details
regarding force measurement have been given in our previous
publications.6,7,18–23 Briefly, the rostral tendon of the SM
muscles was severed close to the insertion, tied with a 2–0
suture, and connected to a servomotor lever arm (model 305B
Dual-Mode Lever Arm System; Aurora Scientific Inc, Aurora,
Ontario, Canada) to record titanic force at optimal muscle
length. Muscle force of the right SM was measured first by
stimulating with a bipolar electrode the SH nerve branch
supplying the NMEG, whereas muscle force of the left control
muscle was measured by stimulating the intact SM nerve. A
stimulation and recording system (National Instruments
Corp) controlled by user-written LabVIEW software (National
Instruments Corp) was used to deliver biphasic rectangular
pulses to the nerve stimulated.

![Fig. 1](image-url)

Fig. 1 NMZs of recipient SM and donor SH muscles and operative procedures for NMEG-NMZ technique in the rat. (A) Removed right SM
muscles, showing the NMZ (between dashed lines) of the muscle as indicated by motor point (arrowhead) in fresh muscle (left image),
intramuscular nerve supply in Sihler’s stained muscle (middle image), and MEP band in AChE-stained muscle (right image). (B) Removed right SH
muscles, illustrating the NMZ of the muscle. (C) A photograph from a rat during surgery, showing surgically outlined NMZ in the right SM
(between fiber cuts on the surface of the muscle as indicated by arrows) and in the SH (boxed region). The vertical dashed line indicates the
midline. (D) Surgically outlined NMZ in the right SH muscle (boxed region). The right SM was removed to show the SH nerve (arrowhead).
Note that either SM or SH is supplied by a single motor nerve branch (arrowheads in A–D) which enters into the middle portion of the muscle.
(E) A NMEG pedicle was harvested from the NMZ of the right SH muscle and a muscular defect was made in the NMZ of the right SM muscle
(between arrows). (F) The NMEG pedicle was implanted into the muscular defect made in the SM and sutured (pale arrows). Note that a nerve
branch (large black arrow) and blood vessels (small black arrow) can be seen on the surface of the implanted NMEG pedicle. AChE,
acetylcholinesterase; H, hyoid bone; L, left; MEP, motor endplate; NMEG, nerve–muscle-endplate band grafting; NMZs, native motor zones;
R, right; S, sternum; SH, sternohyoid; SM, sternomastoid.
Isometric contraction of the SM muscle was produced with 200-millisecond trains of biphasic rectangular pulses. The duration of each phase of stimulation pulse was set at 0.2 milliseconds and the train frequency was set at 200 pulses per second. The stimulation current was gradually increased until the tetanic force reached a plateau. A break of at least 1 minute was taken between two stimulations. The maximum value of muscle force during the 200-millisecond contraction was identified, as well as initial passive tension before stimulation. The difference between the maximal active force and the preloaded passive force was used as the muscle force measurement. The force generated by the contraction of the SM muscle was transduced with the servomotor of a 305B lever system and displayed on a computer screen. At the moment of force measurement, the lever arm was stationary, and the muscle was adjusted to the optimal length for the development of maximum force. During the experiment, the rat was placed supine on a heating pad, and the core body temperature was monitored with a rectal thermistor and maintained at 36°C. The muscle connected at the distal end to a servomotor lever arm and nerve examined was bathed regularly with warmed mineral oil throughout the testing to maintain muscle temperature between 35 and 36°C.

The force data were obtained and processed by an acquisition system built from a multifunction I/O National Instruments Acquisition Board (NI USB-6251; 16-bit, 1.25 MS/s; National Instruments) connected to a Dell laptop with a custom-written program using LabVIEW 8.2 software. The system produced stimulation pulses, which, after isolation from the ground through an optical isolation unit (Analog Stimulus Isolator model 2200; AM Systems, Inc, Carlsborg, Washington), were used for the current controlled nerve stimulation. The acquisition system was also used to control muscle length and to collect a muscle force signal from the 305B Dual-Mode Lever System. Collected data were analyzed offline with DIAdem 11.0 software (National Instruments). Muscle force was reported as a ratio of the operated to the control side.

**Wet Muscle Weight Measurement and Tissue Preparation**

After muscle force measurements, SM muscles on both sides in each rat were excised, photographed, and weighed. A muscle mass ratio was computed (muscle mass ratio = weight of operated muscle/weight of contralateral muscle).

Each of the removed SM muscles in both groups was divided into three segments: rostral, middle, and caudal. The muscle segments were then frozen in melting isopentane cooled with dry ice and cut on a cryostat (Reichert-Jung 1800; Mannheim, Germany) at −25°C. The rostral and caudal segments were cut transversely and serial cross sections (10 µm) were stained with routine hematoxylin and eosin staining to examine muscle structure and myofiber morphology. The middle segment containing the NMZ and/or implanted NMEG was cut sagittally (60 µm) and stained using immunohistochemical methods to detect and quantify regenerated axons and MEPs.

**Immunohistochemical Labeling of Regenerated Axons and Motor Endplates**

Intramuscular axons and MEPs in the operated, control, and denervated SM muscles were detected with immunohistochemical methods as described later.

**Neurofilament Staining**

Some sagittal sections were immunostained with a monoclonal antibody phosphorylated neurofilament (NF)(SMI-31, Covance Research Products, Berkeley, CA) as a marker for all axons as described in our previous publications. Briefly, the sections were treated in PBS containing 0.3%
triton and 2% bovine serum albumin for 30 minutes and incubated with primary antibody SMI-31 (dilution 1:800) in PBS containing 0.03% triton at 4°C overnight. The sections were then incubated for 2 hours with the biotinylated secondary antibody (antimouse, 1:1,000, Vector, Burlingame, CA). The incubated sections were processed with avidin–biotin complex method with a Vectastain ABC kit (1:1,000 ABC Elite, Vector) and reacted with diaminobenzidine-nickel as chromogen to visualize peroxidase labeling. Control sections were stained as described except that the incubation with the primary antibody was omitted.

For quantitative analysis, images were taken at ×200 with the aid of a USB digital microscope camera (INFINITY 3–3URC, Lumenera Corp., Ottawa, Canada) attached to a Zeiss fluorescence microscope (Axioplan–1; Carl Zeiss, Gottingen, Germany) and analyzed using ImageJ software (v. 1.45s; NIH, Bethesda, MD) as described in our publications.7,23 The intramuscular axonal density was assessed by estimating the number of the NF-immunoreactive (NF-ir) axons and the area fraction of the axons within a section area (1.0 mm²). For a given muscle, three sections stained for NF were selected at different spatial levels to quantify NF-ir axons and areas. For each section, five microscopic fields with NF-ir axons were photographed. Areas with NF-positive staining were outlined and measured with public domain ImageJ software. For each rat, the number and area fraction of the NF-ir axons in the treated muscle were compared with those in the contralateral control.

Double Fluorescence Labeling

Double fluorescence labeling was used to detect MEPs and their innervating axons in the NMZ of the SM muscles as described in our publications.7,23 Briefly, some sagittal muscle sections were fixed in Zamboni fixative with 5% sucrose for 20 minutes at 4°C. The fixed sections were treated with 0.1 mol/L of glycine in 1.5 Tris buffer (pH 7.6) for 30 minutes and dipped in 100% methanol at –20°C for 20 minutes. The sections were blocked in 1.5 Tris buffer containing 4% normal goat serum for 30 minutes and incubated overnight at 4°C with primary antibodies (SMI-31 to detect NFs and SMI-81 to label thinner axons; Covance Research Products Inc). The sections were then incubated at room temperature for 2 hours both with a secondary antibody (goat antimouse antibody conjugated to Alexa 488) and with α-bungarotoxin conjugated with Alexa 596 (Invitrogen Corporation, Carlsbad, CA). The sections were washed several times with 1.5 Tris buffer with 0.05% Tween-20 between steps and the stained sectioned were coverslipped.

Fig. 3 Comparison of muscle mass and histology among operated, control, and denervated SM muscles of rats. (A) The right operated and left control SM muscles from a rat 3 months after NMEG-NMZ transplantation and intraoperative 1 hour of electrical stimulation. Note that there is no significant difference in muscle mass between the R operated and L control muscles. (B) A denervated SM, noting that 3-month denervation resulted in a marked reduction of muscle mass as compared with the operated and control muscles. (C–E) Hematoxylin and eosin–stained cross sections from the (C) operated, (D) contralateral control, and (E) denervated SM muscles. Note that the operated SM had slight muscle fiber atrophy as compared with the control. The denervated SM exhibited significant muscle fiber atrophy. Bar = 100 µm for (C) through (E). L, left; NMEG-NMZ, nerve–muscle-endplate band grafting-native motor zone; R, right; SM, sternomastoid.
The stained sections were viewed under a Zeiss fluorescence microscope and photographed using USB 3.0 digital microscope camera. SMI-31 and SMI-81 detected axons (green), while α-bungarotoxin-labeled postsynaptic acetylcholine receptor site in the MEPs (red). For each muscle sample, at least 100 labeled MEPs were randomly selected from stained sections to determine the percentages of the innervated (visible axon attachment) and noninnervated (no visible axon attachment) MEPs.

Data Analysis
Force values, muscle weights, the number and the area fraction of NF-ir axons, and innervated and noninnervated MEPs of the operated and unoperated SM muscles in each rat were computed. The variables of the reinnervated SM muscles were expressed as the percentages of the values of the contralateral control muscles. Data were presented as mean ± standard deviation. The Student’s t test (paired, two-tailed) was used to compare differences in the mean values of the variables examined between operated and unoperated SM muscles. A difference was considered statistically significant at \( p < 0.05 \).

Results
Functional Recovery of the Treated Muscles
Maximal muscle force was successfully measured from both sides in 14 rats treated with NMEG-NMZ plus intraoperative 1-hour ES. As reported in our previous publications, muscle force was measured when muscle was stretched at optimal tension of 0.08 N. There was a higher average threshold of nerve stimulation current to generate muscle contraction for operated muscles (mean, 0.027 mA) than control muscles (mean, 0.019 mA), but this difference did not reach statistical significance (\( p = 0.17 \), \( t = 1.47 \), two-tailed, paired t-test) (►Fig. 2A). Increasing stimulation current was accompanied by a greater muscle force until it reached horizontal asymptote. Stimulation current \( \geq 0.2 \) mA produced maximal muscle force in operated muscle, whereas \( \geq 0.1 \) mA in control muscle.

Maximal muscle force was calculated as average muscle contraction to five stimulation currents ranging from 0.6 to 1.0 mA. For each rat, the percentage of functional recovery of the treated SM muscles was determined as compared with the force value of the contralateral control muscle. The treated SM muscles produced 90% of the maximal tetanic tension of the contralateral control muscles (►Fig. 2B). Averaged maximal muscle force at the treated side was 1.08 N, whereas 1.21 N at the contralateral control side. The difference between these averages (0.13 N) was statistically significant (\( p = 0.035 \), \( t = 2.35 \), two-tailed, paired t-test).

Wet Muscle Weight and Muscle Histology
Wet muscle weight and myofiber morphology are indicators for the effectiveness of muscle reinnervation. In this study, the size of the treated SM was similar to that of the contralateral control, but larger than that of 3-month-denervated SM (►Fig. 3A, B). Specifically, the mean wet weight of the treated SM muscles (0.309 g) was 90% of the control muscles (0.344 g) (►Table 1), whereas that of the denervated SM muscles was 0.138 g. The mean wet weight of treated SM muscles was much higher than that of the denervated SM muscles (\( p < 0.0001 \)). Hematoxylin and eosin–stained cross muscle sections showed the histological profiles of the treated, control, and denervated SM muscles. The treated SM (►Fig. 3C) exhibited better muscle structure and myofiber morphology with less fiber atrophy as compared with the contralateral control (►Fig. 3D) and denervated muscle which exhibited prominent fiber atrophy (►Fig. 3E).

Regenerated Axons and Innervated Motor Endplates in the Treated Muscles
Microscopic imaging of the sagittal sections processed with NF staining showed that NF-ir axons were confined in the NMZ of the treated and contralateral control SM muscles. By counting NF-ir axons (green) per field at \( \times 200 \) magnification, we observed that in the treated SM, the regenerating axons from the implanted NMEG supplied the NMZ of the treated muscle. The mean number and area fraction of the NF-ir axons in the treated SM muscles were measured to be 81 and 84% of the contralateral control muscles (►Fig. 4 and ►Table 2), respectively.

Double fluorescence labeling showed the innervated and noninnervated MEPs (►Fig. 5). In the SM muscles cotreated

<table>
<thead>
<tr>
<th>Animal (No.)</th>
<th>Body weight (g)</th>
<th>Right treated SM (g)</th>
<th>Left control SM (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>337</td>
<td>0.276</td>
<td>0.296</td>
</tr>
<tr>
<td>2</td>
<td>345</td>
<td>0.320</td>
<td>0.336</td>
</tr>
<tr>
<td>3</td>
<td>385</td>
<td>0.272</td>
<td>0.310</td>
</tr>
<tr>
<td>4</td>
<td>388</td>
<td>0.264</td>
<td>0.350</td>
</tr>
<tr>
<td>5</td>
<td>364</td>
<td>0.266</td>
<td>0.362</td>
</tr>
<tr>
<td>6</td>
<td>356</td>
<td>0.284</td>
<td>0.315</td>
</tr>
<tr>
<td>7</td>
<td>370</td>
<td>0.300</td>
<td>0.355</td>
</tr>
<tr>
<td>8</td>
<td>342</td>
<td>0.383</td>
<td>0.412</td>
</tr>
<tr>
<td>9</td>
<td>346</td>
<td>0.353</td>
<td>0.384</td>
</tr>
<tr>
<td>10</td>
<td>343</td>
<td>0.319</td>
<td>0.339</td>
</tr>
<tr>
<td>11</td>
<td>320</td>
<td>0.317</td>
<td>0.336</td>
</tr>
<tr>
<td>12</td>
<td>325</td>
<td>0.361</td>
<td>0.386</td>
</tr>
<tr>
<td>13</td>
<td>305</td>
<td>0.301</td>
<td>0.305</td>
</tr>
<tr>
<td>14</td>
<td>338</td>
<td>0.327</td>
<td>0.349</td>
</tr>
<tr>
<td>15</td>
<td>311</td>
<td>0.298</td>
<td>0.328</td>
</tr>
<tr>
<td>Average</td>
<td>345</td>
<td>0.309</td>
<td>0.344</td>
</tr>
<tr>
<td>SD</td>
<td>24.6</td>
<td>0.036</td>
<td>0.032</td>
</tr>
<tr>
<td>Ratio, %</td>
<td></td>
<td>90</td>
<td>100</td>
</tr>
</tbody>
</table>

Abbreviations: SM, sternomastoid; SD, standard deviation.
with NMEG-NMZ and brief ES, the regenerated axons were identified in the NMZ of the target muscle to innervate the denervated MEPs (►Fig. 5A–J). On average, 83% of the denervated MEPs in the treated muscles were reinnervated by regenerated axons and only 17% of the MEPs were unoccupied by axons. In the treated muscles, innervated and noninnervated MEPs (►Fig. 5A–E), small newly formed MEPs (►Fig. 5F, G), and axonal sprouts (►Fig. 5H, I) were identified. Terminal axons within the innervated MEPs were visualized (►Fig. 5J). In 3-month-denervated muscles, denervated MEPs were still present and remained noninnervated. A few fragments and/or accumulations of axon debris and noninnervated MEPs (no visible axon attachment) were observed (►Fig. 5K, L).

### Discussion

To our knowledge, this is the first study to combine NMEG-NMZ reinnervation technique with intraoperative brief (1 hour) low-frequency (20 Hz) ES for muscle reinnervation. Our study demonstrated that NMEG-NMZ plus brief ES resulted in extensive axonal regeneration (mean number of the regenerated axons, 81% of the control), well-preserved muscle mass (mean muscle weight, 90% of the control), and optimal functional motor recovery (mean maximal tetanic force, 90% of the control). The majority of MEPs (83%) in the treated muscles regained motor innervation.

Muscle paralysis caused by PNI is frequently treated with nerve anastomosis, nerve transfer, nerve grafting, direct...
nerve implantation, and many others.\textsuperscript{25,26} Despite advances in microsurgical techniques for nerve repair, functional recovery is frequently poor. Therefore, restoration of useful function after PNI is a major challenge for reconstructive surgery and rehabilitation medicine.\textsuperscript{27} Many studies have demonstrated that functional motor recovery after PNI and nerve repair is primarily determined by the absolute number of regenerated motor axons that reach target and the time to MEP reinnervation.\textsuperscript{2–5} Our research efforts focus on creating strategies for MEP reinnervation to treat muscle paralysis caused by PNIs. We have demonstrated the importance of MEP reinnervation in motor recovery of the target muscle. For example, 3 months after transplantation of the NMEG into a MEP-free area, the mean maximal tetanic force of the treated muscles was 67% of the controls.\textsuperscript{6} In contrast, transplantation of the NMEG into the NMZ of the target muscle yielded better functional recovery (mean maximal tetanic force, 82% of the control).\textsuperscript{7} In addition, direct nerve implantation into the NMZ also resulted in satisfactory muscle reinnervation and functional recovery. These findings suggest that NMZ in the target muscle is the best region for muscle reinnervation.

Optimal axon regeneration, MEP reinnervation, and muscle force recovery observed in this study should be attributed to several factors. First, NMEG-NMZ procedure shortens nerve regeneration distances and facilitates rapid axon-MEP connections. As the NMEG pedicle from the donor muscle was transplanted into the NMZ of the recipient muscle, the regenerating axons derived from the transplant could easily reach and reinnervate the denervated MEPs in the target muscle. Second, the NMEG pedicle harvested from the NMZ of the donor muscle provides an abundant source of nerve terminals for axonal regeneration. Finally, there are sufficient pedicle-recipient muscle interfaces that favor axons to regenerate at multiple points and reinnervate the denervated MEPs in the target muscle. The re-established functional synapses could avoid muscle atrophy and achieve optimal functional recovery. Our findings suggest that the combination of NMEG-NMZ with 1 hour 20-Hz ES could be an option for muscle reinnervation.

Despite the regenerative capacity of injured peripheral nerves, functional recovery remains suboptimal after primary nerve repair.\textsuperscript{28–30} There is an increasing interest in using brief low-frequency ES to enhance nerve regeneration for improving functional recovery after nerve transection and microsurgical repair. Recent work by Al-Majed et al (2000a)\textsuperscript{8} has demonstrated that 1 hour of 20-Hz ES of the proximal stump of a transected and repaired peripheral nerve in the rat accelerates axon regeneration. The 20-Hz frequency of ES was chosen as it is the mean frequency of action potential generation in motoneurons\textsuperscript{31} and 1 hour ES is considered to be a clinically feasible period in the operating room for human nerve surgical repair.\textsuperscript{8,17} ES at a frequency of 20 Hz for 1 hour accelerates axon outgrowth across the site of surgical repair of transected nerve stumps, resulting in accelerated target muscle reinnervation.

\begin{table}
\centering
\begin{tabular}{|c|c|c|c|c|c|c|c|}
\hline
Animal (no.) & Right SM & & Left SM & & & & \\
\hline & Count & Percentage of area & Count & Percentage of area & Count & Percentage of area & \\
\hline 1 & 559 & 0.721 & 798 & 0.945 & 0.701 & 0.763 & \\
2 & 670 & 0.640 & 729 & 0.724 & 0.919 & 0.884 & \\
3 & 725 & 0.728 & 913 & 0.946 & 0.794 & 0.770 & \\
4 & 630 & 0.621 & 824 & 0.789 & 0.765 & 0.787 & \\
5 & 610 & 0.658 & 816 & 0.827 & 0.748 & 0.796 & \\
6 & 655 & 0.710 & 904 & 0.900 & 0.725 & 0.789 & \\
7 & 978 & 0.697 & 1,014 & 0.811 & 0.964 & 0.859 & \\
8 & 601 & 0.803 & 988 & 0.970 & 0.608 & 0.828 & \\
9 & 894 & 1.060 & 1,043 & 1.200 & 0.857 & 0.883 & \\
10 & 792 & 0.736 & 967 & 0.856 & 0.819 & 0.860 & \\
11 & 993 & 1.102 & 1,103 & 1.205 & 0.900 & 0.915 & \\
12 & 839 & 0.735 & 993 & 0.840 & 0.845 & 0.875 & \\
13 & 1,008 & 0.833 & 1,186 & 0.997 & 0.850 & 0.836 & \\
14 & 781 & 0.638 & 883 & 0.704 & 0.884 & 0.906 & \\
15 & 683 & 0.596 & 837 & 0.698 & 0.816 & 0.854 & \\
Average & 761 & 0.752 & 933 & 0.894 & 0.813 & 0.840 & \\
SD & 151 & 0.149 & 125 & 0.156 & 0.093 & 0.051 & \\
\hline
\end{tabular}
\caption{Comparison of count and percentage of area of neurofilament-immunoreactive axons between right treated and left control SM muscles in rats ($n = 15$)}
\end{table}

Abbreviations: L, left; R, right; SD, standard deviation.
reported, the percentage of regenerating neurons innervating the target muscle increased from 40% without ES to 75% with ES. These beneficial effects have been documented to be associated with a faster and enhanced upregulation of brain-derived neurotrophic factor and its tyrosine kinase B receptor in motoneurons. The efficacy of the 1 hour of ES of the proximal stump of an injured nerve in promoting axon outgrowth has been confirmed not only in acute animal experiments performed in many independent studies but also in delayed nerve repair model and in human studies. As reported by Gordon et al (2010), the 1 hour of 20-Hz ES of the median nerve after carpal tunnel release surgery in humans also resulted in earlier recovery of muscle reinnervation and sensory compound action potentials. These findings indicate that the brief low-frequency ES could become a clinically useful therapeutical approach for accelerating axon regeneration and muscle reinnervation. The combination of nerve reconstruction surgery with brief ES appears to be effective for maximizing postoperative functional recovery.

**Conclusion**

First, the NMZ of the target muscle is an ideal site for implantation of NMEG and for the development of novel strategies to treat muscle paralysis caused by PNIs. Regenerating axons from a NMEG or a nerve stump implanted into the NMZ of the target muscle could easily reach and innervate the muscles. This technique can be used in combination with nerve reconstruction surgery to improve functional outcomes in the affected limb.

---

**Fig. 5** Images of double immunofluorescence staining of sagittal sections (A–J) from right operated SM muscle of a rat cotreated with NMEG-NMZ implantation and intraoperative 1-hour of electrical stimulation and (K–L) from a denervated SM muscle. (A–C) Low-power view of the stained sections, showing the distribution of MEPs and axons in the NMZ of the operated muscle. Note that the majority of the MEPs in the operated SM were reinnervated by regenerated axons (arrows). The noninnervated MEPs were indicated by arrowheads. Bar = 100 µm for A through C. (D–I) High-power view of the stained sections, showing innervated (arrows) and noninnervated (arrowheads) (D and E) MEPs, (F and G) small newly formed MEPs (asterisks), and (H and I) ultraterminal sprouts (arrows). Bar = 100 µm for D through I. (J) Closeup photograph of an innervated MEP, showing terminal axons (arrows) and acetylcholine receptors at the MEP. Bar = 50 µm. (K–L) Immunostained sections from a rat SM muscle denervated for 3 months. Note that only a few fragments and/or accumulations of neurofilament-immunoreactive decomposed nerve fibers (arrows) and noninnervated MEPs (no visible axon attachment) were observed. Bar = 100 µm. MEPs, motor endplates; NMEG-NMZ, nerve-muscle-endplate band grafting-native motor zone; SM, sternomastoid.
reinnervate the denervated MEPs, re-establishing functional synapses.

Second, MEP reinnervation is critical for motor functional recovery after PNI and nerve reconstruction. This study showed that the majority (83%) of MEPs in the muscles treated with NMEG-NMZ and brief ES regained motor innervation. This is most likely due to such a fact that the NMEG-NMZ procedure physically shortens regeneration distances and facilitates rapid MEP reinnervation, thereby avoiding irreversible loss of the denervated MEPs in the target muscle.

Third, the outcomes of NMEG-NMZ technique can be further improved by a combination of NMEG-NMZ technique with intraoperative brief ES. Future directions will be to build upon this combination strategy, with other therapies targeted to various aspects of axonal regeneration.

Finally, although our experiments showed the potential of NMEG-NMZ in immediate muscle reinnervation, further work is needed to determine if the combination of NMEG-NMZ with brief ES has the potential for delayed reinnervation that is not uncommon in clinical practice.

Acknowledgments

This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs under Award No. W81XWH-14-1-0442 (to Dr. Liancai Mu). The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014 is the awarding office. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. In conducting research using animals, the investigators adhere to the laws of the United States and regulations of the Department of Agriculture. This protocol was approved by the USAMRMC Animal Care and Use Review Office for the use of rats. The authors thank the anonymous reviewers for their constructive comments on the article.

References

Outcomes of Muscle Reinnervation with Direct Nerve Implantation into the Native Motor Zone of the Target Muscle

Stanislaw Sobotka, PhD, DSc1,2 Jingming Chen, MD1 Themba Nyirenda, PhD1 Liancai Mu, MD, PhD1

1 Department of Research, Hackensack University Medical Center, Upper Airway Research Laboratory, Hackensack, New Jersey 2 Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York

J Reconstr Microsurg 2017;33:77–86.

Abstract

Background Our recent work has demonstrated that the native motor zone (NMZ) within a given skeletal muscle is the best site for muscle reinnervation. This study was designed to explore the outcomes of direct nerve implantation (DNI) into the NMZ of denervated sternomastoid (SM) muscle in a rat model.

Methods The right SM muscle was experimentally denervated by transecting its innervating nerve. The proximal stump of the severed SM nerve was immediately implanted into a small muscle slit made in the NMZ of the muscle where denervated motor endplates were concentrated. The outcomes of DNI-NMZ reinnervation were evaluated 3 months after surgery. Specifically, the degree of functional recovery was examined with muscle force measurement. The extent of nerve regeneration and endplate reinnervation was assessed using histological and immunohistochemical methods.

Results This study showed that the mean muscle force of the treated muscles was 64% of the contralateral control. Reinnervated SM muscles weighed 71% of the weight of the control muscles. Abundant regenerated axons were identified in the NMZ of the target muscle. The mean number and area of the regenerated axons in the treated muscles was computed to be 62% and 51% of the control muscles, respectively. On average, 66% of the denervated endplates in the treated muscles were reinnervated by regenerated axons.

Conclusion Our results suggest that the NMZ within a muscle is an ideal site for endplate reinnervation and satisfactory functional recovery. Further studies are needed to promote the efficacy of DNI-NMZ technique for muscle reinnervation.

Keywords
► direct nerve implantation
► nerve regeneration
► muscle force measurement

Peripheral nerve injuries (PNIs) are very common in both military1 and civil2,3 circumstances. Current nerve repair methods include nerve end-to-end anastomosis, end-to-side neurorrhaphy, nerve grafting, nerve transfer, muscular neurotization, tubulization techniques, and many others.4–9 Unfortunately, the currently used methods result in poor muscle reinnervation and functional recovery. Therefore, there is a great need to seek new strategies for the treatment of PNI-related muscle paralysis.

Direct nerve implantation (DNI) or muscular neurotization is commonly performed when the distal stump of the injured nerve is not available for nerve repair.8,10 The proximal stump
of the original nerve or a healthy but less valuable foreign motor nerve can be implanted into a denervated muscle to restore its motor function. DNI has been used for selective reinnervation of paralyzed laryngeal and facial muscles\textsuperscript{11,12} as well as the extremities.\textsuperscript{8,10} However, further studies are needed to determine the potential of DNI in muscle reinnervation and functional recovery.

Our recent study has demonstrated that the native motor zone (NMZ) of the target muscle is the best site for muscle reinnervation.\textsuperscript{13} The concept is that the NMZ in a muscle contains numerous motor endplates which are preferentially reinnervated. Previous studies showed that after nerve injury regenerating axons preferentially grow into and reinnervate the regions of the original endplates.\textsuperscript{14–18} Using DNI model, some investigators observed preferential reinnervation of the native endplates in the target muscle by abundant regenerating axons and sprouts.\textsuperscript{19,20} However, little is known whether DNI-NMZ reinnervation could result in satisfactory functional recovery.

This study was designed to test our hypothesis that better functional outcome could be achieved by implanting a nerve stump into the NMZ of the target muscle. The reinnervated muscles were assessed using morphological, immunohistochemical, and electrophysiological techniques to determine the extent of muscle reinnervation and functional recovery.

**Materials and Methods**

**Animals**

Experiments were performed on 3-month-old female Sprague-Dawley rats (Taconic Laboratories, Cranbury, NJ) with body masses ranging from 200 to 250 g at initial operation. The experiments and procedures were ethically reviewed and approved by the Institutional Animal Care and Use Committee prior to the onset of experiments. All animals were handled in accordance with the Guide for Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication no. 85–23, revised 1996). The animals were housed at a constant temperature (22°C) on a 12 hour light–dark cycle and were provided with food and water in the state of the art animal housing facilities of Hackensack University Medical Center.

**Direct Nerve Implantation-Native Motor Zone Procedures**

A total of 15 animals were used to perform the DNI-NMZ procedure. The right sternomastoid (SM) muscle was experimentally denervated and reinnervated with DNI-NMZ. As SM muscle model was used in our previous muscle reinnervation studies,\textsuperscript{21–27} there is a solid database regarding its innervation pattern and contractile properties available for comparison.

Surgical procedures were conducted under aseptic conditions. Animals underwent general anesthesia with a mixture of ketamine (80 mg/kg body weight) and xylazine (5 mg/kg body weight) administered intraperitoneally. A midline cervical incision was made extending from the hyoid bone to the sternum to expose the right SM muscle and its innervating nerve under an operating microscope. The right SM muscle was denervated by transecting its innervating nerve at its entrance to the muscle. The proximal stump of the severed nerve was immediately buried into a small slit made in the NMZ of the denervated SM muscle and secured in position with an epineurial suture of 10–0 nylon (\textendash Fig. 1). After surgery, the wound was closed.

Additional control study was run on 17 denervated rats in an identical experimental setup to that described earlier. The only difference between the surgery in the control and the DNI-NMZ groups was that in the control group after denervation rats were not subjected to the DNI-NMZ reinnervation. The right SM muscle was denervated by resecting a 5 mm segment of its innervating nerve and the cut ends of the nerve were then coagulated with a bipolar cautery to prevent nerve regeneration.

At the end of the 3-month recovery period, all experimental animals underwent postoperative evaluations to assess functional recovery, nerve regeneration, and muscle reinnervation. For each animal, contralateral intact SM served as a control.

**Maximal Tetanic Force Measurement**

The degree of functional recovery of the reinnervated SM was detected using muscle force measurement as previously reported in our previous publications\textsuperscript{21,24–27} and others.\textsuperscript{12,28,29} Briefly, SM was exposed and dissected. The rostral tendon of the muscle was severed close to the insertion, tied with a 2–0 suture, and connected to a servomotor lever arm (model 305B Dual-Mode Lever Arm System; Aurora Scientific Inc, Aurora, Ontario, Canada). The SM nerve on each side was stimulated using a bipolar stimulating electrode.

A stimulation and recording system (National Instruments Corp, Austin, TX) controlled by user-written LabVIEW software (National Instruments Corp) was used to deliver biphasic rectangular pulses to the nerve stimulated. Isometric contraction of the SM muscle was produced with 200-millisecond trains of biphasic rectangular pulses. The duration of each phase of stimulation pulse was set at 0.2 milliseconds and the train frequency was set at 200 pulses per second. The stimulation current was gradually increased until the tetanic force reached a plateau. A break of at least 1 minute was taken before the next measurement was attempted. The maximum value of muscle force during the 200-millisecond contraction was identified, as well as initial passive tension before stimulation. The difference between the maximal active force and the preloaded passive force was used as the muscle force measurement. The force generated by the contraction of the SM muscle was transduced with the servomotor of a 305B lever system and displayed on a computer screen. At the moment of force measurement, the lever arm was stationary, and the muscle was adjusted to the optimal length for the development of maximum force. During the experiment, the rat was placed supine on a heating pad, and the core body temperature was monitored with a rectal thermistor and maintained at 36°C. The muscle and nerve examined were bathed regularly with mineral oil warmed to 35°C.

The force data were obtained and processed by an acquisition system built from a multifunction I/O National Instruments Acquisition Board (NI USB 6251; 16 bit, 1.25 Ms/s;
National Instruments) connected to a Dell laptop with a custom-written program using LabVIEW 8.2 software. The system produced stimulation pulses, which, after isolation from the ground through an optical isolation unit (Analog Stimulus Isolator model 2200; AM Systems, Inc, Carlsborg, WA), were used for the current controlled nerve stimulation. The acquisition system was also used to control muscle length and to collect a muscle force signal from the 305B Dual-Mode Lever System. Collected data were analyzed with DIAdem 11.0 software (National Instruments).

Muscle Tissue Preparation
Immediately after force measurement, SM muscles on both sides in each animal were removed and weighed. Each muscle was divided into three segments: rostral, middle, and caudal. The muscle segments were frozen in melting isopentane cooled with dry ice and cut in a cryostat (Reichert-Jung 1800; Mannheim, Germany) at −25°C. For each muscle, the caudal and rostral segments were cut transversely (10 µm). The cross sections were stained with routine hematoxylin and eosin staining to examine muscle structure and myofiber morphology. The middle muscle segment was cut sagittally (60 µm) and immunostained to document nerve regeneration and reinnervation of the denervated endplates in the target muscle. For comparison, five right SM muscles denervated for 3 months by resecting a 5-mm segment of its innervating nerve in five additional rats were also prepared as described earlier and processed together with the experimental muscles.

Assessments of Regenerated Axons and Reinnervated Endplates
Neurofilament Immunostaining
Some sagittal sections were immunostained with a monoclonal antibody against phosphorylated neurofilament (NF)
(SMI-31, Covance Research Products, Berkeley, CA) as a marker for all axons as described in our previous publications. Briefly, the sections were: (1) placed in Zamboni fixative with 5% sucrose for 20 minutes at 4°C, (2) treated with 1.0 mol/L of glycine in 1.5 T buffer for 30 minutes and dipped in 100% methanol at –20°C, (3) blocked in 1.5 T buffer containing 4% normal goat serum for 30 minutes, (4) incubated overnight at 4°C with primary antibodies (SMI-31 to detect neurofilaments and SMI-81 to label thinner axons; Covance Research Products, Berkeley, CA), (5) incubated at room temperature for 2 hours both with a secondary antibody (goat antimouse antibody conjugated to Alexa 488) and with α-bungarotoxin-labeled postsynaptic acetylcholine receptor site in the endplates (red). For each muscle sample, 50 labeled endplates were randomly selected to determine the percentages of the innervated (visible axon attachment) and noninnervated (no visible axon attachment) endplates.

### Statistical Analysis

Muscle weights, force values, the number and the area fraction of NF-ir axons, and innervated and noninnervated endplates of the operated and unoperated SM muscles in each rat were computed. The variables of the reinnervated SM muscles were expressed as the percentages of the values of the contralateral control muscles. All data were presented as mean ± standard deviation. The Student t test (paired, 2-tailed) was used to compare differences in the mean values of the variables examined between operated and unoperated SM muscles. A difference was considered statistically significant at p < 0.05.

### Results

#### Muscle Force Recovery

Muscle force data were successfully collected from both sides in 14 rats as the nerve on the operated side in one rat was damaged during muscle force recording. The degree of functional recovery of the reinnervated SM muscle was determined as compared with the force value of the contralateral control muscle in each rat. The DNI-NMZ reinnervated SM muscles produced 63.6% of the maximal tetanic tension of the contralateral control muscles (Fig. 2). Averaged maximal muscle force at the operated side was 0.763 N, whereas 1.200 N at the contralateral control side. The difference between these averages (0.437 N) was statistically significant (p = 0.0013, t = 4.08, df = 13, two-sided t test). The average rate (calculated between operated and control muscles) was 0.640. This rate was statistically different from 1 (p = 0.0022, t = 3.80, two-sided single sample t test).

#### Muscle Mass and Morphology

At the end of experiment, muscle examination showed that the mass of the DNI-NMZ reinnervated muscle was smaller than that of the contralateral control (Fig. 3A and B). The mean value of the wet weight of the reinnervated SM muscles (0.251 g) was smaller compared with that of the control muscles (0.352 g), but larger than that of the denervated SM muscles (0.199 g). Specifically, DNI-NMZ reinnervated SM muscles weighed 71% of the weight of contralateral control muscles (Table 1). The SM muscles reinnervated with the DNI-NMZ technique and studied 3 months later were greater in size than the SM muscles left with complete denervation for 3 months. The mean percent rate of wet weight of DNI-NMZ reinnervated SM muscles in relation to normal contralateral side (71%, with standard deviation [STD] = 0.11, n = 15) was much higher than the rate of the denervated SM muscles in relation to normal contralateral side (44%, with STD = 0.20, n = 17; t = 4.72, df = 30, p < 0.00001). Man–Whitney U test confirmed strong significant difference in percentage rates between the two groups (U_A = 223.5, U_B = 31.5, p = 0.00012).

Stained histological sections showed that the DNI-NMZ reinnervated muscles exhibited slight-to-moderate fiber atrophy as compared with the controls (Fig. 3C and D). In contrast, denervation resulted in significant myofiber atrophy as indicated by a reduction in fiber size and an increase in connective tissue (data not shown).

#### Nerve Regeneration and Endplate Reinnervation

Three months after surgery, muscle sections immunostained for NF exhibited abundant axons in the NMZ of the target muscle. The regenerating axons were derived from the implanted SM nerve and supplied the denervated NMZ of the treated muscle (Fig. 4A). The density of the regenerated axons in the reinnervated muscles as indicated by the number...
and the area fraction of labeled axons was summarized in Table 2. The mean number and area of the NF-ir axons in the reinnervated SM muscles (Fig. 4A and 4A’) was computed to be 62% and 51% of the contralateral control muscles (Fig. 4B and 4B’), respectively.

Double fluorescence staining showed the innervated and noninnervated endplates. In the treated SM, the regenerated axons were identified in the NMZ of the target muscle to innervate the denervated endplates (Fig. 5). On average, 66% of the denervated endplates in the treated muscles were reinnervated by regenerated axons and 34% of the endplates were unoccupied by axons. In addition, axonal sprouts and newly formed small endplates were identified in the DNI-NMZ reinnervated muscles.

Discussion

To our knowledge, this is the first study to explore whether DNI into the NMZ of the denervated muscle could restore better motor function in a rat model. There are several key findings. First, DNI-NMZ resulted in satisfactory functional recovery as indicated by muscle force measurement. Specifically, DNI-NMZ reinnervated SM muscles produced 64% of the maximal tetanic force of the contralateral control muscles 3 months after surgery. Second, the muscle mass (71% of the control) and myofiber morphology of the DNI-NMZ reinnervated muscles were preserved well. Third, reinnervated muscles gained abundant regenerated axons as indicated by the mean number (62% of the control) and area (51% of the control) of the NF-ir axons in the target muscle. Finally, 66% of the denervated endplates in the treated muscles were reinnervated by regenerated axons.

DNI into the denervated muscle (neurotization) has been used in animal studies and clinical practice to reinnervate denervated muscles. Preclinical and clinical studies have demonstrated that the outcome of DNI is associated with the chronicity of denervation, regeneration distance, and surgical techniques. However, little is known whether DNI-NMZ reinnervation results in satisfactory functional recovery.

The NMZ is generally located in the middle region of a skeletal muscle and contains an endplate band with numerous neuromuscular junctions and their innervating nerve terminals. As endplate reinnervation is critical for motor recovery, we implanted a nerve stump into the NMZ of the target muscle to determine the outcomes of DNI-NMZ procedure. The data from this study showed that DNI-NMZ resulted in better functional recovery (64% of the control) as compared with the method reported in other studies (50%), in which DNI was not specifically performed in the NMZ of the denervated muscles. Our encouraging results should be attributed to such a fact that DNI-NMZ procedure shortens...
Table 1  Comparison of wet muscle weight between right operated and left control sternomastoid (SM) muscles in rats \( (n = 15) \)

<table>
<thead>
<tr>
<th>Animal (No.)</th>
<th>Body weight (g)</th>
<th>Right reinnervated SM (g)</th>
<th>Left intact SM (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>353</td>
<td>0.234</td>
<td>0.352</td>
</tr>
<tr>
<td>2</td>
<td>347</td>
<td>0.250</td>
<td>0.392</td>
</tr>
<tr>
<td>3</td>
<td>343</td>
<td>0.220</td>
<td>0.312</td>
</tr>
<tr>
<td>4</td>
<td>340</td>
<td>0.286</td>
<td>0.382</td>
</tr>
<tr>
<td>5</td>
<td>327</td>
<td>0.275</td>
<td>0.298</td>
</tr>
<tr>
<td>6</td>
<td>322</td>
<td>0.300</td>
<td>0.417</td>
</tr>
<tr>
<td>7</td>
<td>355</td>
<td>0.277</td>
<td>0.355</td>
</tr>
<tr>
<td>8</td>
<td>328</td>
<td>0.212</td>
<td>0.390</td>
</tr>
<tr>
<td>9</td>
<td>316</td>
<td>0.160</td>
<td>0.282</td>
</tr>
<tr>
<td>10</td>
<td>332</td>
<td>0.229</td>
<td>0.310</td>
</tr>
<tr>
<td>11</td>
<td>355</td>
<td>0.210</td>
<td>0.361</td>
</tr>
<tr>
<td>12</td>
<td>378</td>
<td>0.253</td>
<td>0.356</td>
</tr>
<tr>
<td>13</td>
<td>349</td>
<td>0.299</td>
<td>0.341</td>
</tr>
<tr>
<td>14</td>
<td>407</td>
<td>0.312</td>
<td>0.390</td>
</tr>
<tr>
<td>15</td>
<td>380</td>
<td>0.255</td>
<td>0.336</td>
</tr>
<tr>
<td>Average</td>
<td>349</td>
<td>0.251</td>
<td>0.352</td>
</tr>
</tbody>
</table>

| Ratio, %     | 71              | 100                       |

Fig. 3  Photographs of a pair of sternomastoid (SM) muscles removed from a rat 3 months after surgery, showing the morphological difference between the reinnervated and contralateral control muscles. (A) An image taken before removal of the SM muscles, showing the implanted SM nerve (arrow). (B) Removed SM muscles from the same animal in A. Note that the mass of the right (R) operated SM muscle (0.312 g) was smaller as compared with that of the left (L) control muscle (0.390 g). (C–D) Hematoxylin and eosin -stained cross sections from the SM muscles in B. Note that the right reinnervated muscle (C) exhibited mild to moderate myofiber atrophy as compared with the control (D). Initial magnification 200× for C and D.
the distance between the nerve implantation site and the denervated endplates in the target muscle. Therefore, the regenerating axons from the implanted nerve could easily reach and reinnervate the denervated endplates in the NMZ of the treated muscle. In contrast, if a nerve cut end is implanted into an area outside the NMZ it will take time to form new motor endplates and synapses. As reported, functional recovery may not be achieved for a long period after

Fig. 4 Images of sagittal sections immunostained for neurofilament (NF) from the operated and unoperated sternomastoid (SM) muscles of the rat number 15. (A) Six microscopic fields in a stained section from the right operated SM (first column), showing the NF-positive axons (dark staining) in the native motor zone of the target muscle. Magnification 200×. (A') The images in the first column were converted to black and white (second column) by use of ImageJ software to calculate the number and percent area of staining in each section (mean axon count, 533; 56% of the control; mean area, 0.636; 43% of the control). (B–B') Images from the left unoperated SM (mean axon count, 974; mean area, 1.479). Magnification 200×.
DNI surgery. Studies have demonstrated that after nerve injury, functional motor recovery is primarily determined by endplate reinnervation and the absolute number of regenerated motor axons that reach target.

Although our experiments showed the potential of DNI-NMZ in immediate muscle reinnervation, this study also has some limitations. For example, postoperative evaluations were performed at the end of 3 months after surgery. Three-month recovery period may be not enough to provide a complete picture of what occurs after DNI-NMZ. Further studies are needed to determine morphological and functional alterations at different time points after DNI-NMZ reinnervation. This information would be helpful for better understanding the time-related changes of muscle reinnervation and functional recovery. In addition, it remains unknown if the DNI-NMZ has the potential for delayed reinnervation that is not uncommon in clinical practice. One of our ongoing studies is to determine the efficacy of DNI-NMZ for chronic muscle denervation. For this purpose, it is important to know the decreasing rate of the endplates in the completely denervated muscle and to determine the time point when all the endplates cannot be detected.

For future clinical application of this technique, our ongoing work is to promote the efficacy of DNI-NMZ reinnervation by further refining surgical procedure and accelerating

**Table 2** Comparison of count and percent area of neurofilament-positive axons between right operated and left control sternomastoid (SM) muscles in rats (n = 15)

<table>
<thead>
<tr>
<th>Animal (No.)</th>
<th>Right SM</th>
<th></th>
<th></th>
<th>Left SM</th>
<th></th>
<th></th>
<th>Ratio (R/L)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Count</td>
<td>Percent area</td>
<td>Count</td>
<td>Percent area</td>
<td>Count</td>
<td>Percent area</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>511</td>
<td>0.412</td>
<td>1640</td>
<td>1.336</td>
<td>0.312</td>
<td>0.308</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>668</td>
<td>0.430</td>
<td>678</td>
<td>0.626</td>
<td>0.985</td>
<td>0.687</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>420</td>
<td>0.552</td>
<td>1160</td>
<td>1.145</td>
<td>0.362</td>
<td>0.482</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>300</td>
<td>0.456</td>
<td>720</td>
<td>0.566</td>
<td>0.417</td>
<td>0.806</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>473</td>
<td>0.762</td>
<td>510</td>
<td>0.908</td>
<td>0.927</td>
<td>0.839</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>441</td>
<td>0.560</td>
<td>1074</td>
<td>1.358</td>
<td>0.411</td>
<td>0.412</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>312</td>
<td>0.370</td>
<td>600</td>
<td>1.100</td>
<td>0.520</td>
<td>0.336</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>340</td>
<td>0.247</td>
<td>649</td>
<td>0.931</td>
<td>0.524</td>
<td>0.265</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>624</td>
<td>0.623</td>
<td>861</td>
<td>1.295</td>
<td>0.725</td>
<td>0.481</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>671</td>
<td>0.660</td>
<td>752</td>
<td>1.303</td>
<td>0.892</td>
<td>0.507</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>499</td>
<td>0.640</td>
<td>623</td>
<td>1.557</td>
<td>0.801</td>
<td>0.411</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>435</td>
<td>0.511</td>
<td>814</td>
<td>1.496</td>
<td>0.534</td>
<td>0.342</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>319</td>
<td>0.509</td>
<td>893</td>
<td>1.280</td>
<td>0.357</td>
<td>0.398</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>748</td>
<td>0.630</td>
<td>751</td>
<td>0.716</td>
<td>0.996</td>
<td>0.880</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>533</td>
<td>0.636</td>
<td>947</td>
<td>1.479</td>
<td>0.563</td>
<td>0.430</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average</td>
<td>486</td>
<td>0.533</td>
<td>845</td>
<td>1.140</td>
<td>0.622</td>
<td>0.506</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: L, left; R, right.

**Fig. 5** Sagittal sections immunostained with double fluorescence staining of the right sternomastoid (SM) muscle reinnervated by direct nerve implantation-native motor zone in a rat, showing reinnervated and nonreinnervated motor endplates. Note that some of the endplates were reinnervated by the regenerated axons (arrows in A–C), while others in the same muscle were unoccupied by regenerated axons (arrowheads in A–C). Original magnification 200× for A through C.
axonal regeneration. For example, the nerve stump can be divided into two or more fascicles before implantation. Direct implantation of the divided nerve fascicles into the target muscle has shown to enhance end results. This procedure can be applied to DNI-NMZ for better results. For accelerating axonal regeneration, a very brief 1-hour period of low-frequency (20 Hz) continuous electrical stimulation of the proximal nerve stump at the time of operation and local administration of neurotrophic factors could be combined with DNI-NMZ technique to enhance axonal regeneration. We believe that these approaches would promote the outcomes of the DNI-NMZ technique.

Conclusion

In summary, DNI-NMZ technique appears to be a promising reconstructive option for muscle reinnervation. DNI-NMZ has the potential for functional motor restoration of denervated muscles in certain conditions. For optimal outcome, further studies are needed to promote the efficacy of this technique.

Acknowledgments

The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702–5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs under Award No. W81XWH-14-1-0442 (to Dr. Liancai Mu). Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense.

In conducting research using animals, the investigators adhere to the laws of the United States and regulations of the Department of Agriculture. This protocol was approved by the USAMRMC Animal Care and Use Review Office (ACURO) for the use of rats.

References

1 Brininger TL, Antczak A, Breland HL. Upper extremity injuries in the U.S. military during peacetime years and wartime years. J Hand Ther 2008;21(2):115–122, quiz 123
4 Siemionow M, Brzezicki G. Chapter 8: current techniques and concepts in peripheral nerve repair. Int Rev Neurobiol 2009;87:141–172
9 de Medinaceli L, Prayon M, Merle M. Percentage of nerve injuries in which primary repair can be achieved by end-to-end approximation: review of 2,181 nerve lesions. Microsurgery 1993;14(4):244–246
13 Mu L, Sobotka S, Chen J, Nyirera T. Reinnervation of denervated muscle by implantation of nerve-muscle-endplate band graft to the native motor zone of the target muscle. Brain Behav 2016. PMID: 27737470
22 Zhang X, Mu L, Su H, Sobotka S. Locations of the motor endplate band and motoneurons innervating the sternomastoid muscle in the rat. Anat Rec (Hoboken) 2011;294(2):295–304
42 Jubran M, Widenfalk J. Repair of peripheral nerve transections with fibrin sealant containing neurotrophic factors. Exp Neurol 2003;181(2):204–212
# Immunohistochemical Detection of Motor Endplates in the Long-Term Denervated Muscle

<table>
<thead>
<tr>
<th>Journal:</th>
<th><em>Journal of Reconstructive Microsurgery</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>JRM-17-09-0252</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Original Article</td>
</tr>
<tr>
<td>Keywords:</td>
<td>denervation, peripheral nerve injury, motor endplate</td>
</tr>
</tbody>
</table>
Immunohistochemical Detection of Motor Endplates in the Long-Term Denervated Muscle

Liancai Mu, MD, PhD, Jingming Chen, MD, Jing Li, BS, Themba Nyirenda, PhD, Mary Fowkes, MD, PhD, Stanislaw Sobotka, PhD, DSc

1 Department of Biomedical Research,
Hackensack University Medical Center,
Hackensack, New Jersey

2 Department of Neurosurgery,
Icahn School of Medicine at Mount Sinai,
New York, New York

3 Department of Pathology,
Icahn School of Medicine at Mount Sinai,
New York, New York

Running title: Motor Endplates in the Long-Term Denervated Muscle

Correspondence to: Liancai Mu, MD, PhD,
Department of Biomedical Research,
Hackensack University Medical Center,
Hackensack, NJ 07601
Tel. (551) 996-5178
FAX: (201) 996-3263
Email: Liancai.Mu@hackensackmeridian.org
Abstract

**Background** We have demonstrated that the native motor zone (NMZ) within a muscle is an ideal target for performing nerve-muscle-endplate band grafting (NMEG) to restore motor function of a denervated muscle. This study was designed to determine spatiotemporal alterations of the myofibers, MEPs and axons in the NMZ of long-term denervated muscles for exploring if NMEG-NMZ technique would have the potential for delayed reinnervation.

**Methods** Sternomastoid (SM) muscles of adult female Sprague-Dawley rats (n = 21) were experimentally denervated and denervation-induced changes in muscle weight, myofiber size, MEPs, and intramuscular nerve axons were evaluated histomorphometrically and immunohistochemically at the end of 3, 6, and 9 months after denervation. The values obtained from the ipsilateral normal side served as control.

**Results** The denervated SM muscles exhibited a progressive reduction in muscle weight (38%, 31%, and 19% of the control) and fiber diameter (52%, 40%, and 28% of the control) for 3-, 6-, and 9-month denervation, respectively. The denervated MEPs were still detectable even 9 months after denervation. The mean number of the denervated MEPs was 79%, 65%, and 43% of the control in the 3-, 6-, and 9-month denervated SM, respectively. Degenerated axons in the denervated muscles became fragmented.

**Conclusion** Persistence of MEPs in the long-term denervated SM suggests that some surgeries targeting the MEPs such as NMEG-NMZ techniques should be effective for delayed reinnervation. However, more work is needed to develop strategies for preservation of muscle mass and MEPs after denervation.

**Keywords** denervation; peripheral nerve injury; motor endplate; acetylcholine receptor; muscle fiber atrophy; native motor zone
Introduction

Peripheral nerve injury (PNI) results in muscle denervation characterized by deleterious changes including progressive myofiber atrophy, loss of muscle mass, and functional impairment. These denervation-induced morphological and functional changes can be reversed by reinnervation. However, functional recovery is frequently poor following PNI and nerve repair, especially in cases with chronic denervation or delayed nerve reconstruction. The poor functional recovery after PNI and nerve repair is closely associated with insufficient axonal regeneration and reinnervation of the denervated motor endplates (MEPs) in the target muscle. Recent studies by Dr. Gordon’s laboratory have demonstrated that chronic distal nerve stump denervation, induced by delayed nerve repair or prolonged regeneration distance, is the key factor leading to reduced axonal regeneration and subsequently poor functional outcome.

Our recent studies highlight the importance of native motor zone (NMZ) of the target muscle in reinnervation surgeries. We developed a novel microsurgical method called “nerve-muscle-endplate band grafting (NMEG)” for muscle reinnervation. The idea is that a paralyzed muscle could be reinnervated by transplanting an NMEG from a neighboring donor muscle. A healthy nerve branch and terminals that innervate an expendable muscle can be transplanted to a more functionally important denervated muscle for restoring its motor function. In our animal experiments, a NMEG pedicle containing a nerve branch and a muscle block with nerve terminals and MEPs was harvested from the sternohyoid (SH) muscle and transplanted into the ipsilateral experimentally denervated sternomastoid (SM) muscle. In a rat immediate reinnervation model, we recently demonstrated that implantation of the NMEG into the NMZ of the target muscle, which lies in the midregion of the muscle, yielded better functional recovery (82% of the control) 3 months after surgery when compared with implantation of the NMEG into an aneural region in the target muscle (67%). Our studies have documented that the NMZ of the target muscle is the best site to design some microsurgical procedures such as NMEG-NMZ and/or direct nerve implantation (DNI) into the NMZ for muscle reinnervation. The satisfactory outcomes of NMEG-NMZ and DNI-NMZ reinnervation procedures should be attributed to such a fact that both techniques could reduce nerve regeneration distances.
and favor rapid axon-MEP connections. The regenerating axons from the implanted nerve or NMEG pedicle could easily reach and reinnervate the denervated MEPs in the NMZ of the target muscle. The re-established functional synapses could avoid muscle atrophy and restore motor function.

Although NMEG-NMZ or DNI-NMZ has the potential for immediate muscle reinnervation, it remains unknown if such techniques are effective for restoration of motor function of long-term denervated muscles. In the clinical setting, some patients suffer from PNI-induced muscle denervation for years. It has been reported that prolonged delay in the reinnervation of skeletal muscle leads to poor functional recovery because reinnervation is incomplete. The incomplete restoration of long-term denervated muscle is related to a failure of regenerating nerves to reach all of the atrophic muscle fibers and establish mature muscle-nerve contacts. Time to reinnervation is one of the most important determinants of functional outcome because muscle fibers progressively undergo an irreversible degeneration process, if reinnervation does not occur. The degree of functional restoration of the target muscle following reinnervation procedures is inversely related to the denervation time: i.e., the longer the muscle denervation, the poorer the functional outcome following reinnervation surgeries. It is therefore important to directly determine if MEPs are preserved in the chronically denervated muscles. However, neuromuscular alterations induced by long-term denervation of the SM muscle have yet to be determined. The time-course of morphological changes and progression of postdenervation atrophy of the muscle have never been determined. It is necessary to determine the presence or absence of the MEPs in the long-term denervated muscle because the presence of a greater number of preserved MEPs in the target muscle is important for more efficient and successful reinnervation.

The purpose of this study was to investigate the effect of prolonged denervation on the degradation of the existing junctional acetylcholine receptors (AChRs) at MEPs of the rat SM muscle. Specifically, we sought to determine whether or not the MEPs can be detected after prolonged periods of denervation for providing the baseline for future application of the NMEG-NMZ reinnervation technique to treat PNI-induced chronic muscle paralysis. The information about the morphological and histochemical alterations in
myofibers and MEPs at different time points following denervation can help to design effective surgical procedures and other therapeutic strategies to delay or prevent myofiber atrophy and MEP degradation following PNI. We hope to gain greater insight into the potential treatment of chronic muscle paralysis by NMEG-NMZ and other therapies.

Materials and Methods

Animals

Twenty-one three-month-old female Sprague-Dawley rats (Taconic Laboratories, Cranbury, NJ) weighing from 200 to 250 g were used. All protocols for animal procedures were approved by the Institutional Animal Care and Use Committee prior to the onset of experiments. All animals were handled in accordance with the Guide for Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23, revised 1996). The rats were housed at a constant temperature (22°C) on a 12 hours light/dark cycle and were given food and water as desired.

Muscle Denervation

The 21 rats were randomly allocated into 3 groups each comprising 7 animals on the basis of the observation period after SM nerve resection. The animals in the 3 groups were euthanized with an overdose of ketamine and xylazine 3 months, 6 months, or 9 months after SM denervation. For each animal, all the assessments were performed from both SM muscles and the contralateral SM served as a control.

Muscle denervation was performed using aseptic techniques. The animals were anesthetized with intraperitoneal ketamine (80 mg/kg) and xylazine (5 mg/kg). Under an Olympus SZX12 Stereo zoom surgical microscope (Olympus America Inc, Center Valley, Pennsylvania), the right or left SM muscle was exposed via a vertical midline skin incision and its innervating nerve was identified and isolated from surrounding tissues. The muscle was denervated by resecting a 5-mm segment of SM nerve. Both the distal and proximal ends of the nerve were then coagulated with a bipolar cautery to prevent nerve regeneration.
After completing muscle denervation, the wound was closed in layers with interrupted simple sutures of 4-0 Prolene.

Denervation of the SM muscles was prolonged for periods of 3, 6, and 9 months. At the end of each denervation period, muscle weight, fiber size, and MEPs were measured and compared between denervated and contralateral control SM muscles.

**Muscle Weight Measurement and Tissue Preparation**

At the end of the experiment 3, 6, and 9 months after denervation, both SM muscles for each rat were harvested, photographed, and weighed. Wet muscle weights, shown to closely reflect the degree of denervation, were reported as a ratio of the denervated to the contralateral control side. Each of the removed SM muscles was divided into three segments: rostral, middle, and caudal. The muscle segments were then frozen in melting isopentane cooled with dry ice and cut on a cryostat (Reichert-Jung 1800; Mannheim, Germany) at –25°C. The rostral and caudal segments were cut transversely and serial cross-sections (10 µm) were stained histologically and immunohistochemically to examine denervated and atrophic myofibers. The middle segment containing the NMZ was cut sagittally (60 µm) and immunostained to detect and quantify MEPs and axons.

**Identification of Denervated and Atrophic Myofibers**

*Immunofluorescent Labeling of Neural Cell Adhesion Molecule*

Denervated myofibers were detected from whole SM cross sections using immunohistochemical labeling for neural cell adhesion molecule (N-CAM), a molecular marker of muscle fiber denervation. N-CAM is a developmental molecule, is present on the surface of embryonic myotubes, declines in level as development proceeds, nearly disappears in the adult muscle, reappears when adult muscles are denervated, and is lost after reinnervation. 19-21 N-CAM immunoreactivity on muscle fiber membranes in cross-sections provides a sensitive means of detecting denervated fibers in the denervated muscles. 20,22,23 In this study,
immunofluorescent labeling of N-CAM protein was performed to detect N-CAM immunoreactive myofibers in the rat SM muscles by using the method as described previously.\textsuperscript{23} Briefly, some cross-sections were: (1) fixed with methanol for 20 minutes at \(-20^\circ\text{C}\); (2) incubated with 5\% goat serum (Sigma, St. Louis, MO) in phosphate-buffered saline (PBS) for 30 minutes to inhibit non-specific binding; (3) incubated with a highly purified primary monoclonal rabbit antirat N-CAM antibody (Chemicon, Temecula, CA) for 2 hours; and (4) incubated with a secondary CY3-conjugated goat antirabbit IgG (Jackson ImmunoResearch laboratories, West Grove, PA) at room temperature for 1 hour. The sections were washed extensively in PBS between steps. Control sections were stained as described above except that the incubation with the primary antibody was omitted. The stained sections were mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA) and kept in dark at 4\(^\circ\text{C}\).

The stained sections were examined under a Zeiss fluorescence microscope (Axioplan-1; Carl Zeiss, Gottingen, Germany) and photographed using a USB 3.0 digital microscope camera (Infinity 3-3URC, Lumenera Corp., Ottawa, Canada).

**Fiber Diameter Measurement**

Some cross-sections were immunostained with a monoclonal antibody NOQ7-5-4D against type I myosin heavy chain for fiber diameter measurement as this staining outlines fiber contour clearly. The avidin-biotin complex method was used as described in our previous publication.\textsuperscript{24} Briefly, the sections were fixed in 4\% paraformaldehyde for 10 minutes, blocked in 2\% bovine serum albumin (BSA) with 0.1\% Triton X-100 for 20 minutes, incubated with primary antibody NOQ7-5-4D (Sigma, 1:1,000 dilution) for 1 hour at room temperature (RT), incubated with an antimouse IgG (ATCC, Rockville, MD) for 1 hour and reacted in avidin-biotin complex reagent (Vector Laboratories) for 1 hour at RT, reacted for 10 minutes at RT with a solution containing 3,3’-diaminobenzidine as chromogen to localize peroxidase for primary antibody according to a 3,3’-diaminobenzidine substrate kit (SK-4100; Vector Laboratories), and dehydrated in
graded concentrations of ethanol, cleared in xylene, and mounted with Permount (Fisher Scientific, Fair Lawn, NJ).

For a given muscle, three stained sections were randomly selected and photographed. For each section, images were taken at x200 from four microscopic fields at 4 quadrants of the muscle. The photographed images were imported into an image-processing program (ImageJ v. 1.45s; NIH, Bethesda, MD) to measure fiber diameter. In each muscle, at least 100 myofibers were randomly selected to measure the least fiber diameter (the maximum diameter across the least aspect of the muscle fiber) using a previously described method. Atrophic changes in the SM muscle were evaluated by comparing the mean fiber diameters between the denervated and control sides.

**Immunohistochemical detection of MEPs and Axons**

Some sagittal sections from the NMZ (middle segment) of the denervated and contralateral SM muscles in each rat were immunostained with triple fluorescence labeling to detect MEPs and intramuscular nerve axons, as described previously, with some modifications. Briefly, the sections were fixed for 20 minutes in Zamboni fixative with 5% sucrose at 4ºC. The fixed sections were washed extensively in 1.5T buffer (0.05 M Tris, pH 7.6 and 1.5% NaCl), treated with 0.1 mol/L of glycine in 1.5T buffer for 30 minutes, and dipped in 100% methanol at –20ºC for 20 minutes. The sections were blocked in 1.5T buffer containing 4% normal goat serum for 30 minutes to inhibit non-specific protein binding. Axons and terminals were detected by incubating the sections overnight at 4ºC with primary monoclonal antibodies (SMI-31 to detect neurofilaments, 1:1,000, Biolegend, San Diego, CA; and SVP-38 to reveal the presynaptic nerve terminals, occupying the primary synaptic gutters, 1:1,000, Sigma, St. Louis, MO). After washing with 1.5T buffer, the sections were incubated at room temperature for 2 hours both with Alexa Fluor 488 goat anti-mouse IgG secondary antibody (1:500; Invitrogen Corp., Carlsbad, CA) to label axons and with Alexa Fluor 596–conjugated α-bungarotoxin (1:500; Invitrogen) to visualize postsynaptic AChRs at MEPs. Control sections were stained as described, except that the incubation with the primary antibody was omitted. The sections
were washed several times with 1.5T buffer with 0.05% Tween-20 between steps. The stained sections were mounted with Vectashield mounting medium (Vector Laboratories) and kept in dark at 4°C.

The immunostained sections were viewed under a Zeiss fluorescence microscope and photographed using a USB 3.0 digital microscope camera. SMI-31 and SVP-38 detected axons and terminals (green), while α-bungarotoxin labeled postsynaptic AChRs at the MEPs (red). For each muscle sample, three stained sections were selected at different spatial levels through the muscle and photographed to examine MEP and axon profiles. The stained MEPs in the SM muscles on both sides were counted and denervated/control (D/C) ratio for each animal was computed.

Statistical Analysis
Wet muscle weights, fiber diameters, and MEP counts of the SM muscles in each rat were computed. All data were reported as mean ± standard deviation. The variables of the denervated SM muscles were expressed as the percentages of the values of the contralateral control muscles. Average rates in 3 studied groups were compared with one-way ANOVA for independent samples. Post hoc analysis was made with Tukey HSD test. Difference with \( p < 0.05 \) was treated as statistically significant. SAS v. 9.4 software was used in statistical analyses.

Results

Muscle Mass and Wet Weight
Denervation of the SM resulted in significant reductions in muscle mass. The size of the denervated SM was smaller than that of the contralateral control (Fig. 1A). The muscle weights of the denervated and control SM muscles and D/C ratio for each animal, as well as mean value and standard deviation of the wet weight for each group are summarized in Table 1. The mass values of the denervated muscles were inferior to those of the controls. The presence of muscle atrophy was confirmed post-mortem by the reduced weight of the denervated muscles which dropped to 38, 31, and 19% of the control muscles after 3-, 6-, and 9-month
denervation, respectively. The average muscle weight was significantly smaller in denervated than in control muscles \((t = 19.7, \text{df} = 20, p < 0.00001)\). Statistical analysis (one-way ANOVA) of the averaged rates of SM muscle weight (denervated to control) in these 3 groups indicated a strong trend toward decreasing rate with denervation time, but did not show statistical significant differences between these 3 groups \((F = 3.25, \text{df} = 2/18, p = 0.0627)\).

Note that the analysis was performed on assumption of normality holds, however when sample sizes are less than 10 (such as 7) the Shapiro-Wilk test of normality has little power to detect deviations from normality. In fact, the Kruskal-Wallis test reported a statistically significant difference between these groups \((p = 0.0422)\). The box plots illustrating the distribution of data in 3-month, 6-month, and 9-month groups are shown in Figure 2. Clearly, the reduction in the muscle mass is associated with denervation time.

Average body weights of all 3 groups (341g, 324g, and 366g) were not statistically different \((F = 1.57, \text{df} = 2/18, p = 0.235)\).

**Denervated and Atrophic Myofibers**

Muscle fibers after SM denervation underwent progressive atrophy (Fig. 1B). Long-term denervated muscles exhibited increased connective tissue with small atrophic muscle fibers. Most of the atrophic fibers were angular in shape.

Mean fiber diameters of the denervated and control muscles were summarized in Figure 3. The fiber diameters of the denervated muscles were reduced versus those of the controls. Specifically, the mean fiber diameters were reduced to 52%, 40%, and 28% of the control for 3-, 6-, and 9-month-denervation groups, respectively. Statistical analysis (one-way ANOVA) of the rates (denervated to control) of the muscle fiber diameter showed strong statistical significant difference between these 3 groups \((F = 17.7, \text{df} = 2/13, p = 0.000196)\). Post-hoc testing (Tukey HSD test) shows statistical difference between means of each pair of 3 groups. Average of 3-month denervation group is significantly larger than average of 9-month denervation group \((p < 0.01)\). Also average of 3-month denervation group is significantly larger than that of 6-month
denervation group \( (p < 0.05) \) and average of 6-month denervation group is significantly larger than that of 9-month denervation group \( (p < 0.01) \).

Denervated and atrophied myofibers in the SM were immunopositive for N-CAM protein. N-CAM was expressed around muscle fibers and/or muscle fibers displayed sarcoplasmic expression (Fig. 4). The N-CAM-positive fibers were very few in the control muscle (Fig. 4A). However, the majority of the myofibers in the long-term denervated muscles were labeled positively for N-CAM protein. Most of the N-CAM-positive fibers in the SM muscles were atrophied (Fig. 4B-D).

**Motor Endplates and Intramuscular Nerve Axons**

NMZ in the rat SM muscle contains intramuscular nerve terminals (Fig. 5A) and a MEP band with numerous neuromuscular junctions (Fig. 5B, C) as documented in our previous studies.\(^{12}\) The MEP band in the rat SM muscle was also visualized in the muscle sections immunostained with triple fluorescence staining (Fig. 6A-D). In the control muscle, the axons were confined in the NMZ (Fig. 6A) to innervate the MEPs (Fig. 6A\(^1\), A\(^2\)). A typical MEP had an elaborate, complex distribution of AChRs with a pretzel-like appearance (Fig. 6A\(^2\)), as described previously.\(^{28}\) In contrast, noninnervated MEPs (no visible axon attachment) were identified in all the denervated SM muscles. The mean number of the denervated MEPs was 79\%, 65\%, and 43\% of the control in the 3-, 6-, and 9-month denervated SM, respectively (Table 2). Statistical analysis (one-way ANOVA) of the rates (denervated to control) of MEP counts showed strong statistical significant difference between these 3 groups \( (F = 30.2, df = 2/18, p < 0.0001) \). Post-hoc testing (Tukey HSD test) shows statistical difference between means of each pair of 3 groups. Average of 3-month denervation group is significantly larger than average of 6-month \( (p < 0.05) \) and 9-month \( (p < 0.01) \) denervation groups. Also average of 6-month group is significantly larger than that of 9-month group \( (p < 0.05) \).

In the stained muscle sections, fragments and/or accumulations of axonal debris were identified (Fig. 6B-D\(^2\)). The long-term denervated muscles, especially 9-month-denervated muscles (Fig. 6D-D\(^2\)), showed
the presence of small, shrunken and distorted MEPs. Some of the denervated MEPs displayed broken and fragmented forms, and thin lengthened shapes.

Discussion

In this study, we investigated neuromuscular alterations induced by long-term denervation and demonstrated that complete SM denervation in the rat resulted in progressive reduction in muscle mass and myofiber size. We found that normal axons almost disappeared and replaced by accumulations of axonal debris 3 months after denervation. In contrast, MEP band was readily recognizable at all time points. Some denervated MEPs still remained certain characteristics such as a typical pretzel-like structure after the prolonged period of denervation. These findings suggest that some surgeries targeting the MEPs such as NMEG-NMZ and DNI-NMZ techniques should be effective for delayed reinnervation.

Denervation has been widely used in reinnervation and nerve regeneration studies. Our findings are in agreement with those observed by previous investigators, who reported that muscle denervation is followed by the progressive muscle atrophy and a loss of muscle mass. However, there is no consensus regarding denervation-induced MEP alterations, as increase, decrease, and no change in the MEP area have been reported. The number of junctional AChRs was shown to increase in the first week and to decrease at later times. In agreement with other investigators, we observed that a decrease in presynaptic nerve terminals preceded the decrease in the postsynaptic AChRs. When the nerve supply to muscle is interrupted, the MEP degenerates although the MEP itself may remain unaltered for relatively long periods. This study showed that MEPs were detected in 9-month-denervated SM muscle. These findings support the notion that postsynaptic AChRs of the vertebrate MEPs are remarkably stable in that they persist for long periods following denervation.

The MEP is the primary connection between lower motor neurons and its target skeletal muscle fiber. Communication between these two structures is vital for muscle contraction and movement, which is essential for maintaining myofiber properties. It is known that each of the mammalian skeletal muscle
fibers usually has one MEP which is located mid-way between its origin and insertion, thereby forming a narrow band in the middle of the muscle. MEP regions of mammalian muscle fibers are preferentially reinnervated as a consequence of some special property of the muscle fiber at this site. After nerve injury and/or direct nerve implantation, regenerating axons and sprouts have been identified to preferentially grow into the sites of the original MEPs and form synapses. Synaptic basal lamina at the MEP contains molecules that direct the formation of synaptic specializations on regenerating axon terminals and myofibers. Some other chemotropic substance released from the MEPs may attract the regenerating axons in the vicinity. Hence, reinnervation of the denervated MEPs in the NMZ of a target muscle must occur as a consequence of some property of the muscle fiber at this site which favors synapse formation.

The MEP band is a potential site for clinical and experimental manipulations since MEP is the physiological interface between the motoneuron and the muscle fiber. The NMZ in a muscle contains a MEP band with numerous neuromuscular junctions and their innervating axons. We have demonstrated that the NMZ within a given muscle is an ideal site for muscle reinnervation. Using an immediate reinnervation model, we have documented that NMEG-NMZ resulted in optimal functional recovery. However, it remains unknown if this technique has the potential for reinnervation of the long-term denervated muscles. The results from this study would be helpful for determining the proper timing for reinnervation of denervated muscles by NMEG-NMZ, DNI-NMZ, and/or other procedures that target MEPs. Our results suggest that the muscles denervated even for 6 months should have a good chance to be successfully reinnervated by NMEG-NMZ technique based on the preserved muscle mass and the reasonable number of the preserved original MEPs in these denervated muscles.

Denervation-induced neuromuscular alterations cause impairment of muscle functional properties that represent major impediments to successful surgical interventions. Previous studies showed that the muscle experienced irreversible muscle atrophy and weakness after 6 month of denervation. For optimal outcome of NMEG-NMZ and other reinnervation techniques in the treatment of long-term denervated muscle, additional approaches should be considered to maintain muscle mass and original MEPs before
irreversible structural or functional impairments occur. Without significant restoration of muscle mass and MEPs, delayed reinnervation of denervated muscle may produce limited effect on muscle function. Further research is needed to identify viable therapeutic targets to delay and/or prevent deterioration of the denervated muscle following PNI. When immediate nerve reconstruction is not possible, sensory protection may offer an option to avoid irreversible muscle atrophy and loss of opportunity for successful delayed reinnervation. Sensory protection provides a temporal protective effect on the denervated muscle before nerve repair and reinnervation procedures can be performed. Sensory protection techniques have been investigated in animal models\textsuperscript{55-62} and applied to humans.\textsuperscript{63} A donor sensory nerve can be coapted to the distal motor nerve stump or directly implanted into the denervated muscle (neurotization) for maintenance of muscle bulk. The donor sensory nerve is thought to provide trophic support to denervated muscle, thereby retarding and preventing irreversible denervation atrophy and preserving muscle volume and myofiber structures, and improving muscle function following denervation.\textsuperscript{55-64} In the sensory protected muscle, an increased number of MEPs has been also observed.\textsuperscript{62}

More work is needed to reveal specific therapeutic strategies for preventing MEP degradation following PNI. Preservation of the original MEPs in the denervated muscle is important for precise contact, synaptic differentiation, and maintenance of reestablished neural connections,\textsuperscript{47,65} and for successful reinnervation by NMEG-NMZ\textsuperscript{12} and DNI-NMZ.\textsuperscript{13} The benefit of surgery and successful functional rehabilitation is related to the time delay following onset of denervation and surgery. This study showed that the morphometric changes in muscle mass, fiber size, and MEPs were more pronounced in the 9-month-denervated muscles as compared with those in the 3- and 6-month-denervated muscles. Neurotrophic factors, which have neuroprotective and regenerative properties, have been intensely studied for their therapeutic potential in both the preclinical and clinical setting. There is growing evidence suggesting that some neurotrophic factors such as nerve growth factor (NGF), basic fibroblast growth factor (FGF-2), glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), and ciliary neurotrophic factor (CNTF) are intimately involved in the maturation, maintenance and reinnervation of the
MEPs and the recovery of motor function after denervation. Therefore, local administration of these neurotrophic factors to the MEP zone in the target muscle may serve as a therapeutic option for preserving the denervated MEPs in the chronically denervated muscle. Preservation of MEPs for a longer period of time could enlarge the therapeutic time-window for NMEG-NMZ and promote functional recovery of the muscles with delayed reinnervation. Indeed, the outcomes of NMEG-NMZ technique can be further improved by a combination of NMEG-NMZ surgery with other supplementary therapies to obtain a synergistic effect.

Conclusion

The results from this study allow us to make the following conclusions.

First, prolonged denervation resulted in a progressive reduction of muscle mass and myofiber size. Fiber atrophy was more pronounced in the 9-month-denervated muscle than that in the 3- and 6-month-denervated muscles. As muscle atrophy is one of the main factors for hampering successful recovery from muscle denervation, it is necessary for the development of strategies to rescue muscle from atrophy. In the absence of alternative primary treatments, sensory protection would provide temporary trophic support to prevent denervation atrophy, thereby preserving muscle volume for delayed reinnervation.

Second, normal axons almost disappeared and replaced by fragmented or accumulated axonal debris 3 months after denervation. In contrast, MEPs were still detectable in the 9-month-denervated muscles, suggesting that MEPs are more stable when compared with nerve axons after denervation.

Finally, further research should focus on the protection of MEPs in the long-term denervated muscle. Therapeutic strategies aimed at preserving MEPs would be the most effective for successful functional recovery of the delayed reinnervated muscle by NMEG-NMZ and/or DNI-NMZ techniques. One therapeutic strategy is the direct delivery of exogenous neurotrophic factors to the MEP zone in the denervated muscle, which could delay or prevent myofiber atrophy and degradation of MEPs following PNI. Maintenance of original MEPs in the long-term denervated muscle could facilitate rapid axon-MEP connections, thereby improving functional outcomes of NMEG-NMZ, DNI-NMZ, and/or other nerve repair procedures.
Acknowledgements

This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs under Award No. W81XWH-14-1-0442 (to Dr. Liancai Mu). The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. In conducting research using animals, the investigators adhere to the laws of the United States and regulations of the Department of Agriculture. This protocol was approved by the USAMRMC Animal Care and Use Review Office (ACURO) for the use of rats.
References

1. Fu SY, Gordon T. Contributing factors to poor functional recovery after delayed nerve repair: prolonged

2. Gordon T, Tyreman N, Raji MA. The basis for diminished functional recovery after delayed peripheral

J Hand Surg Am 1997;22(4):640-643

2000;16(5):379-383

5. Ma CH, Omura T, Cobos EJ, et al. Accelerating axonal growth promotes motor recovery after peripheral

6. Barbour J, Yee A, Kahn LC, Mackinnon SE. Supercharged end-to-side anterior interosseous to ulnar


8. Sulaiman OA, Gordon T. Role of chronic Schwann cell denervation in poor functional recovery after
nerve injuries and experimental strategies to combat it. Neurosurgery 2009;65(4 Suppl):A105-114

denervation and the presence of a sensory nerve reduce motor axonal regeneration. Exp
Neurol 2002;176(2):342-354

10. Sulaiman OA, Gordon T. Effects of short- and long-term Schwann cell denervation on peripheral nerve

Neurosurgery 2011;69(2 Suppl Operative):ons208-ons224, discussion ons224


34. Frank E, Gautvik K, Sommerschild H. Cholinergic receptors at denervated mammalian motor endplates. 
   Acta Physiol Scand 1975;95(1):66-76
35. Szabo M, Salpeter EE, Randall W, Salpeter MM. Transients in acetylcholine receptor site density and 
36. Fumagalli G, Balbi S, Cangiano A, Lomo T. Regulation of turnover and number of acetylcholine 
37. Kumai Y, Ito T, Matsukawa A, Yumoto E. Effects of denervation on neuromuscular junctions in the 
   thyroarytenoid muscle. Laryngoscope 2005;115(10):1869-1872
38. Birks R, Katz B, Miledi R. Physiological and structural changes at the amphibian myoneural junction, in 
   the course of nerve degeneration. J Physiol 1960;150:145-168
39. Frank E, Gautvik K, Sommerschild H. Persistence of junctional acetylcholine receptors following 
   St. Louis (MO): Mosby; 1980
41. Steinbach JH. Neuromuscular junctions and alpha-bungarotoxin-binding sites in denervated and 
   contralateral cat skeletal muscles. J Physiol 1981;313:513-528
42. Sanes JR, Lichtman JW. Development of the vertebrate neuromuscular junction. Annu Rev Neurosci 
   1999;22:389-442
   2006;75:19-37
44. Wu H, Xiong WC, Mei L. To build a synapse: signaling pathways in neuromuscular junction assembly. 
   Development 2010;137(7):1017-1033


52. McMahan UJ, Wallace BG. Molecules in basal lamina that direct the formation of synaptic specializations at neuromuscular junctions. Dev Neurosci 1989;11(4-5):227-247


60. Veltri K, Kwiecien JM, Minet W, Fahnestock M, Bain JR. Contribution of the distal nerve sheath to nerve and muscle preservation following denervation and sensory protection. J Reconstr Microsurg 2005;21(1):57-70, discussion 71-74


Figure Legends

Fig. 1  Comparison of muscle mass and myofiber morphology between control and denervated sternomastoid (SM) muscles in the rat. (A) Photographs of the removed control SM and denervated SM muscles, showing a progressive decline in muscle mass with denervation time. (B) Hematoxylin and eosin-stained cross-sections from the control and denervated SM muscles, showing a progressive reduction in fiber size of the denervated SM. 3-mon-den, 3-month-denervation; 6-mon-den, 6-month-denervation; 9-mon-den, 9-month-denervation.

Fig. 2  Box plots showing the distribution of sternomastoid (SM) muscle weight ratios (denervated to control) in 3-month, 6-month, and 9-month denervation groups. Median ratio is the largest in 3-month group (0.40) and decreases with length of denervation time to 0.26 in 6-month group and finally to 0.19 in 9-month group.

Fig. 3  Comparison of myofiber diameters of the sternomastoid (SM) muscles between denervated and control sides and among denervation groups. (A) Distribution of mean fiber diameters of the denervated and control SM muscles. (B) Ratio of the mean fiber size of the denervated to control muscles. Note that the fiber diameters of the denervated muscles are reduced progressively with denervation time. Vertical bars represent standard error.

Fig. 4  Immunofluorescent photomicrographs of cross-sections of the rat sternomastoid (SM) muscles on the normal and denervated sides. The sections were processed with N-CAM immunostaining to label denervated muscle fibers in the muscles studied. (A) Normal SM. (B) SM muscle denervated for 3 months. (C) SM muscle denervated for 6 months. (D) SM muscle denervated for 9 months. Note that most of the N-CAM-positive fibers (bright staining) in the denervated SM were atrophied. Scale bar = 50 µm for (A) through (D).
Fig. 5 Native motor zone (NMZ) of the rat sternomastoid (SM) muscle visualized by Sihler’s wholemount nerve staining (A) and acetylcholinesterase (AChE) staining (B-C). Note that the NMZ in the SM muscle is located in the middle portion of the muscle (outlined region in A and B) and contains a single nerve branch with numerous intramuscular nerve terminals (A) and a motor endplate band (B, C) with numerous neuromuscular junctions (black dots).

Fig. 6 Immunofluorescence labeling of sagittal sections from normal (A–A²) and denervated (B–D²) rat sternomastoid (SM) muscles. The immunostained sections show labeled axons and terminals (green) and motor endplates (MEPs, red). The low-magnification images (left column) show the MEP band, whereas the high-magnification images (middle and right columns) show alterations in acetylcholine receptor clusters in the denervated SM muscles. 3-mon-den, 3-month-denervation; 6-mon-den, 6-month-denervation; 9-mon-den, 9-month-denervation.
Table 1 Wet muscle weights of 3-month-, 6-month-, and 9-month-denervated and control sternomastoid (SM) muscles in rats (n = 21)

<table>
<thead>
<tr>
<th>Animal (No.)</th>
<th>Body weight (g)</th>
<th>Denervated SM (g)</th>
<th>Control SM (g)</th>
<th>Ratio D/C</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-month DEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>259</td>
<td>0.150</td>
<td>0.342</td>
<td>0.439</td>
</tr>
<tr>
<td>2</td>
<td>370</td>
<td>0.151</td>
<td>0.335</td>
<td>0.451</td>
</tr>
<tr>
<td>3</td>
<td>353</td>
<td>0.075</td>
<td>0.311</td>
<td>0.241</td>
</tr>
<tr>
<td>4</td>
<td>324</td>
<td>0.101</td>
<td>0.357</td>
<td>0.283</td>
</tr>
<tr>
<td>5</td>
<td>319</td>
<td>0.075</td>
<td>0.309</td>
<td>0.243</td>
</tr>
<tr>
<td>6</td>
<td>379</td>
<td>0.164</td>
<td>0.413</td>
<td>0.397</td>
</tr>
<tr>
<td>7</td>
<td>386</td>
<td>0.250</td>
<td>0.425</td>
<td>0.588</td>
</tr>
<tr>
<td>Average</td>
<td>341.4</td>
<td>0.138</td>
<td>0.356</td>
<td>0.377</td>
</tr>
<tr>
<td>SD</td>
<td>44.6</td>
<td>0.062</td>
<td>0.046</td>
<td>0.129</td>
</tr>
<tr>
<td>6-month DEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>296</td>
<td>0.258</td>
<td>0.386</td>
<td>0.668</td>
</tr>
<tr>
<td>2</td>
<td>390</td>
<td>0.117</td>
<td>0.372</td>
<td>0.315</td>
</tr>
<tr>
<td>3</td>
<td>378</td>
<td>0.039</td>
<td>0.380</td>
<td>0.103</td>
</tr>
<tr>
<td>4</td>
<td>282</td>
<td>0.075</td>
<td>0.298</td>
<td>0.252</td>
</tr>
<tr>
<td>5</td>
<td>304</td>
<td>0.047</td>
<td>0.390</td>
<td>0.121</td>
</tr>
<tr>
<td>6</td>
<td>296</td>
<td>0.166</td>
<td>0.374</td>
<td>0.444</td>
</tr>
<tr>
<td>7</td>
<td>324</td>
<td>0.101</td>
<td>0.391</td>
<td>0.258</td>
</tr>
<tr>
<td>Average</td>
<td>324.3</td>
<td>0.115</td>
<td>0.370</td>
<td>0.309</td>
</tr>
<tr>
<td>SD</td>
<td>42.3</td>
<td>0.077</td>
<td>0.033</td>
<td>0.196</td>
</tr>
<tr>
<td>9-month DEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>323</td>
<td>0.082</td>
<td>0.376</td>
<td>0.218</td>
</tr>
<tr>
<td>2</td>
<td>330</td>
<td>0.138</td>
<td>0.415</td>
<td>0.333</td>
</tr>
<tr>
<td>3</td>
<td>300</td>
<td>0.066</td>
<td>0.353</td>
<td>0.187</td>
</tr>
<tr>
<td>4</td>
<td>394</td>
<td>0.049</td>
<td>0.371</td>
<td>0.132</td>
</tr>
<tr>
<td>5</td>
<td>398</td>
<td>0.037</td>
<td>0.369</td>
<td>0.100</td>
</tr>
<tr>
<td>6</td>
<td>412</td>
<td>0.052</td>
<td>0.382</td>
<td>0.136</td>
</tr>
<tr>
<td>7</td>
<td>408</td>
<td>0.073</td>
<td>0.378</td>
<td>0.193</td>
</tr>
<tr>
<td>Average</td>
<td>366.4</td>
<td>0.071</td>
<td>0.378</td>
<td>0.186</td>
</tr>
<tr>
<td>SD</td>
<td>46.9</td>
<td>0.033</td>
<td>0.019</td>
<td>0.077</td>
</tr>
</tbody>
</table>

Abbreviations: DEN, denervation; D/C, denervated/control; SD, standard deviation.
Table 2 Motor endplate counts for the 3-month-, 6-month-, and 9-month-denervated and control sternomastoid (SM) muscles in rats (n = 21)

<table>
<thead>
<tr>
<th>Animal (No.)</th>
<th>Denervated SM</th>
<th>Control SM</th>
<th>Ratio D/C</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3-month DEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>81</td>
<td>115</td>
<td>0.704</td>
</tr>
<tr>
<td>2</td>
<td>76</td>
<td>104</td>
<td>0.730</td>
</tr>
<tr>
<td>3</td>
<td>72</td>
<td>93</td>
<td>0.774</td>
</tr>
<tr>
<td>4</td>
<td>87</td>
<td>110</td>
<td>0.790</td>
</tr>
<tr>
<td>5</td>
<td>69</td>
<td>87</td>
<td>0.793</td>
</tr>
<tr>
<td>6</td>
<td>109</td>
<td>121</td>
<td>0.900</td>
</tr>
<tr>
<td>7</td>
<td>98</td>
<td>118</td>
<td>0.830</td>
</tr>
<tr>
<td><strong>Average</strong></td>
<td><strong>84.6</strong></td>
<td><strong>106.9</strong></td>
<td><strong>0.789</strong></td>
</tr>
<tr>
<td><strong>SD</strong></td>
<td><strong>14.5</strong></td>
<td><strong>12.9</strong></td>
<td><strong>0.064</strong></td>
</tr>
<tr>
<td><strong>6-month DEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>68</td>
<td>101</td>
<td>0.673</td>
</tr>
<tr>
<td>2</td>
<td>71</td>
<td>115</td>
<td>0.617</td>
</tr>
<tr>
<td>3</td>
<td>39</td>
<td>88</td>
<td>0.443</td>
</tr>
<tr>
<td>4</td>
<td>94</td>
<td>128</td>
<td>0.734</td>
</tr>
<tr>
<td>5</td>
<td>63</td>
<td>98</td>
<td>0.643</td>
</tr>
<tr>
<td>6</td>
<td>78</td>
<td>104</td>
<td>0.750</td>
</tr>
<tr>
<td>7</td>
<td>52</td>
<td>79</td>
<td>0.658</td>
</tr>
<tr>
<td><strong>Average</strong></td>
<td><strong>66.4</strong></td>
<td><strong>101.9</strong></td>
<td><strong>0.645</strong></td>
</tr>
<tr>
<td><strong>SD</strong></td>
<td><strong>17.7</strong></td>
<td><strong>16.3</strong></td>
<td><strong>0.101</strong></td>
</tr>
<tr>
<td><strong>9-month DEN</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>58</td>
<td>123</td>
<td>0.471</td>
</tr>
<tr>
<td>2</td>
<td>65</td>
<td>108</td>
<td>0.601</td>
</tr>
<tr>
<td>3</td>
<td>47</td>
<td>99</td>
<td>0.474</td>
</tr>
<tr>
<td>4</td>
<td>40</td>
<td>112</td>
<td>0.357</td>
</tr>
<tr>
<td>5</td>
<td>38</td>
<td>104</td>
<td>0.365</td>
</tr>
<tr>
<td>6</td>
<td>43</td>
<td>111</td>
<td>0.387</td>
</tr>
<tr>
<td>7</td>
<td>46</td>
<td>128</td>
<td>0.359</td>
</tr>
<tr>
<td><strong>Average</strong></td>
<td><strong>48.1</strong></td>
<td><strong>112.1</strong></td>
<td><strong>0.431</strong></td>
</tr>
<tr>
<td><strong>SD</strong></td>
<td><strong>9.9</strong></td>
<td><strong>10.2</strong></td>
<td><strong>0.091</strong></td>
</tr>
</tbody>
</table>

Abbreviations: DEN, denervation; D/C, denervated/control; SD, standard deviation.
Fig. 1 Comparison of muscle mass and myofiber morphology between control and denervated sternomastoid (SM) muscles in the rat. (A) Photographs of the removed control SM and denervated SM muscles, showing a progressive decline in muscle mass with denervation time. (B) Hematoxylin and eosin-stained cross-sections from the control and denervated SM muscles, showing a progressive reduction in fiber size of the denervated SM. 3-mon-den, 3-month-denervation; 6-mon-den, 6-month-denervation; 9-mon-den, 9-month-denervation.
Fig. 2  Box plots showing the distribution of sternomastoid (SM) muscle weight ratios (denervated to control) in 3-month, 6-month, and 9-month denervation groups. Median ratio is the largest in 3-month group (0.40) and decreases with length of denervation time to 0.26 in 6-month group and finally to 0.19 in 9-month group.
Fig. 3  Comparison of myofiber diameters of the sternomastoid (SM) muscles between denervated and control sides and among denervation groups. (A) Distribution of mean fiber diameters of the denervated and control SM muscles. (B) Ratio of the mean fiber size of the denervated to control muscles. Note that the fiber diameters of the denervated muscles are reduced progressively with denervation time. Vertical bars represent standard error.

95x54mm (600 x 600 DPI)
Fig. 4  Immunofluorescent photomicrographs of cross-sections of the rat sternomastoid (SM) muscles on the normal and denervated sides. The sections were processed with N-CAM immunostaining to label denervated muscle fibers in the muscles studied. (A) Normal SM. (B) SM muscle denervated for 3 months. (C) SM muscle denervated for 6 months. (D) SM muscle denervated for 9 months. Note that most of the N-CAM-positive fibers (bright staining) in the denervated SM were atrophied. Scale bar = 50 µm for (A) through (D).
Fig. 5  Native motor zone (NMZ) of the rat sternomastoid (SM) muscle visualized by Sihler’s wholemount nerve staining (A) and acetylcholinesterase (AChE) staining (B-C). Note that the NMZ in the SM muscle is located in the middle portion of the muscle (outlined region in A and B) and contains a single nerve branch with numerous intramuscular nerve terminals (A) and a motor endplate band (B, C) with numerous neuromuscular junctions (black dots).

254x338mm (300 x 300 DPI)
Fig. 6  Immunofluorescence labeling of sagittal sections from normal (A-A2) and denervated (B-D2) rat sternomastoid (SM) muscles. The immunostained sections show labeled axons and terminals (green) and motor endplates (MEPs, red). The low-magnification images (left column) show the MEP band, whereas the high-magnification images (middle and right columns) show alterations in acetylcholine receptor clusters in the denervated SM muscles. 3-mon-den, 3-month-denervation; 6-mon-den, 6-month-denervation; 9-mon-den, 9-month-denervation.